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Abstract  
Allergen-reactive CD4+ T cells are implicated in the pathogenesis of allergic disease. 
Peptide immunotherapy (PIT) involves therapeutic administration of short 
immunodominant peptides from within the protein allergen to which CD4+ T cell 
responses are directed. This approach can induce tolerance of allergen-reactive CD4+ 
T cells, while negating the risk of severe allergic reactions associated with whole 
allergen specific immunotherapy. PIT therefore holds promise as a disease-
modifying treatment for allergic patients. However, further information regarding the 
mechanisms of action of PIT are required to aid translation to the allergy clinic.  
 
Chicken ovalbumin (OVA) is a commonly used model allergen in mouse models of 
allergic airways inflammation (AAI). Trackable, T cell receptor transgenic T cells 
recognizing the immunodominant 323-339 peptide of OVA (pOVA) allow 
mechanistic investigation of PIT in response to pOVA. This thesis investigated the 
hypothesis that strong, systemic T cell responses induced by intravenous 
administration of soluble pOVA will induce i) tolerance to pOVA and ii) linked 
suppression to any additional OVA T cell epitopes, hence improving OVA-induced 
AAI. Contrary to the hypothesis, intravenous pOVA PIT did not improve disease in a 
C57BL/6 model of OVA-induced AAI. Models of OVA-induced allergic 
sensitisation and AAI were therefore developed incorporating trackable CD4+ 
pOVA-reactive T cells (OT-II cells). pOVA PIT induced tolerance of these cells in 
an allergic sensitisation setting, but had limited impact on the overall OVA response. 
Yet, in a model of AAI driven solely by Th2 polarised CD4+ OT-II cells, pOVA PIT 
did improve disease. It was concluded that, in non-tra sgenic C57BL/6 mice, CD4+ 
T cells responding to additional epitope(s) within OVA were important in driving 
disease and that these T cells were not subject to linked suppression following pOVA 
PIT. Using a panel of overlapping peptides constituting the sequence of OVA, a 
novel CD4+ epitope within OVA was characterised. The effects of PIT using pOVA 
in combination with a peptide containing this additional epitope on OVA-induced 
AAI were then assessed. Findings from this project therefore hold importance for 
future mechanistic work surrounding PIT in allergic d sease. 
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Allergic asthma is a substantial clinical problem and often originates in childhood 
(Simpson and Sheikh, 2010). It is increasingly evidnt that allergy can be viewed as 
a systemic disease, and that allergic asthma may develop in some patients who 
already have one allergic disease, such as allergic eczema (Punekar and Sheikh, 
2009). Current mainstream allergic asthma treatments are directed towards symptom 
control and generalised suppression of immune responses (Haslett et al., 2002). 
However, current treatments are not curative and have not reliably been 
demonstrated to modify disease progression. 
 
CD4+ T cell responses to allergens are strongly implicated in the pathogenesis of 
allergic asthma [reviewed in (Larché et al., 2003)]. In health, allergen-reactive CD4+ 
T cells do not mount an allergic response to inhaled a roallergens, i.e. they are 
tolerant. Allergen-specific therapies aim to specifically induce tolerance of allergen-
reactive T cells. Such targeted therapeutics have the potential to improve/ablate the 
symptoms of allergic disease such as allergic asthma, but may also be effective in 
altering the progression of allergic disease, if given early in life (Larché, 2007, 
Jacobsen et al., 2007). Specific immunotherapy (SIT), which involves administering 
whole protein allergen to induce tolerance, has been found in some clinical trials to 
be efficacious in the treatment of allergic disease (Calderon et al., 2007). However, 
giving allergen as a treatment has the potential to induce severe allergic responses, 
including anaphylaxis, as a consequence of IgE binding to multiple sites on the 
allergen and subsequent IgE cross linking on mast cells, leading to mast cell 
degranulation (Borchers et al., 2004, Peavy and Metcalf , 2008). Severe allergic 
reactions induced by SIT are more likely to occur in allergic asthmatics and have 
been associated with fatalities in rare cases (Abramson et al., 2010, Borchers et al., 
2004).  
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Peptide immunotherapy (PIT) offers a potentially safer pproach to allergen-specific 
immunotherapy. PIT involves administering short allergen-derived peptides to which 
the T cell response is directed (known as immunodominant peptides), to induce T 
cell tolerance [reviewed in (Larché, 2007, Wraith, 2009)]. The short nature of these 
peptides means that they do not facilitate IgE cross linking, therefore abrogating the 
risk of severe allergic reactions. 
 
PIT has been shown to be capable of inducing T cell tolerance in some animal 
models (predominantly in the autoimmune setting), and in a small number of clinical 
trials involving allergic patients (Metzler and Wraith, 1993, Gaur et al., 1992, 
Campbell et al., 2009, Tarzi et al., 2006). However, the effects of PIT in the clinical 
setting have varied (Oldfield et al., 2002), and detrimental effects, or lack of 
therapeutic effect, have been reported in some allergy-based animal studies (Janssen 
et al., 1999, Barbey et al., 2004). Better understanding of the mechanisms of action 
of PIT in the allergic setting is therefore required in order to facilitate clinical 
translation.  
 
In this thesis, the effects of PIT in the context of murine models of chicken 
ovalbumin (OVA)-induced allergic airways disease arinvestigated. The focus of 
this introduction will therefore be:-  
• CD4+ T cell biology relevant to this project 
• mechanisms thought to be involved in the induction of T cell tolerance  
• the immunological aspects of allergic asthma and how these can be modelled 
in vivo 
• current knowledge surrounding both specific immunotherapy and peptide 
immunotherapy 
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1.2 CD4+ T cell development and selection  
1.2.1 CD4+ T cell development in the thymus 
T cells develop from haematopoietic stem cells. These migrate from the bone 
marrow to the thymus, an organ which represents a carefully controlled environment 
that facilitates T cell development [reviewed in (Zamoyska and Lovatt, 2004)].  
 
Mature CD4+ T cells are generated in the thymus throughout life, but output 
diminishes with age as a consequence of thymic atrophy [reviewed in (Heng et al., 
2010)]. CD4+ and CD8+ T cells develop from the α:β T cell lineage (Zamoyska and 
Lovatt, 2004). During development, thymocytes must successfully pass through 
various stages to avoid apoptosis (Zamoyska and Lovatt, 2004). Key phases involve 
the progression from double negative thymocytes (which do not express CD4 or 
CD8) to become double positive thymocytes [which expr ss both CD4 and CD8 
(Zamoyska and Lovatt, 2004)]. Such progression requi s the effective generation of 
a pre-T cell receptor (-TCR) consisting of a β chain in association with a pre-Tα 
chain (Zamoyska and Lovatt, 2004, Murphy et al., 2008). Subsequent thymocyte 
proliferation is followed by expression of the CD4 and CD8 co-receptors (Zamoyska 
and Lovatt, 2004). Double positive thymocytes then proceed to gene rearrangement 
of the α chain, leading to the expression of a mature α:β TCR (Zamoyska and 
Lovatt, 2004). Thymocytes that survive this far then undergo positive and negative 
selection. Such a developmental pathway ensures diversity in TCR antigen 
specificity. 
 
1.2.2 Positive CD4 + T cell selection 
In order for CD4/CD8 double positive thymocytes to become single positive CD4 or 
CD8 expressing T cells, requires them to pass through a further checkpoint known as 
positive selection [reviewed in (Germain, 2002)]. In the context of CD4+ T cell 
development, the TCR of double positive thymocytes must be capable of binding to 
self-peptide presented by thymic cortical epithelial cells in the context of major 
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histocompatibility complex (MHC) II. If this occurs, the T cell escapes apoptosis and 
down regulates the CD8 co-receptor, becoming a single positive CD4 T cell.   
 
1.2.3 Negative selection  
If T cells were only selected based on their ability to recognise self-peptide in the 
context of MHC, T cells with TCRs with high affinity for self peptides would also be 
selected, resulting in many high affinity autoreactive T cells in the periphery. T cells 
developing in the thymus are thus also subject to negative selection [reviewed in 
(Starr et al., 2003)]. This involves the deletion of T cells with TCRs with high 
affinity for self peptide/MHC and can be illustrated in a study by Zal et al utilising 
transgenic mice that possessed CD4+ T cells reactive to an MHC II-restricted peptide 
from the C5 complement protein (Zal et al., 1994). In that study, CD4+ T cells were 
present in the periphery of mice that did not express C5, but were deleted in the 
thymus in mice that did express C5 (Zal et al., 1994). Evidence strongly supports the 
requirement for negative selection to prevent autoimmunity (Starr et al., 2003, 
Kishimoto and Sprent, 2001). Hence, negative selection in the thymus is known as 
central tolerance.  
 
Overall, therefore, the mechanisms involved in T cell d velopment result in a 
population of CD4+ T cells in the periphery that are restricted to the recognition of 
antigen in the context of MHC II, and are also tolerant towards self-antigens. 
 
1.3 Innate immune responses 
The innate immune response ensures rapid responses to invading pathogens. Innate 
immune cells such as neutrophils, eosinophils, basophils, mast cells and 
macrophages are derived from a common myeloid progenitor cell (Murphy et al., 
2008). The actions of innate immune cells are vital for efficient responses to 
pathogens, and can, in some cases, be sufficient to i duce pathogen clearance alone, 
through actions such as phagocytosis and the release of factors which promote the 
killing of pathogens [reviewed in (Chaplin, 2010)]. However, innate immune 
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responses alone do not induce immunological memory and do not elicit antigen-
specific responses; the key features of adaptive immunity (Murphy et al., 2008). 
 
Triggering of innate immune responses involves the recognition of so-called 
“danger-signals” by innate immune cells [reviewed in (Matzinger, 2002)]. Innate  
immune cells possess pattern recognition receptors (PRRs) which can bind to a 
variety of pathogen associated molecular patterns (PAMPS), [reviewed in (Bianchi, 
2007)]. Prime examples of PRRs are the toll-like receptors (TLRs), which can 
respond to a variety of PAMPs. TLR-4 for example, in association with CD14 and 
the myeloid differentiation factor-2 (MD-2) protein, can recognise bacterial 
lipopolysaccharide (LPS), whereas TLR-3 can recognise viral-derived double-
stranded DNA (Bianchi, 2007). Other PRRs include mannose-binding lectin and the 
cytoplasmically located nucleotide-binding oligomerization domain-containing 
proteins (NOD proteins). Danger can also be signalled through the presence of 
substances whose presence outside a cell are indicative of cellular damage or distress 
e.g. uric acid,  adenosine-5’-triphosphate (ATP) and heat shock proteins (Gallucci 
and Matzinger, 2001, Bianchi, 2007). The recognitio of danger by innate immune 
cells can induce the production of an array of inflammatory mediators e.g. IL-12, 
tumor necrosis factor-α (TNF-α) and IL-1 [reviewed in (Bianchi, 2007)]. 
 
1.4 Requirements for the activation of CD4 + T cells 
1.4.1 Dendritic cells (DCs) and the importance of S ignal 0 
The potential for DCs [known to be highly effective antigen presenting cells (APCs)] 
to respond to PAMPs and other danger-associated signal , means that they are ideally 
placed to bridge innate and adaptive immunity. Recognition of danger signals (e.g. 
LPS), by DCs leads to increased antigen sampling, antigen processing and 
presentation on MHC, and increased expression of costimulatory molecules such as 
CD80 and CD86 (Bianchi, 2007, Shi et al., 2003, Eisenbarth et al., 2002). 
Furthermore, the recognition of danger signals by DCs also induces them to migrate 
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to draining lymph nodes (LNs) where they can present antigen to T cells (Eisenbarth 
et al., 2002).  
 
The activation of DCs via their detection of danger signals, can be referred to as 
Signal 0 in the requirement for activation of CD4+ T cells, since this promotes 
antigen uptake and processing, and is therefore the first step towards inducing T cell 
activation. How a DC responds to different danger signals influences the nature of 
the ensuing T cell effector response (Peters et al., 2010); this is further discussed in 
later sections. 
 
1.4.2 Antigen processing 
In order for a peptide to bind to MHC II and be presented on the surface of an APC, 
it first has to be generated from an antigen (often a protein). This process is discussed 
in (Watts et al., 2003, Murphy et al., 2008), and is briefly summarised below.  
 
Proteins that are endocytosed by an APC enter an intracellular processing pathway. 
During processing, the pH of the endosomes reduces inducing the activation of 
various proteases. These can then cleave the protein in o peptides. Meanwhile, MHC 
II is generated by the cell which is then transported from the endoplasmic reticulum 
to endosomes. In the initial stages of transit, peptid s are prevented from binding to 
MHC II by the presence of the invariant chain [which s later cleaved to the class II-
associated invariant-chain peptide (CLIP)], in the MHC II binding groove. When 
endosomes containing newly generated peptides and MHC II fuse, this presents the 
opportunity for peptide to bind to MHC II [with the aid of the chaperone molecule 
human leucocyte antigen (HLA) –DM, or the mouse equivalent H-2M]. It is thought 
likely that long peptides can initially bind to MHC II and these are then shortened by 
further protease activity (Watts et al., 2003). The end result is a peptide that is 
typically 10-25 amino acids in length bound to MHC II. This complex is then 
transported to the cell surface to permit interaction with TCRs on CD4+ T cells.  
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T cell responses are usually predominantly directed towards one or more epitopes 
contained within antigen-derived peptides. Such epitopes are thus termed 
“immunodominant” [discussed in (Sant et al., 2005)]. Many variables influence 
whether or not a particular antigen-derived peptide s immunodominant. For 
example, the nature of the peptides generated by APCs will depend upon the actions 
of proteases (Sant et al., 2005). The peptides that are generated then need to be 
capable of binding to MHC II, and processes such as peptide editing by HLA-DM 
ensure that stable peptide-MHC II interactions are favoured (Sant et al., 2005). 
Hence, some peptides containing particular epitopes may not be displayed on MHC 
II following antigen processing. This is relevant to the existence of “cryptic epitopes” 
which only elicit T cell responses when they are contained within exogenously 
delivered peptides, whereas T cell responses are not directed towards these epitopes 
during processing of the full antigen (Sweenie et al., 2007). Immunodominance can 
also be affected by the frequency of CD4+ T cells with TCRs reactive to particular 
peptide-MHC-II complexes, since this frequency is known to vary (Chu et al., 2010). 
Overall, the T cell response to an antigen is often predominantly directed towards 
only a few (or even one) immunodominant epitopes, as a consequence of variations 
in antigen processing and of the availability, and ensuing response, of peptide-
reactive CD4+ T cells. 
 
1.4.3 Signal 1: TCR engagement and resultant signal ling 
Signal 1 refers to the TCR on a CD4+ T cell recognising peptide expressed on an 
APC in the context of MHC II [reviewed in (Smith-Garvin et al., 2009)]. The α and 
β chains together form the site of antigen binding. These chains must also be 
associated with the CD3 complex (itself formed from 4 chains - one CD3γ chain, one 
CD3δ chain and two CD3ε chains), and the ζ chain [reviewed in (Qian and Weiss, 
1997)]. All these chains possess cytoplasmic tails containing immunoreceptor 
tyrosine-based activation motifs (ITAMs)], (Qian and Weiss, 1997). Together these 
associations form the TCR complex. TCR engagement with peptide-MHC II leads to 
phosphorylation of tyrosines present within the ITAMs. The actions of the tyrosine 
kinases proto-oncogene tyrosine protein kinase Fyn ( ) and lymphocyte-specific 
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protein tyrosine kinase (Lck) are implicated in this phosphorylation (Qian and Weiss, 
1997, Smith-Garvin et al., 2009). In CD4+ T cells, signalling through the TCR is also 
mediated by the CD4 co-receptor which associates with the TCR, binds to MHC II 
and is itself associated with Lck, hence promoting ITAM phosphorylation (Janeway, 
1992). ITAM phosphorylation enables another tyrosine kinase, known as zeta-
associated protein-70 (ZAP-70), to bind to the ζ chain, become phosphorylated itself 
and then become activated (Qian and Weiss, 1997). This sets into play further down 
stream signalling events which can cumulate in the activation of the transcription 
factors nuclear factor κB (NFκB), nuclear factor of activated T cells (NFAT) and 
activator protein 1 (AP-1),  which are required for the CD4+ T cell to proliferate and 
differentiate (Qian and Weiss, 1997). 
 
1.4.4 Signal 2: Co-stimulation 
Signal 2 refers to the additional stimulus provided by co-stimulation between the 
APC and T cell. TCR ligation with peptide-MHC without signal 2 inhibits the 
development of an effector T cell response and can induce a state of 
unresponsiveness, known as anergy [reviewed in (Schwartz, 2003)]. The requirement 
for Signal 2 to elicit productive effector T cell responses represents a means of 
regulating against harmful T cell responses to self p ptides.  
 
Co-stimulation via CD28, a molecule constitutively xpressed on naïve as well as 
activated T cells, has been well characterised (Acuto and Michel, 2003). CD28 can 
bind to CD80 and CD86 on the APC, the expression of which are increased upon DC 
activation (Bianchi, 2007). Costimulation via CD28-CD80/86 facilitates IL-2 
production, proliferation and effector cytokine production by the T cell [reviewed in 
(Alegre et al., 2001)]. In contrast, lack of costimulation via CD28 significantly 
impairs the T cell response, and often leads to anergy or cell death [discussed in 
(Alegre et al., 2001, Schwartz, 2003, Croft et al., 1994)]. Co-stimulation also occurs 
via molecules such as CD40L and OX40 which are expressed by activated T cells 
(Quezada et al., 2004, Croft et al., 2009). OX40 binds to OX40L on DCs, the 
expression of which is induced by PRR stimulation or in response to co-stimulation 
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[reviewed in (Croft et al., 2009)]. OX40-OX40L interactions subsequently promote T 
cell survival (Rogers et al., 2001).  
 
Negative co-stimulatory molecules also exist and are necessary to prevent excessive 
immune responses that would be detrimental to the host. These include molecules 
such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-
1). Like CD28, CTLA-4 can also bind to CD80 and CD86, but with greater avidity 
[reviewed in (Rudd et al., 2009)]. CTLA-4-CD80/86 interactions significantly impair 
T cell proliferation and IL-2 production (Krummel and Allison, 1995). CTLA-4 is 
expressed by activated T cells and its importance i limiting immune responses is 
demonstrated by CTLA-4 deficient mice, which develop extensive 
lymphoproliferative disease at an early age (Waterhouse et al., 1995). 
 
1.4.5 Signal 3: The effect of cytokines on T cell d ifferentiation 
The combined effects that cytokines exert during T cell activation are termed Signal 
3. The cytokine milieu that is present during CD4+ T cell activation profoundly 
affects T cell differentiation and, consequently, the nature of the effector response 
[reviewed in (O'Shea and Paul, 2010)]. Cytokines (such as those produced by innate 
cells in response to PRR stimulation), can bind to receptors on CD4+ T cells, 
activating tyrosine kinases from the Janus kinase (JAK) family which in turn activate 
signal transducers and activators of transcription (STATs), [reviewed in (Zhou et al., 
2009, Adamson et al., 2009)]. Different cytokine environments thus promote the 
activation of different STATs, which, following their translocation to the nucleus, 
will differentially result in the activation of a variety of T cell genes. The activation 
of different STATs can also lead to the induction of other transcription factors known 
as “master-regulators”, the expression of which are associated with particular T cell 
lineages.  
 
Differentiation of naïve CD4+ T cells into effector T cells therefore requires Signals 
0, 1, 2, and 3. Figure 1.1 summarises these requirements for T cell activation.
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Figure 1-1: Signals required for the induction of an effector CD4+ T cell response
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1.5 CD4+ T cell subsets 
Several subsets of CD4+ T cells have been described, which possess different 
effector properties and can differentiate from naïve CD4+ T cells in response to 
different cytokines (Signal 3) [reviewed in (Zhou et al., 2009)]. Figure 1.2 provides 
an overview of CD4+ T cell differentiation, the understanding of which has evolved 
over time. 4 main lineages have been described [Th1, 2, Th17 and T regulatory 
(Treg) cells] which can be identified by their expression of different transcription 
factors. Considerable plasticity is increasingly being demonstrated between different 
CD4+ subsets [reviewed in (Zhou et al., 2009)]. The different cytokine signatures of 
differentiated CD4+ T cells, influences the nature of the immune respon e (Zhou et 
al., 2009). The different CD4+ T cells subsets are briefly discussed in the next 
section. Those subsets thought to be particular relevance in allergic asthma will be 
further discussed in section 1.7.10. 
Chapter 1 Introduction 
 12 
Figure 1-2: CD4+ T cell subset
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1.5.1 Th1 and Th2 cells 
Th1 and Th2 cells were the CD4+ T cell subsets first to be described (Mosmann and 
Coffman, 1989). Th1 cells are key in the defence against pathogens, particularly 
intracellular pathogens, and are primarily associated with their ability to produce 
interferon-γ (IFN-γ) [reviewed in (Wan, 2010)]. Th1 differentiation is associated 
with the activation of STAT1 and STAT4 and of the transcription factor T box 
expressed in T cells (T-bet), which is crucial for Th1 effector function [reviewed in 
(Zhu and Paul, 2010, Adamson et al., 2009)]. While vital for anti-pathogenic 
responses, Th1 responses are also prominent features of inflammatory diseases such 
as rheumatoid arthritis and inflammatory bowel disease (Wan, 2010).  
 
Th2 cells produce the signature cytokines IL-4, IL-5 and IL-13 [reviewed in (Paul 
and Zhu, 2010)]. Th2 responses are particularly important for host defence against 
helminths [reviewed in (Harris and Gause, 2011)], but are also heavily implicated in 
allergic responses, as further discussed in section 1.7.10. Through the provision of B 
cell help, Th2 cells enable the B cell class-switching that is required for the 
generation of IgE [reviewed in (Harris and Gause, 2011)]. GATA-binding protein 3 
(GATA-3) is known as the master transcription factor f r Th2 cells [reviewed in 
(Paul and Zhu, 2010)]. Hence, GATA-3 depletion has been found to abrogate Th2 
responses, and GATA-3 is required for Th2 differentiated cells to maintain Th2 
cytokine production (Pai et al., 2004, Zhu et al., 2004). Th2 cells can differentiate in 
response to IL-4 which leads to STAT6 activation and the activation of GATA-3 
[(Kurata et al., 1999) and reviewed in (Paul and Zhu, 2010, Adamson et al., 2009)]. 
GATA-3 expression can also be induced via STAT5 activ tion, for example in 
response to stimulation of the TCR with low doses of antigen (Yamane et al., 2005). 
STAT5 activation can also occur via IL-2 signalling (Cote-Sierra et al., 2004) and 
also via the actions of IL-7 and IL-15 (Liao et al., 2008).  
 
Reciprocal inhibition between the Th1 and Th2 subsets has been described. GATA-3 
plays a role in the inhibition of Th1 responses, as evidenced in a study by Zhu et al, 
who found that conditional depletion of GATA-3 in CD4+ T cells prior to culture in 
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Th2-promoting conditions, suppressed IL-4 expression and promoted IFN-γ 
expression (Zhu et al., 2004). IL-4 has also been shown to interfere with the 
expression of a component of the IL-12 receptor during T cell differentiation, thus 
further directing the T cell towards a Th2 rather than a Th1 phenotype (Szabo et al., 
1997).  
 
It is generally felt that Th2 cells represent a relatively stable cell phenotype, 
compared to some of the other CD4+ T cell subsets such as Th17 cells (Zhou et al., 
2009). However, there is evidence to suggest that culturing Th2 cells in the presence 
of transforming growth factor-β (TGF-β) can lead to down regulation of Th2 
signature cytokines and upregulation of IL-9. The resultant cells have been described 
as Th9 cells (Veldhoen et al., 2008), and are further discussed below. Hence, Th2 
cells may also exhibit a degree of plasticity in vivo. 
 
1.5.2 Th17 cells 
Th17 cells represent a much more recently identified lineage and have the ability to 
produce cytokines such as IL-17A, IL-17F, IL-21 and IL-22 [reviewed in (Kolls and 
Khader, 2010)]. Th17 differentiation is associated with the induction of the 
transcription factor retinoic acid-related orphan receptor γT (RORγT) and, more 
recently, with the induction of the retinoic acid-related orphan receptor αT (RORαT) 
(Yang et al., 2008). Cytokines responsible for Th17 differentiation vary between 
mice and humans [reviewed in (Oboki et al., 2008)], but in mice IL-6 together with 
TGF-β are able to promote differentiation of naive CD4+ T cells to Th17 cells. Th17 
cells appear to be important for defence against mucosal pathogens, particularly 
fungi (Kolls and Khader, 2010). Th17 cells have also been implicated in a number of 
autoimmune diseases such as multiple sclerosis (Durelli et al., 2009) and arthritis 
(Singh et al., 2010). Increasingly, Th17 cells are being found to exhibit considerable 
plasticity in terms of their potential to develop different phenotypes, e.g. by 
developing the ability to produce IFN-γ in response to different cytokine stimuli (Lee 
et al., 2009). 
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1.5.3 Th9 cells 
Th9 cells have been proposed as an IL-9 producing T cell subset in their own right, 
and can develop from naïve CD4+ T cells in the presence of TGF-β and IL-4 
(Dardalhon et al., 2008), or from Th2 cells in the pr sence of TGF-β (Veldhoen et 
al., 2008). Recently a transcription factor PU.1 has been identified as being important 
for Th9 differentiation (Chang et al., 2010), however a true “master regulator” 
transcription factor is yet to be defined, meaning that Th9 cells do not as yet 
represent a fully accepted T cell lineage. The potential role of Th9 cells in allergy is 
discussed in section 1.7.10.6. 
 
1.5.4 T regulatory cells 
1.5.4.1 FoxP3+ T regulatory cells 
A variety of subsets of T cells with regulatory proerties have been described, these 
are vital for the inhibition of excessive inflammatory responses [reviewed in 
(Sakaguchi et al., 2008)]. Natural T regulatory cells (nTregs) develop in the thymus, 
constitute around 5-10% of the peripheral CD4+ T cell population, possess the 
transcription factor forkhead box P3 (FoxP3) and expr ss CD25 [(Hori et al., 2003) 
and reviewed in (Sakaguchi et al., 2008, Hawrylowicz and O'Garra, 2005)]. In 
humans, mutations in the FOXP3 gene result in the immune dsyregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), where multiple 
autoimmune and allergic conditions develop (Wildin et al., 2001). A similar 
phenotype is seen in scurfy mice, which have mutations in FoxP3 (Bennett et al., 
2001). FoxP3+ T regulatory cells can also be induced from naïve CD4+ T cells, and 
are termed inducible T regulatory cells (iTreg), [reviewed in (Sakaguchi et al., 
2010)]. These can be generated in vitro by culturing naïve CD4+ CD25- T cells in the 
presence of IL-2 and TGF-β (Davidson et al., 2007), although the requirements for 
their generation in vivo may vary [(Coombes et al., 2007) and discussed in 
(Sakaguchi et al., 2010)]. Both nTregs and iTregs are c pable of regulating immune 
responses as demonstrated by their ability to suppress ongoing inflammatory 
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responses or prevent the development of autoimmune disease upon adoptive transfer 
in some animal models (DiPaolo et al., 2005, Aricha et l., 2008).  
 
1.5.4.2 FoxP3 - T regulatory cells 
FoxP3- T regulatory cells also exist. Th3 cells, which produce TGF-β and exhibit 
regulatory properties, appear to be particularly reevant to the regulation of immune 
responses in the gut [reviewed in (Weiner, 2001)]. IL-10 is known to have potent 
immunoregulatory activities as illustrated in animal studies where IL-10 deficiency 
or blockade leads to immunopathology (Berg et al., 1996, Asseman et al., 2003). Tr1 
cells have been defined by some as CD4+ T cells with regulatory properties that 
produce IL-10, yet also require IL-10 for their differentiation [reviewed in (Grazia 
Roncarolo et al., 2006)], as depicted in Figure 1.2. Tr1 cells encompassed by this 
definition consist of a heterogeneous population for, although they may only produce 
IL-10, they may also produce other cytokines such as IFN-γ and IL-5 in different 
situations [(Barrat et al., 2002, Buer et al., 1998, Groux et al., 1997) and reviewed in 
(Grazia Roncarolo et al., 2006, Hawrylowicz and O'Garra, 2005)]. A variety of 
protocols can lead to the generation of Tr1 cells in vitro, such as culturing naïve 
CD4+ T cells together with antigen and IL-10 (Groux et al., 1997), or with vitamin 
D3 and the glucocorticoid dexamethasone (Barrat et l., 2002), or by pre-treating of 
DC (e.g. with TGF-β) prior to culture with naïve CD4+ T cells (Sato et al., 2003). 
However, others would argue that Tr1 cells have little relevance in vivo and that  
emphasis should put on the production of IL-10 by effector cells, such as Th1 cells 
and other subsets, which can be promoted in settings of chronic or strong antigenic 
stimulation, thus modifying the effector response (Jankovic et al., 2007, Gabrysova 
et al., 2009). Overall, the induction of IL-10 secreting T cells is highly 
therapeutically desirable [as discussed in (Sabatos-Peyton et al., 2010)], and will be 
further discussed in later sections. 
 
In summary, a variety of T cell responses can be elicited through the combined 
effects of Signals 0-3; these responses can be inflammatory or regulatory in nature.  
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1.6 Peripheral Tolerance 
1.6.1 Requirement for peripheral tolerance 
Despite the robust mechanisms that constitute central tolerance, T cells capable of 
reacting to self-antigens still exist within the peri hery (Liu et al., 1995). 
Furthermore, T cells in the periphery will have the capacity to recognise harmless 
antigens (Jenkins et al., 2010). It is paramount tha mechanisms exist to maintain 
peripheral T cell tolerance in order to guard against autoimmunity and inflammatory 
responses against harmless antigens [reviewed in (Ryan et al., 2007)]. Peripheral 
tolerance holds particular importance for the lung, which is continually exposed to 
environmental antigens and where continually mounting an inflammatory response 
would be extremely detrimental to the host [discussed in (Lloyd and Hawrylowicz, 
2009)]. So how is peripheral tolerance effected? 
 
1.6.2  Mechanisms of tolerance induction 
Several mechanisms have been demonstrated to be integral in maintaining peripheral 
tolerance [reviewed in (Ryan et al., 2007)]. The way in which DCs present antigen to 
T cells is key in orchestrating whether a tolerogenic or inflammatory response is 
elicited (Hochweller and Anderton, 2005). Hence a DC in a steady state, e.g. one 
which has not become activated by the detection of PAMPs, will not undergo 
upregulation of costimulatory molecules such as CD80 and CD86 (Hochweller and 
Anderton, 2005). Insufficient costimulation of T cells by DCs promotes a tolerogenic 
T cell response, rather than an inflammatory T cell r sponse (Hochweller and 
Anderton, 2005, Sotomayor et al., 1999). Tolerogenic responses may occur in a 
variety of ways. 3 pillars of peripheral tolerance have been proposed, encompassing 
deletion, adaptation/anergy and regulation. 
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1.6.2.1 Deletion  
Deletion represents a crucial mechanism whereby central tolerance is effected, but 
also remains an important way in which T cell tolerance is maintained in the 
periphery [reviewed in (Mueller, 2010, Ryan et al., 2007)]. For example, 
abnormalities in apoptotic pathways can lead to loss f peripheral tolerance and 
autoimmunity (Hutcheson et al., 2008). Deletion of antigen-reactive T cells is also 
implicated in some models of therapeutic tolerance induction. For example, 
administration of high doses of soluble peptide has been found to lead to deletion of 
peptide-reactive CD4+ T cells (Hochweller and Anderton, 2005, Kearney et al., 
1994). Analysis of the kinetics of such tolerogenic responses have shown that high 
dose, soluble peptide induces a T cell proliferative phase followed by a deletional 
phase (Hochweller and Anderton, 2005, Kearney et al., 1994). OX40-OX40L 
interactions have been shown to be important in such ituations (Bansal-Pakala et al., 
2001). OX40 is expressed following T cell activation. DCs are induced to express 
OX40L when they become activated, for example in response to PRR stimulation, 
and/or in response to CD40 ligation [reviewed in (Croft et al., 2009)]. OX40L-OX40 
interactions have been found to increase T cell expression of anti-apoptotic proteins 
such as Bcl-2 and Bcl-xL (Rogers et al., 2001). Using agonistic antibodies against 
OX40 has been shown to prevent T cell tolerance induce  by high dose peptide 
(Bansal-Pakala et al., 2001). The timing of OX40L expr ssion on DCs together with 
the kinetics of T cell responses to high-dose soluble peptide, are thus consistent with 
T cells entering into a proliferative phase, but later dying on account of deficient 




The term anergy is very broad and can be taken to mean a state of unresponsiveness 
of a T cell in response to antigenic stimulation [reviewed in (Mueller, 2010, 
Schwartz, 2003)]. Different forms of anergy have been described. Clonal anergy 
tends to refer to an anergic state that develops in vitro in effector T cells (or T cell 
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lines) that receive insufficient costimulation [(Jenkins et al., 1987, Mueller et al., 
1991) and discussed in (Schwartz, 2003)]. This results in (reversible) inhibition of 
proliferation and IL-2 production, but usually does not prevent effector cytokine 
production in vitro (Schwartz, 2003, DeSilva et al., 1991, Mueller et al., 1991, 
Jenkins et al., 1987). However, the relevance of clnal anergy in maintaining 
peripheral tolerance in vivo is uncertain [discussed in (Schwartz, 2003, Mueller, 
2010)].  
 
Another form of anergy known as adaptive tolerance has been proposed to be most 
applicable in vivo [discussed in (Schwartz, 2003)]. Adaptive tolerance is thought to 
be particularly relevant to naïve T cells and usually results in widespread inhibition 
of proliferation and cytokine production (Schwartz, 2003, Pape et al., 1998). 
Evidence suggests that such effects can be mediated by a block in the translation of 
mRNA that encodes effector cytokines (Villarino et al., 2011), and that persistence of 
antigen is required for the maintenance of adaptive tol rance (Rocha et al., 1993). 
The reversible nature of adaptive tolerance has implications for therapies designed to 
induce tolerance, since T cells undergoing adaptive tolerance are likely to retain the 
potential to become pathogenic in the future (Villarino et al., 2011, Rocha et al., 
1993, Schwartz, 2003). 
 
1.6.2.3 Regulation 
The vital role that Tregs play in maintaining peripheral tolerance is evidenced by the 
autoimmune and allergic phenotypes displayed by patients with IPEX syndrome 
(described in section 1.5.4.1), and by multiple studies demonstrating that targeted 
deletion of Tregs leads to autoimmune manifestations [reviewed in (Sakaguchi et al., 
2008)]. Regulatory cell subsets such as iTregs and Tr1 cells, have also been shown to 
be important in the induction of peripheral tolerance (Thompson et al., 2011, Meiler 
et al., 2008), and will be discussed later in the context of immunotherapy. 
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Mechanisms such as bystander suppression and linked suppression are particularly 
applicable to the regulation pillar of tolerance, and have been demonstrated after the 
therapeutic induction of tolerance [discussed in (Larche and Wraith, 2005, Wraith, 
2009, Hochweller et al., 2006b)]. Bystander suppression refers to a situation where 
tolerance induced towards an epitope within one molecule (for example a protein), 
also results in tolerance towards epitope(s) within another protein. For example, 
Anderton et al found that inducing tolerance using a peptide contained within 
proteolipid protein (a constituent of myelin), followed by immunisation with whole 
myelin, induced tolerance to proteolipid protein and also to peptides derived from 
other myelin proteins (Anderton and Wraith, 1998). Bystander suppression has also 
been demonstrated in other studies (Backstrom and Dahlgren, 2004). Linked 
suppression refers to the scenario when tolerance induced towards one epitope within 
a protein leads to tolerance towards other epitopes within the same protein, and is 
thought to require both epitopes to be presented by the same APC [discussed in 
(Cobbold et al., 2010, Hochweller et al., 2006b)]. Linked suppression has been 
demonstrated in animal models of therapeutic tolerance induction (Bauer et al., 1997, 
Anderton and Wraith, 1998, Briner et al., 1993), and also recently in humans 
(Campbell et al., 2009).  
 
Another mechanism related to regulation is that of infectious tolerance where CD4+ 
T cells are induced to become Tregs through the effects of other Tregs [reviewed in 
(Cobbold et al., 2010)]. Shevach et al have recently proposed that this can occur by 
nTregs inducing FoxP3 expression in FoxP3- T cells via the actions of surface-bound 
TGF-β  (Shevach et al., 2008). 
 
In summary, peripheral tolerance harnesses mechanisms that comprise deletion, 
adaptation and regulation. Mechansims such as linked suppression hold particular 
interest for the field of therapeutic tolerance induction, and will therefore be further 
discussed in this thesis. 
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1.7 Allergic asthma 
1.7.1 Clinical aspects 
Asthma is a chronic inflammatory disease of the airw ys characterised by reversible 
airways obstruction and airway hyperresponsiveness (AHR), [reviewed in (Holgate, 
2008)]. In allergic asthma, bronchoconstriction occurs in response to aeroallergens, 
leading to symptoms such as wheeze, cough and shortness of breath (Haslett et al., 
2002). Allergic asthma is also associated with increases in the size and frequency of 
goblet cells within the airways; these produce mucous, further compromising airway 
patency (Holgate, 2008). Chronic inflammation leads to airway remodelling over 
time, which can lead to a non-reversible component of he airways obstruction 
(Holgate, 2008, Haslett et al., 2002).  
 
1.7.2 Epidemiology 
Asthma is a heterogeneous disease, however the majority of asthma is thought to be 
allergic in nature [discussed in (Kim et al., 2010)]. Asthma is a particularly apparent 
problem in the paediatric population since around 10-20% of children have a 
diagnosis of asthma, although this figure can vary between studies, often on account 
of variations in study design (Anderson et al., 2007, Punekar and Sheikh, 2009). 
Allergic asthma, together with other allergic diseas such as allergic rhinitis and 
allergic eczema, are a significant burden on the healt care system (Anandan et al., 
2009, Hoskins et al., 2000). Furthermore, the emergence of one allergic condition is 
often followed by additional allergic conditions (Punekar and Sheikh, 2009). Allergic 
eczema is the most common allergic condition to be initially diagnosed and, in many 
children, is later followed by the diagnosis of allergic asthma and/or allergic rhinitis 
(Punekar and Sheikh, 2009). Recently, Cadot et al have demonstrated that 
sensitisation to one aeroallergen can promote sensitisation to others (Cadot et al., 
2010). 
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1.7.3 The atopic march 
The observations described above have given rise to the concept of the “atopic 
march” whereby allergic sensitisation via the skin leads to allergic eczema, which in 
turn can progress to allergic rhinitis and/or asthma [reviewed in (Zheng et al., 2011)]. 
This is supported by studies demonstrating that mutations in the gene encoding 
filagrin, a protein important for the barrier function of the skin, are not only 
associated with the risk of atopic dermatitis (Palmer et al., 2006), but are also 
associated with the combination of asthma and atopic dermatitis (Rodríguez et al., 
2009). Recently, an association between filagrin deficiency, atopic dermatitis and 
peanut allergy has also been demonstrated (Brown et al., 2011). 
 
1.7.4 The hygiene hypothesis 
In 1989 Strachan hypothesised that the increased prvalence of allergic disease was 
as a result of a reduction in exposure to pathogens in childhood, as a consequence of 
the improved hygiene standards associated with modern living (Strachan, 1989). 
Strachan found that children from large families (particularly children born further 
down the birth order), were less likely to have allergic rhinitis or allergic eczema 
(Strachan, 1989). Subsequent studies have often supported this initial hypothesis. For 
example, children who live on a farm or attend day-c re early in life, both of which 
are associated with an increased exposure to potential pa hogens, have been shown to 
have a reduced risk of developing allergic disease (von Mutius and Vercelli, 2010, 
Nicolaou et al., 2008). Ever since, the “hygiene hypothesis” has continually been 
revisited, adapted and modulated. Nowadays, the hygiene hypothesis is no longer 
taken to be simply an imbalance between infection-induced Th1 responses and 
allergy-promoting Th2 responses, since this would not account for recent increases in 
Th1-mediated diseases such diabetes mellitus, nor thei reported association with 
allergic disease (Simpson et al., 2002). Such an interpretation of the hygiene 
hypothesis would also not support the protective rol  f Th2-inducing helminth 
infections against allergic disease (Yazdanbakhsh et al., 2002). More recently, there 
has been more emphasis on a dsyregulation facet to the hygiene hypothesis. Hence 
the influence of factors such as exposure to pathogens and microbial products in 
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early life (and even in utero), is now thought to be important in the development of 
regulatory responses, which together with Th1 respon es, may act to counteract 
allergic responses [discussed in (Warner, 2004)]. 
 
1.7.5 What constitutes an allergen? 
Many hundreds of allergens have been identified (which can be derived from sources 
such as house dust mite (HDM) faeces, pollen, animal dander, foods and insect-
venom) and, while no general consensus has been reached regards what constituents 
an allergen, certain features are often present [reviewed in (Traidl-Hoffmann et al., 
2009)]. Most allergens are proteins but, although structural similarities have been 
described for some allergens, the allergenicity of a protein cannot yet be predicted 
from structure alone (Traidl-Hoffmann et al., 2009). Particular biological activities of 
some allergens seem important for their allergenic potential. Some of the most well-
characterised (and common) allergens are derived from HDM faeces. HDM allergen 
contains proteins such as Der p1 which has protease activity and has been shown 
capable of inducing epithelial tight junction breakdown (Wan et al., 1999). This may 
lead to increased allergen uptake and presentation by APC beneath the epithelium 
and facilitate allergen sensitisation. Other allergens exhibit other biological 
characteristics that may aid their allergenicity. For example some allergens have 
lipid-binding properties. These can facilitate TLR activation and may activate innate 
immune cells (Karp, 2010). Indeed, pollen-associated lipid mediators (PALMS) have 
been shown to be capable of directly activating eosinophils, and the actions of 
PALMS on DCs can favour the induction of Th2 rather than Th1 responses (Gilles et 
al., 2009).  
 
Overall, allergens often possess properties that aid heir presentation to the immune 
system and facilitate the development of Th2 respones. Despite possessing these 
properties, most potential allergens remain innocuous f r the vast majority of people. 
So why do some people become allergic and others do not? 
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1.7.6 Genetic factors 
It is generally accepted that a complex interplay of genetic and environmental factors 
are implicated in the susceptibility to, and pathogenesis of, allergic asthma [reviewed 
in (Holloway et al., 2010)]. Although some HLA-associations do exist for asthma 
and for other allergic diseases, these are not as strong nor as consistent as, for 
example, is the case for some autoimmune diseases [ discussed in (Shiina et al., 
2004)]. The heterogeneous nature of asthma can also make it difficult to accurately 
assess genetic associations, since genetic studies hav  often investigated asthma as a 
whole, rather than studying asthma in respect to different phenotypic categories. That 
said, the majority of twin studies support a strong genetic component to asthma 
[discussed in (Koppelman et al., 1999)]. It is likely that a multitude of genetic factors 
are associated with asthma and that reciprocal interactions between these genetic 
factors and the environment are key (Holloway et al., 2010).  For example, as 
discussed in section 1.7.3, mutations in the gene ecoding filagrin, a protein 
important for epithelial integrity, have been associated with asthma (Rodríguez et al., 
2009). Genes implicated in the way in which the innate immune system responds to 
its environment, such as in TLRs, have also been associated with asthma (Tesse et 
al., 2011). As would be expected, genome-wide associati n studies (GWAS) studies 
also highlight a multitude of genes associated with T 2 immune responses 
(Holloway et al., 2010). Genes expressed by cells such as smooth muscle cells and 
fibroblasts, such as the disintegrin and metalloproteinase domain-containing protein 
33 (ADAM 33), have also been associated with asthma (Van Eerdewegh et al., 
2002). Mutations in such genes may be implicated in the airways remodelling seen in 
some asthmatic patients (Jie et al., 2009). 
 
It is thus likely that a combination of genetic factors and how these modify the 
body’s response to its environment, together with variations in environmental factors 
themselves, contribute to the pathogenesis of allergic asthma.  
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1.7.7 Early life influences 
There is evidence that in utero influences and early life events may alter the risk of a 
child developing allergy, including allergic asthma [discussed in (Warner, 2004)]. 
Initial priming to a vast number of environmental proteins appears to occur in utero 
(Prescott et al., 1998). Exposure of the fetus to environmental proteins and potential 
allergens has been proposed to occur via the placent  and the amniotic fluid (Warner, 
2004). 
 
Evidence suggests that, at birth, an infant’s immune response is skewed towards Th2 
responses (Prescott et al., 1998), and that the extent of these Th2 responses, and the 
degree to which they are modulated by Th1 and regulatory components of the 
immune response, may be shaped early in life (Warner, 2004). For example, 
mononuclear cells from cord blood of infants whose mothers were exposed to a 
farming environment, have reduced Th2 responses in vitro and increased regulatory 
T cells, when compared to control infants (Schaub et al., 2009). 
 
The potential for a pregnant mother’s diet to influence a child’s risk of allergic 
disease is also evident. Pregnant mothers have previously been advised to avoid 
highly allergenic foods such as peanuts, with the aim of reducing the risk of their 
child developing peanut allergy (McLean and Sheikh, 2010). However, recent 
evidence suggests that the opposite may in fact be true and has led to changes in 
advice for pregnant mothers (McLean and Sheikh, 2010). Either way, there is 
increasing interest in the effects of maternal nutrition upon a child’s risk of 
developing allergic disease. Influences such as matern l diet and other environmental 
factors have been proposed to lead to epigenetic changes in the fetus (Kabesch et al., 
2010). These are phenotypic changes that are not due o changes in DNA sequence 
(Kabesch et al., 2010). In this respect, alterations in DNA methylation have been 
found to be associated with allergic asthma in some animal models (Hollingsworth et 
al., 2008), and epigenetics in relation to allergy is likely to be an important area for 
future study (Kabesch et al., 2010).  
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1.7.8 Airway epithelium 
Abnormalities in, and responses of, airway epithelium are increasingly being 
attributed in the pathogenesis of allergic asthma [discussed in (Holgate et al., 2010)]. 
Epithelial damage has been found in bronchial biopsies from asthmatic children 
(Barbato et al., 2006). Such a reduction in epithelial integrity has been proposed to 
lead to increased allergen uptake (Holgate et al., 2010). Furthermore, primary 
epithelial cells derived from asthmatic patients appear to more readily undergo 
epithelial-mesenchymal transition than primary epithel al cells derived from non-
asthmatic patients (Hackett et al., 2009). Such cells were found to lose markers 
associated with epithelial cells and gain expression of molecules associated with 
mesenchymal cells (Hackett et al., 2009). This has been hypothesised to play a role 
in asthma-associated airway remodelling (Hackett et al., 2009, Holgate et al., 2010).  
 
The way in which epithelial cells respond to their nvironment is also likely to be 
implicated in the pathogenesis of allergic asthma. For example, thymic stromal 
lymphopoietin (TSLP) has been shown to be released by epithelial cells in response 
to TLR stimulation (Kato et al., 2007), and also in response to proteases present 
within allergens (Kouzaki et al., 2009). TSLP is known to promote Th2 responses 
through its actions on DCs (Ito et al., 2005). Such data point to an important role for 
airway epithelial cells in bridging the innate and adaptive immune responses. 
 
1.7.9 Experimental models of allergic airways infla mmation 
There continues to be debate as to how best to model allergic asthma in vivo. The 
majority of models of allergic airways inflammation (AAI) utilise the mouse, which 
does not naturally develop asthma [these models are revi wed in (Finkelman and 
Wills-Karp, 2008)]. There are key differences too in the anatomy of the mouse lung 
compared to the human lung. These include major differences in the gross anatomy 
such as the number of lung lobes and airway branches (Finkelman and Wills-Karp, 
2008). Importantly, some therapeutic approaches such as the blocking of Th2 
cytokines which have shown therapeutic effects in mice, have not shown widespread 
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efficacy when translated to asthmatic patients [discus ed in (Holgate, 2010)]. It is 
therefore important to remember the limitations of mouse models of AAI. That said, 
mouse models of AAI do represent an important tool f r the study of allergic asthma 
and for the initial development of therapeutic approaches.  
 
Acute models of AAI in mice often involve a sensitisation phase to a model allergen, 
followed by an airway inhalation phase [reviewed in (Nials and Uddin, 2008)]. Many 
allergens have been used, including antigens from HDM- and animal dander- derived 
allergens (Nials and Uddin, 2008). Chicken ovalbumin (OVA), is also often used as a 
model allergen mainly because of the availability of tools such as OVA-reactive 
transgenic mice (Barnden et al., 1998), which can aid mechanistic studies. Protocols 
for the induction of acute AAI vary widely in terms of exact time points, doses and 
routes of allergen exposure (Nials and Uddin, 2008). AAI can also be induced 
following adoptive transfer of allergen-reactive Th2 cells (as well as other CD4+ T 
cell subsets), and subsequent allergen challenge via the airways (McKinley et al., 
2008). Models also exist whereby allergen-pulsed DCs can induce AAI (van Rijt et 
al., 2005). Such approaches can induce disease with important similarities to human 
asthma such as eosinophil infiltration into the lungs, the development of allergen-
specific IgE, the presence of goblet cells in the airways and AHR (Finkelman and 
Wills-Karp, 2008).  
 
Many AAI protocols utilise BALB/c rather than C57BL/6 mice (Janssen et al., 1999, 
Takeda et al., 2001). This is because of the natural tendency of the BALB/c response 
to be towards a Th2 phenotype compared to the Th1 phenotype associated with 
C57BL/6 mice (Heinzel et al., 1989). As a result of this, AAI protocols involving 
BALB/c mice tend to require lower antigen doses than required for C57BL/6 mice 
(Janssen et al., 1999, de Vries et al., 2009). Thatsaid, C57BL/6 can be induced to 
develop all the features of AAI (although notably lung function changes are more 
difficult to detect) (Morokata et al., 1999, Takeda et al., 2001). Furthermore, the 
wealth of transgenic mice on the C57BL/6 background means that AAI models 
developed in C57BL/6 mice are likely to have an advantage in terms of rapid 
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mechanistic assessment. Thus when using AAI models decisions need to be made as 
to whether to use BALB/c mice (in which allergic response is easier to induce, lung 
function changes are usually measurable but future work requiring transgenics will 
be delayed), or C57BL/6 mice (where allergy is still inducible, transgenic tools can 
be readily employed, but with the caveat that lung function changes may be more 
difficult to detect). After weighing up the options the C57BL/6 background was 
chosen for this project. 
 
At present, AAI models are usually acute in nature and are likely to resolve over time 
(Leech et al., 2007a). There are continued efforts to develop and modify acute 
models of AAI which could offer new ways in which to model human asthma. 
Chronic AAI models are also being developed. These are particularly interesting 
with respect to their ability to induce airway remodelling, often a feature in chronic 
asthma (McMillan and Lloyd, 2004). There are also cntinued calls for the 
development of more epithelial-focused AAI models, in view of the apparent 
contribution of epithelial responses to the development of allergic responses in the 
airways (Holgate, 2010). 
 
1.7.9.1 The role of alum  
The alum preparation used to induce allergic sensitisation in many animal models 
(and used in this project), consists of a preparation of aluminium hydroxide and 
magnesium hydroxide [further discussed in (Flach et al., 2011)]. Similar preparations 
are also often used as adjuvants in vaccines for humans (Flach et al., 2011). 
Originally, alum was thought to primarily exert itsadjuvant properties by acting as a 
depot, enabling antigen to remain accessible for long periods of time, but this 
explanation is no longer widely accepted (Marrack et al., 2009). A recent study by 
Flach et al provides insight into how alum may exert its effects. They demonstrated 
that alum crystals strongly bind to lipid molecules in the cell membrane of DCs, but 
are not phagocytosed (Flach et al., 2011). These finding led to the hypothesis that 
soluble antigen is released from alum crystals and is then endocytosed into the DC, 
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by an undefined, non-phagocytic process (Flach et al., 2011). In response to alum 
crystal binding, DCs were shown to upregulate intercellular adhesion molecule 1 
(ICAM-1) and co-stimulatory molecules such as CD86.  ICAM-1 facilitated strong 
binding of DCs to CD4+ T cells via the lymphocyte function-associated antigen 1 
integrin [LFA-1, (Flach et al., 2011)]. Alum has previously been shown to increase 
the recruitment of other immune cells such as neutrophils, macrophages and 
eosinophils to the site of injection (Kool et al., 2008), yet Flach et al only found alum 
to be strongly bound to DCs and not to other cell types (Flach et al., 2011).  
Furthermore, exposing DCs in vitro to alum, then transferring them to recipient mice 
together with OVA, was sufficient to induce OVA-specific antibody responses 
(Flach et al., 2011). These data argue against an obligatory role for uric acid in the 
adjuvant properties of alum, as had been previously described (Kool et al., 2008), 
and strongly support a role for DCs in immune respon es induced using alum 
adjuvants. 
 
1.7.10 Cells implicated in allergic responses in th e lung 
1.7.10.1 Dendritic Cells 
DCs play a vital role in orchestrating CD4+ T cell responses in models of AAI 
[reviewed in (Lambrecht and Hammad, 2009)]. DCs are known to line the airways 
and are often found positioned beneath the epithelium where they are able to extend 
their processes between epithelial cells to facilitte sampling of antigens within the 
airway lumen (Lambrecht and Hammad, 2010). Conventional DCs highly express 
the molecule CD11c (Lambrecht and Hammad, 2009). In mouse models of AAI, 
depletion of CD11c positive cells using a CD11c-diptheria toxin receptor (DTR) 
system has been found to inhibit Th2 cells responses during allergen challenge, 
thereby reducing AAI (van Rijt et al., 2005). Furthermore, some of the therapeutic 
effects of inhaled corticosteroids are thought to be related to a reduction in DCs in 
the lung (Moller et al., 1996).  
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The work of Lambrecht et al, has greatly aided understanding of DC biology in the 
lung, particularly in relation to mice (Lambrecht and Hammad, 2009). Variations in 
the phenotype of DCs present in the non-inflamed versus the inflamed lung have 
been identified (Lambrecht and Hammad, 2009). The majority of DCs resident in the 
non-inflamed lung are thought to be CD11chi CD11b- MHC IIhi (Sung et al., 2006, 
Lambrecht and Hammad, 2009). During pulmonary inflammation, there is an influx 
of so-called “inflammatory DCs” into the lung, thought to mainly be derived from 
circulating blood monocytes (Hammad et al., 2009, Lambrecht and Hammad, 2009). 
But, not all DCs promote inflammation. Plasmacytoid DCs (pDCs), (typically 
CD11c+, Cd11b- PDCA-1+), have been implicated in the induction of tolerance 
towards inhaled proteins (de Heer et al., 2004).  
 
Factors produced by epithelial cells in response to the airway environment can 
influence DCs, and consequently affect the nature of the resultant T cell response. In 
mice, stimulation of TLR4 on epithelial cells has been shown to increase the 
production of cytokines such as IL-33 (Hammad et al., 2009). IL-33 can act on DCs 
via the receptor ST2 (Rank et al., 2009) and IL-33 stimulated bone-marrow derived 
DCs have been found to induce Th2 cytokines from naïve CD4+ T cells (Rank et al., 
2009). TLR4 stimulation of epithelial cells can also induce TSLP (Hammad et al., 
2009).  
 
DCs are thus instrumental in the development of Th2responses to allergen in the 
airways, representing a vital link between the innate and adaptive immune responses. 
Increasing evidence indicates that epithelial-DC interactions can alter the nature of 
the developing T cell response. 
 
1.7.10.2 Basophils 
Basophils have previously been proposed to play a key role as APCs during the 
initiation of Th2 CD4+ responses (Perrigoue et al., 2009). However, more rec nt 
studies have reaffirmed the importance of DCs as the predominant APC in models of 
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allergic disease and helminth infection (Hammad et al., 2010, Phythian-Adams et al., 
2010). In a model of HDM-induced AAI, Hammad et al found that, although 
basophils were recruited to mediastinal lymph nodes (mLN) following HDM 
inhalation, specific depletion of basophils caused only a limited reduction in the 
number of eosinophils in BAL, and did not reduce Th2 responses of mLN cells in 
vitro (Hammad et al., 2010). Furthermore, antigen presentatio  by basophils, in 
contrast to DCs, did not induce proliferation of naïve CD4+ T cells in that study 
(Hammad et al., 2010). The FCεR1 antibody used previously in other studies to 
deplete basophils, was found by Hammad et al to als re ult in depletion of FCεR1 
expressing DCs (Hammad et al., 2010). This led them to hypothesise that DC 
depletion, and not basophil depletion, was responsible for the reduction in Th2 
responses seen by others (Perrigoue et al., 2009). In support of this hypothesis, 
Phythian-Adams et al have found that depleting DCs by targeted depletion of 
CD11c+ cells, severely impaired the Th2-mediated protectiv  response to a helminth 
infection, whereas depletion of basophils had no significant impact (Phythian-Adams 
et al., 2010). Taken together these findings suggest that while in certain 
circumstances basophils may be involved in augmenting Th2 responses, the 
predominate APC implicated in inducing Th2 responses remains the DC. 
 
1.7.10.3 T cell responses in allergic asthma 
T cell responses are strongly implicated in the development of allergic sensitisation 
to allergens and in the pathogenesis of allergic asthma [(Corrigan et al., 1988, 
Robinson et al., 1993b, Walker et al., 1991) and reviewed in (Larché et al., 2003)]. 
Roles for many of the CD4+ T cell subsets in the pathogenesis of different asthma 
phenotypes have previously been proposed [discussed in (Lloyd and Hessel, 2010)], 
however Th2 cells are the subset most strongly associated with the development of 
allergy and allergic asthma (Larché et al., 2003). The focus of this section will 
therefore primarily be on Th2 cells; however roles for other T cells subsets such as 
Th17 and Th9 cells in allergic asthma will also be discussed.  
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1.7.10.4 Th2 cells 
In general, studies of allergic and allergic asthmatic patients have found that Th2 
responses play a vital role in the pathogenesis of allergy and allergic asthma 
[(Robinson et al., 1993a, Del Prete et al., 1993) and reviewed in (Larché et al., 
2003)]. Stimulation of peripheral blood mononuclear cells (PBMCs) from allergic 
patients usually elicits a strongly Th2 polarised rsponse, compared to that elicited 
from PBMCs from non-allergic patients (Movérare et al., 2000). Th2 cytokines also 
tend to predominate in the lung in allergic asthmatics. For example, Pilette et al 
found high levels of Th2 cytokines in bronchoalveolar lavage (BAL) from patients 
following allergen exposure, and increased levels of the chemokines CCL22 and 
CCL17 (known to be ligands for CCR4, expressed on Th2 cells), compared to non-
allergic controls (Pilette et al., 2004). Levels of these chemokines correlated both 
with the number of lymphocytes and levels of IL-5 and IL-13 in BAL (Pilette et al., 
2004).   
 
Animal models of AAI have consistently demonstrated that a Th2 response towards 
allergens generates features that often correspond with those seen in allergic asthma. 
These include the development of allergen-specific IgE, eosinophil infiltration into 
the lungs, goblet cell metaplasia and AHR, which can be all induced via allergen-
induced Th2 responses [reviewed in (Nials and Uddin, 2008)]. Furthermore, Th2 
polarised allergen-specific T cells can induce AAI upon adoptive transfer and 
subsequent allergen airway challenge of naïve recipients (Hansen et al., 1999). If Th1 
polarised cells are transferred, although features of pulmonary inflammation ensue, 
these are not consistent with the features of AAI (Hansen et al., 1999). 
 
The signature Th2 cytokines IL-4, IL-5 and IL-13, combine to promote AAI. Studies 
using mice deficient in specific Th2 cytokines, or using blocking antibodies, have 
aided  understanding of the contribution of different Th2 cytokines to AAI [reviewed 
in  (Larché et al., 2003)]. IL-13 is predominantly associated with goblet cell 
development and mucous production and AHR (Yang et al., 2001). IL-5 is mainly 
associated with eosinophilic responses (Hamelmann et al., 2000) and IL-4 probably 
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exerts a variety of effects including facilitation f class-switching to produce IgE and 
effects on mast cells [discussed in (Larché et al., 2003)]. Targeted depletion of 
GATA-3 in T cells has been found to significantly inh bit the development of AAI 
(Zhang et al., 1999). In some mouse models, Th1 cytokines such as IL-12 delivered 
into the lung, inhibit features of AAI, such as AHR and pulmonary eosinophilia 
(Schwarze et al., 1998). Furthermore, T-bet deficient mice have been found to 
spontaneously develop some features of AAI (Finotto et al., 2002, Finotto et al., 
2005). These studies imply that the antagonist effects of Th1 responses can be 
important for the inhibition of allergic Th2 responses.  
 
1.7.10.5  Th17 cells 
The role of Th17 cells in the pathogenesis of allergic asthma remains unclear 
[reviewed in (Lloyd and Hessel, 2010)]. Th17 responses have been identified as 
being prominent in particular groups of asthmatics such as those with severe, often 
neutrophilic phenotypes. Al-Ramli et al found that the frequency of IL-17 expressing 
cells was significantly higher in airway biopsies from severe asthmatics compared to 
asthmatics with mild or moderate asthma (Al-Ramli et al., 2009). IL-17 mRNA has 
also been found to be increased in induced sputum fro  some asthmatics and 
correlates with the presence of neutrophils in sputum (Bullens et al., 2006). In animal 
models, adoptive transfer of allergen-reactive Th17 cells followed by allergen 
challenge can induce some features of AAI – for example goblet cells and pulmonary 
cellular infiltration (McKinley et al., 2008). Howev r, a neutrophilic rather than 
eosinophilic picture usually develops (McKinley et al., 2008).  
 
The consensus appears to be that Th17 cells may be implicated in some asthma 
phenotypes, particularly those that are severe and h ve a more neutrophilic, rather 
than eosinophilic, phenotype.  
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1.7.10.6 Th9 Cells 
A role for Th9 cells in allergic asthma has also been postulated [reviewed in (Lloyd 
and Hessel, 2010)]. Some studies have found an increased frequency of IL-9 
expressing cells in the allergic asthmatic lung (Shimbara et al., 2000). Temann et al 
found that selective over expression of IL-9 in the lungs of mice led spontaneously to 
features of AAI (Temann et al., 1998). However, more recently McMillan et al found 
that the severity of OVA-induced AAI was not significantly different between IL-9 
deficient mice and wild type mice (McMillan et al., 2002). Therefore, although Th9 
producing T cells may be involved in promoting the features of AAI, IL-9 does not 
appear to be required for AAI to develop. 
 
1.7.10.7 T regulatory cells 
Tregs are likely to be involved in protecting against the development of allergic 
asthma [reviewed in (Lloyd and Hawrylowicz, 2009)]. Treg production of cytokines 
such as IL-10 (such as that produced by Tr1 cells), has been postulated to suppress 
allergic responses to aeroallergens and be involved in the therapeutic development of 
tolerance [(Francis et al., 2003, Campbell et al., 2009) and reviewed in (Hawrylowicz 
and O'Garra, 2005, Larché, 2005)]. 
 
Several findings particularly highlight the importance of regulatory cells in 
maintaining health in the airways. Patients with IPEX syndrome (resulting in loss of 
nTreg frequency or function), often have allergic manifestations, which can include 
asthma (Wildin et al., 2001). In mice, depletion of Tregs (using depleting antibodies 
against CD25), has been found to increase the severity of AAI, upon exposure to 
HDM (Lewkowich et al., 2005). In that study, this appeared to be as a result of 
increased pulmonary DC activation that occurred following Treg depletion 
(Lewkowich et al., 2005). Adoptive transfer of (polyclonal) iTregs in a model of 
HDM-induced AAI, has also been shown to reduce disease (Chen et al., 2003), as 
has adoptive transfer of allergen-reactive CD4+ CD25+ Tregs after allergic 
sensitisation and prior to allergen challenge (Kearley et al., 2005). In the latter study, 
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inhibition of AAI was found to be dependent on IL-10, although interestingly the 
source of this IL-10 was not derived from the transferred T cell population (Kearley 
et al., 2005). FoxP3+ Tregs have also been implicated in the natural resolution of 
AAI in mouse models (Leech et al., 2007a).  
 
The induction of Tregs is thus an attractive theraputic aim for the treatment of 
allergic asthma, and is further discussed below. 
 
1.7.10.8 Eosinophils 
Eosinophils are particularly important in the immune response to helminths 
[reviewed in (Shamri et al., 2010)] but are also strongly associated with allergy. 
Eosinophils are often found in BAL from asthmatics, and are usually present in 
mouse models of AAI (Schwarze et al., 1998, Robinson et al., 1993a, Tanizaki et al., 
1993, Janssen et al., 1999). Eosinophils can become activated in response to a range 
of danger signals such as TLR stimulation, uric acid, and in response to allergen-
associated molecules such as pollen-associated lipid mediators (PALMS) (Shamri et 
al., 2010, Kobayashi et al., 2010, Plotz et al., 2004). Eosinophils contain granules 
which can release a multitude of cytotoxic products, ytokines and growth factors 
which are capable of influencing the allergic inflammatory response [reviewed in 
(Shamri et al., 2010)]. Such a cocktail of eosinophil-derived products can damage 
epithelium and can influence airway remodelling [e.g. via the actions of growth 
factors such as vascular endothelial growth factor (VEGF) and cytokines such as 
TGF-β] (Bochner and Gleich, 2010). Cysteinyl leukotrienes released from 
eosinophils can induce bronchoconstriction and increase mucus production (Shamri 
et al., 2010, Sampson et al., 2000). In certain circumstances, eosinophils have also 
been shown to act as APCs and induce CD4+ T cell responses (Wang et al., 2007).  
 
IL-5 is known to be key for eosinophil maturation ad recruitment from the bone 
marrow [discussed in (Bochner and Gleich, 2010)], and ttempts have been made to 
utilise IL-5 blockade therapeutically. However, although murine AAI studies have 
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found therapeutic benefits of blocking IL-5 (Hamelmann et al., 1999a, Bochner and 
Gleich, 2010), initial clinical trials using a humanised IL-5 blocking antibody did not 
result in therapeutic effects in asthmatics, despit significantly reducing the 
frequency of eosinophils in blood (Leckie et al., 2000). More recently, this approach 
has been shown to reduce the frequency of severe asthm  exacerbations in carefully 
selected patients with high levels of eosinophilia in BAL (Haldar et al., 2009). 
 
1.7.10.9 Mast cells 
Mast cells are implicated in allergic responses because of their ability to release and 
synthesise an abundance of inflammation-promoting mediators and cytokines such as 
histamine, proteases, leukotrienes and factors suchas TSLP [(Okayama et al., 2009) 
and reviewed in (Metz and Maurer, 2007)]. Known to be important for innate 
responses to helminths, and in wound healing, mast cells often reside in the tissues 
and can be activated, for example through activation of TLRs or complement 
components [(Nigo et al., 2006) and reviewed in (Stone et al., 2010)]. Mast cells also 
express the high affinity IgE receptor FcεR1. When IgE binds to multiple sites on an 
allergen and then binds to FcεR1 receptors on a mast cell’s surface, cross-linking of 
FcεR1 receptors induces mast cell degranulation (Stone et al., 2010, Segal et al., 
1977). Mast cells have been found to be particularly increased in the lung 
parenchyma of patients with uncontrolled allergic asthma (Andersson et al., 2011). 
The effects of mast cell derived mediators are diverse but include; direct effects upon 
smooth muscle contractility (driving bronchoconstriction), increased vascular 
permeability, increased mucous production and effects on other cell types such as 
eosinophils (Metz and Maurer, 2007, Alkhouri et al., 2011, Vliagoftis et al., 2004).   
 
1.7.11 Allergen-specific IgE 
In health, IgE is found in low concentrations in serum [discussed in (Stone et al., 
2010)]. Allergic individuals develop allergen-specific IgE, which can then bind to 
IgE receptors, such as FcεR1, present on mast cells. FcεR1 is also present on 
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basophils and DCs (Holgate et al., 2009) and binding of allergen-IgE complexes to 
DCs facilities allergen uptake and presentation (Maurer et al., 1998).  
 
The presence of allergen-specific IgE indicates that an individual has become 
sensitised to that allergen, however this does necessarily translate to clinical 
manifestations of allergy (Celik-Bilgili et al., 2005). As a general rule, the higher the 
level of allergen-specific IgE in a patient’s serum, the more likely it is that they will 
display clinical allergy to that allergen (Celik-Bilgili et al., 2005). Such associations 
led to the development of the humanised monoclonal IgE blocking antibody 
Omalizumab, which can bind to circulating IgE resulting in a reduction of IgE in 
serum (Holgate et al., 2009). This also reduces the expression of FcεR1 receptors on 
cells such as mast cells, reducing the likelihood of allergen-induced mast cell 
degranulation (Holgate et al., 2009). Omalizumab is not effective in all patients and 
is an expensive treatment modality (Holgate, 2010). This means that the use of 
Omalizumab is currently restricted to patients with severe asthma. This targeted 
approach has been found to be effective in improving asthma control in some 
patients (Rodrigo et al., 2011). 
 
In summary, allergic asthma results from a complex interplay of immunological 
responses directed towards allergen(s). Evidence sugge ts that allergen-reactive Th2 
cells, whose effector responses are important for the recruitment of eosinophils, the 
development of allergen-specific IgE and features such as goblet cell hyperplasia, 
play a key role in the pathogenesis of allergic asthma, as summarised in Figure 1.3.
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Figure 1-3: Th2 cells can induce many of the features of allergic asthma through their responses 
to inhaled allergen
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1.7.12 Current treatments for allergic asthma 
Reducing a patient’s exposure to an allergen is vital to improve the symptoms of 
allergic asthma (van den Bemt et al., 2004). However, in practice this can often be 
difficult as is the case for allergens such as HDM or pollen, which are found 
ubiquitously in the environment. The mainstay of pharmacological treatment for 
allergic asthma involves treating symptoms as they arise using β2-agonist inhalers, 
which induce bronchodilatation (Haslett et al., 200). In addition, corticosteroids 
(either delivered locally via inhalation, or in more severe cases, given systemically) 
are used to non-specifically dampen allergic respones. Add-on treatments can 
include drugs such as leukotriene receptor antagonists and rarely, in severe steroid-
resistant asthma, the IgE blocking antibody Omalizumab (Haslett et al., 2002). 
Adequate treatment of other manifestations of allergic disease such as allergic 
rhinitis, can also improve asthma (Fuhlbrigge and Aams, 2003). Current 
pharmacological treatments are both vital and efficacious for the management of 
allergic asthma, however none of these seem to modify disease progression (Guilbert 
et al., 2006).  
 
The increasing awareness of allergy as a systemic disease and the potential for an 
“atopic march” means that treatments that could be giv n early in life, and that 
reduce disease progression, must remain a key goal.This is a primary aim of 
allergen-specific immunotherapy.  
 
1.8 Allergen-specific immunotherapy  
1.8.1 Specific immunotherapy (SIT) for allergy and allergic asthma  
In health, tolerance exists towards aeroallergens. Specific immunotherapy (SIT) is 
built upon the concept of therapeutically inducing tolerance to an allergen. It has 
long been known that administering a protein such as an allergen in the absence of 
danger signals i.e. in the absence of adjuvant, can tolerise T cells reactive towards 
epitopes within that protein. The first clinical report of specific immunotherapy was 
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from Noon, who found that injecting hayfever patiens subcutaneously with grass 
pollen could improve their symptoms (Noon, 1911). 
 
Animal models have consistently demonstrated that administration of whole protein 
allergen in the absence of adjuvant can induce tolerance to that allergen and improve 
allergic sensitisation and AAI. Many routes of administration have proven effective 
including oral, subcutaneous, and intranasal approaches (Nakao et al., 1998, 
Ostroukhova et al., 2004, Janssen et al., 1999). Furthermore, whole protein SIT in 
animal models has been found to be effective if given prior to initial sensitisation 
(Keller et al., 2006), following sensitisation but prior to airway challenge (Vissers et 
al., 2004), and also after airway challenge and before re-challenge (Boudousquié et 
al., 2009). SIT is used on a relatively small scale in some allergy clinics in the UK 
and is currently predominantly used in patients with insect venom allergies, allergic 
asthma (usually mild or moderate forms), and severe allergic rhinitis [reviewed in 
(Calderón et al., 2011)]. Different regimes for SIT administration exist, however 
treatment most often involves subcutaneous administration of protein allergen with 
escalating doses given weekly and a maintenance dos (usually given around once 
every 6 weeks) given thereafter for up to 5 years [reviewed in (Frew, 2010)]. 
Individual clinical trials have reported clinical improvements with SIT in various 
allergic settings, but variations in patient criteria, disease phenotypes, SIT regimes 
and outcome measures, present a challenge to assess the overall efficacy of SIT in 
allergic disease [discussed in (Calderón et al., 2011)]. Recent Cochrane systematic 
reviews assessing outcomes from randomised-controlled SIT trials have provided 
valuable evidence regards the effectiveness of SIT in patients with respiratory 
allergy. These findings can be summarised as follows:- 
 
i) SIT can improve allergic rhinitis (Calderon et al.,2007). 
ii)  A particular form of SIT known as sublingual immunotherapy (SLIT) is 
also efficacious in the treatment of allergic rhinitis (Radulovic et al., 
2010). However, others have noted that SLIT appears to be less effective 
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than subcutaneously delivered SIT [further discussed in (Akdis and 
Akdis, 2009)]. 
iii)  There is some evidence that SIT can be effective at improving allergic 
asthma (Abramson et al., 2010). 
 
Evidence also suggests that if maintenance SIT treatments are continued for 3-4 
years, improvements can be maintained in the longer-term (Durham et al., 2010). 
 
1.8.1.1 Proposed mechanisms involved in SIT 
An array of mechanisms have been proposed to be involved in successful induction 
of tolerance using SIT [reviewed in (Akdis and Akdis, 2009)]. Janssen et al 
examined the effects of SIT using OVA given subcutaneously or intranasally in a 
mouse model of OVA-induced AAI (Janssen et al., 2000a). Using trackable, OVA-
reactive T cells, they found that subcutaneous SIT resulted in an initial rapid and 
widespread T cell response which led to tolerance (Janssen et al., 2000a). In contrast, 
intranasal SIT did not induce tolerance and was associated with a slower, more 
localised T cell response. This led them to hypothesise that a “strong, synchronised 
and systemic T cell response” promoted tolerance induction (Janssen et al., 2000a). 
 
Other SIT studies in mice have suggested a role for the induction of FoxP3+ Tregs, 
and associated TGF-β production, in SIT-mediated tolerance (Ostroukhova et al., 
2004). Interestingly, a study by Boudousquié et al suggested an initial role for 
FoxP3+ Tregs following SIT, but demonstrated that TGF-β expressing CD4+ CD25- 
cells, which also developed later in that model, were able to transfer tolerance to 
recipient mice (Boudousquié et al., 2009). 
 
The induction of IL-10 has also been implicated in tolerance induced by SIT in 
animal models. Vissers et al found that SIT using subcutaneous OVA after 
sensitisation reduced the severity of AAI (Vissers t al., 2004). Although the IL-10 
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concentration in BAL did not increase, a fall in BAL IL-5 levels occurred, resulting 
in an increased IL-10:IL-5 ratio. Blocking IL-10 inthat study significantly inhibited 
the tolerogenic effects of SIT (Vissers et al., 2004). IL-10 has similarly been 
identified as being important for tolerogenic outcomes in several human SIT studies. 
IL-10 has been found to be important for the natural acquisition of tolerance to the 
bee venom allergen, phospholipase A2 (PLA), in beekeepers (Meiler et al., 2008). In 
keeping with these findings, Akdis et al found that bee-venom SIT given to bee-
venom allergic patients reduced the production of Th2 signature cytokines (and IFN-
γ) in response to PLA, but increased IL-10 production (Akdis et al., 1998). In that 
study, the frequency of IL-10 positive CD4+CD25+ T cells was increased shortly 
after SIT (Akdis et al., 1998). IL-10 has also been attributed to tolerance induced 
following grass pollen SIT (Francis et al., 2003). In that study, although SIT did not 
alter the in vitro Th2 (or IFN-γ) recall responses of PBMCs to grass pollen, 
significantly more IL-10 was produced after grass pollen stimulation of PBMCs from 
SIT-treated patients, compared PBMCs from non-SIT controls (Francis et al., 2003). 
 
The mechanisms of action of SIT therefore still remain unclear and may vary with 
different modes of application. However, the induction of IL-10 has often been 
attributed to tolerance induced by SIT.  
 
1.8.1.2 Impact of SIT on multiple allergen sensitis ations 
One of the most attractive aspects of allergen-specific therapy is the potential for 
tolerance induction to modify the course of disease. This is perhaps most easily 
envisaged if the allergen-specific therapy induces regulatory mechanisms, since these 
may have the potential to regulate against additional allergic responses, e.g. via 
bystander or linked suppression. There is some evidence that SIT given to induce 
tolerance to one allergen, may reduce the likelihood of future sensitisation to 
additional allergens.  Des Roches et al compared th development of new allergen 
sensitisations in children who were mono-sensitised to HDM, and who were either 
receiving SIT against HDM or not receiving SIT (Des Roches et al., 1997). 
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Interestingly, while no children in the SIT group developed sensitisation to additional 
allergens, 10 out of 22 children in the non-SIT group did, during the 3 year follow-up 
period (Des Roches et al., 1997). A more recent, larger study compared the 
percentage of mono-sensitised HDM allergic children who developed sensitisation to 
additional allergens over a total period of 6 years. For the first 3 years, children either 
received SIT against HDM or no SIT (Pajno et al., 2001). Only 33% of the non-SIT 
group did not develop sensitisation to additional allergens, compared to 75% of the 
SIT treated group (Pajno et al., 2001). There is also some evidence that SIT for 
allergic rhinitis can reduce the risk of a child going on to develop asthma, even up to 
7 years after cessation of SIT (Jacobsen et al., 2007). 
 
Viewed together, these findings therefore enable the tentative proposal shown in 
Figure 1.4, that early treatment of allergic children with allergen-specific therapy 
could reduce the progression of disease, and possibly even prevent allergic asthma 
from developing. 
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Figure 1-4: Proposed impact that early treatment with allergen-specific immunotherapy may 
have upon allergic disease progression
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1.8.1.3 Is SIT safe? 
SIT comes with risks. The administration of whole protein allergen to allergic 
patients incurs the risk of inducing severe allergic reactions, including anaphylaxis, 
by facilitating cross linking of IgE on mast cells and inducing degranulation 
[reviewed in (Peavy and Metcalfe, 2008)]. SIT is asociated with the induction of 
allergic responses and, although rare, fatalities have been reported (Borchers et al., 
2004). Caubet et al found that systemic allergic reactions (though not necessarily 
anaphylaxis) occurred after around 4% of  SIT injections (Caubet and Eigenmann, 
2008). In that study, systemic reactions were more likely to occur in asthmatics. A 
systematic review of SIT in asthmatics concluded that overall, the risk of a systemic 
allergic reaction occurring was around 1 for every 9 allergic asthmatic patients 
treated with SIT (Abramson et al., 2010).  
 
Hence, although SIT can improve allergic disease, it is associated with the risk of 
severe allergic reactions, particularly in allergic asthmatics. This has meant that SIT 
is not currently recommended in the UK for the treatment of severe allergic 
asthmatics [discussed in (Calderón et al., 2011)]. Furthermore, for allergen-specific 
immunotherapy to have most impact upon the course of disease (as proposed in 
Figure 1.4), treatment may need to be targeted to young children. The risks 
associated with SIT may be too great for such an approach to be widely 
implemented. The development of safer approaches to allergen-specific 
immunotherapy is therefore highly desirable. Peptide immunotherapy (PIT) offers 
such an approach. 
 
1.9 Peptide Immunotherapy (PIT) 
Peptide immunotherapy (PIT) refers to the administration of peptides containing 
immunodominant T cell epitopes, with the aim of inducing tolerance towards the full 
antigen [reviewed in (Larche and Wraith, 2005)]. This approach has been shown in a 
range of animal models to be capable of inducing T cell tolerance [reviewed in 
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(Anderton, 2001, Larche and Wraith, 2005)]. The main advantage of PIT over whole 
protein SIT is that the peptides administrated are short in length meaning they do not 
facilitate cross linking of IgE on mast cells, thus are generally thought to reduce the 
risk of allergic reactions such as anaphylaxis. Furthermore if IgE is generated 
towards a peptide this is likely to recognise a different conformation than found on 
whole protein antigens [discussed in (Larché, 2007, Larche and Wraith, 2005)]. 
Hence, although Pedotti et al reported (IgG1-mediat) anaphylaxis in a model of 
experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple 
sclerosis (Pedotti et al., 2001), this occurred in the context of disease induction using 
immunisation with peptide, rather than protein (Pedotti et al., 2001). 
 
1.9.1 Evidence for therapeutic effects of PIT in an imal models 
1.9.1.1 Autoimmune disease 
Initial studies of PIT were carried out in animal models of EAE. Inflammatory T cell 
responses directed towards components of myelin are important for the pathogenesis 
of EAE (Libbey et al., 2010). It has consistently been shown that administration of 
soluble myelin-derived peptides in the absence of adjuv nt can reduce/abrogate EAE, 
when disease is induced via immunisation with the same peptide in complete 
Freund’s adjuvant (CFA) (Liu and Wraith, 1995, Metzl r and Wraith, 1993, Gaur et 
al., 1992). PIT has also been shown to be effective therapeutically in other models of 
autoimmune disease (Daniel and Wegmann, 1996, Bayrak and Mitchison, 1998). 
Similarly to SIT, multiple routes and regimes of peptide administration are capable 
of inducing tolerance [discussed in (Larche and Wraith, 2005)]. 
 
1.9.1.2 Using PIT for the treatment of allergic dis ease 
In mice, PIT has been found to induce tolerance in some allergy-relevant models. 
Various models have been employed in which PIT can be give prophylactically (i.e. 
prior to sensitisation) (Janssen et al., 1999), after sensitisation and prior to challenge 
(Bauer et al., 1997), or after challenge and prior to rechallenge (Campbell et al., 
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2009). Each approach has its own merits. A prophylactic approach has often been 
favoured for PIT in various allergic and autoimmune models (Janssen et al., 1999, 
Konkel et al., 2010). It has generally been felt that this approach may be the most 
likely to induce tolerance and hence is valuable whn trying to assess whether or not 
tolerance can be induced using PIT in a particular model. Clinically, however, it is 
difficult to envisage a situation where PIT is given to a patient prior to sensitisation, 
although this could perhaps occur if an approach was eventually developed which 
involved giving PIT against a variety of common allergens to children at high risk of 
atopic disease. Campbell et al have recently demonstrated therapeutic effectiveness 
in a model where PIT was administered between challenge and re-challenge 
(Campbell et al., 2009). That type of approach has advantages in terms of clinical 
translation as it could mirror the situation of using PIT to treat a patient who has 
allergic asthma.  
 
Studies investigating the effect of PIT on allergic d sease can be divided in those 
investigating the effects of PIT on the response to allergen/CFA induced responses 
(hence modelling Th1 rather than Th2 responses), and those examining the effects of 
PIT in allergic disease. 
 
1.9.1.2.1 PIT in allergen/CFA immunisation models 
Hoyne et al investigated PIT in a model where mice were immunised with Der p 1 in 
CFA (Hoyne et al., 1993). They found that PIT using a peptide containing an 
immunodominant T cell epitope from Der p 1 induced tolerance, resulting in reduced 
in vitro recall responses of LN cells to both the peptide and to Der p 1 (Hoyne et al., 
1993). Fel d 1 is a common cat allergen which is comp sed of two polypeptide 
chains. Briner et al found that PIT using two immunodominant peptides from 
polypeptide chain 1 of Fel d 1, prior to immunisation with chain 1 in CFA, induced 
tolerance both to the peptides themselves and also reduced in vitro recall responses to 
chain 1 (Briner et al., 1993). There was also evidence suggestive of linked 
suppression in that study (Briner et al., 1993).  
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1.9.1.2.2 PIT in models of allergic sensitisation a nd AAI 
PIT in models of allergic sensitisation and AAI are limited in number.  In an allergic 
sensitisation model where mice were sensitised to the birch pollen allergen bet v 1  
using alum as an adjuvant, Bauer et al found that PIT using one immunodominant 
peptide abrogated in vitro proliferative responses of LN cells to the peptide (Bauer et 
al., 1997). Significant reductions in proliferation f LN cells in response to Bet v 1 
were only found in mice given PIT after sensitisation and not if PIT was given prior 
to sensitisation, although the reasons for this were unclear (Bauer et al., 1997).  In a 
recent study, Campbell et al examined the effects of PIT using an immunodominant 
peptide from Fel d 1, in a model of Fel d 1-induced AAI (Campbell et al., 2009). PIT 
using one Fel d 1-derived peptide was given after sensitisation and challenge, but 
before re-challenge (Campbell et al., 2009). This wa  found to significantly improve 
AAI, and again there was evidence of linked suppression (Campbell et al., 2009). 
 
Importantly, not all models of PIT in allergy have resulted in improvements. Janssen 
et al found that in a model of OVA-induced AAI, PIT using the reported 
immunodominant epitope, pOVA 323-339 (pOVA), given after OVA sensitisation 
and prior to OVA challenge, increased the severity of AAI (Janssen et al., 1999). 
Furthermore, in a model of OVA sensitisation (and not AAI), Barbey et al found that 
intranasal administration of pOVA prior to OVA/alum sensitisation, did not induce 
tolerance to OVA, whereas intranasal application of OVA did (Barbey et al., 2004). 
 
1.9.2 Evidence of therapeutic effects of PIT from h uman studies 
1.9.2.1 Autoimmunity 
PIT has been used in some patients with autoimmune disease. Clinical improvements 
have been seen in some studies in patients with rheumatoid arthritis (Koffeman et al., 
2009) and multiple sclerosis (Warren et al., 2006).  However, early clinical trials of 
PIT in multiple sclerosis patients had to be halted because of hypersensitivity 
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reactions (later found to be IgG-mediated) and possible disease exacerbations 
(Bielekova et al., 2000, Kappos et al., 2000). The peptides used in those studies 
contained alterations in their amino acid sequences, d igned to improve their 
therapeutic effects. Concerns have been raised over such altered peptide ligands 
(APLs), for although they can be designed to promote certain responses from 
responding T cells (Janssen et al., 2000b), or reduce side effects such as IgG1 
binding (Leech et al., 2007b), in practice their effects can be unpredictable [reviewed 
in (Anderton, 2001)]. 
 
1.9.2.2 Allergic disease 
The PIT studies that have taken place in the context of allergy mainly relate to cat 
allergy and bee venom allergy [reviewed in (Moldaver and Larche, 2011)]. Initially, 
PIT using two 27 amino acid long, immunodominant peptides from Fel d 1 were 
used clinically. Several clinical trials demonstrated some clinical improvements in 
some cat allergic patients following PIT, however some patients developed early 
allergic reactions (Norman et al., 1996, Maguire et al., 1999, Pene et al., 1998). It 
appeared that the peptides used in those trials could, in some instances, enable IgE 
cross linking on mast cells.  This led to the use of multiple shorter 15-17 amino acid 
peptides which overlapped and encompassed the majority of the sequence of the Fel 
d 1 protein allergen. Again, improvements in readouts s ch as rhinitis symptoms and 
late-phase cutaneous responses to allergen were demonstrated in some patients 
(Alexander et al., 2005, Oldfield et al., 2002). PIT using immunodominant epitopes 
from the bee venom allergen PLA, have also been demonstrated to significantly 
improve late phase skin reactions induced in respone to bee venom (Tarzi et al., 
2006). 
 
To summarise, although PIT holds promise as potentially safer approach to allergen-
specific immunotherapy, outcomes are variable. If PIT is to be effectively translated 
to the allergy clinic, then further understanding of the mechanisms of action of PIT, 
and of potential factors influencing therapeutic outc mes, is required. 
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1.9.3 Mechanisms involved in PIT 
Mouse models have enhanced our understanding of the mechanisms involved in 
tolerance induction using PIT. Some of these have already been discussed in section 
1.6.2 and the mechanistic effects of PIT will also be discussed in detail in subsequent 
chapters. High dose PIT is often associated with deletion of peptide-reactive T cells 
(Hochweller and Anderton, 2005, Konkel et al., 2010). Such protocols also often 
induce a population of anergic cells (Konkel et al., 2010, Pape et al., 1998). The 
induction of FoxP3+ T regulatory cells following PIT has not often been reported. 
However, Kretschmer et al found that FoxP3+ cells were induced following 
administration of a peptide that was specifically targeted to the DC (Kretschmer et 
al., 2005), and very low dose PIT given subcutaneously and in multiple doses has 
also been postulated to have led to iTreg induction in another study (Kang et al., 
2005). The induction of IL-10 following PIT has been cited in clinical (Campbell et 
al., 2009, Tarzi et al., 2006) and animal (Gabryšová and Wraith, 2010) studies. 
Furthermore, IL-10 dependent mechanisms have also been attributed to linked 
suppression seen following PIT in cat allergic patients  (Campbell et al., 2009). 
Interestingly, Gabrysova et al found that peptides with high affinity for MHC, that 
thus provide a strong signal to responding T cells, promoted the production of IL-10 
from peptide-reactive T cells in a model using repeated intranasal peptide 
administrations (Gabryšová and Wraith, 2010). These effects are discussed further in 
Chapter 6. 
 
Thus, the mechanisms of tolerance effected by PIT appe r to vary in different 
models. This has important implications for how PIT can best be translated to the 
clinic in order to maximise clinical efficacy. 
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1.9.4 Issues relevant to the clinical application o f PIT 
1.9.4.1 Route, regime and dose  
It is likely that the nature of the peptide, the route of delivery and the PIT regime 
employed all have the potential to affect the mechanism(s) of tolerance induction 
and/or the efficacy of PIT. The induction of regulatory responses using PIT is highly 
desirable because of the potential to generate long-term tolerance to an allergen, and 
the possibility that this may regulate immune responses to other allergens. In 
contrast, induction of an adaptive tolerance form of anergy presents the problem that, 
upon removal of the peptide, anergic cells may return o pathogenicity (Schwartz, 
2003). If PIT is to be given to young children, then PIT regimes that start with a low 
dose and then escalate, are likely to represent the safest approach. This could also 
bring advantages by enhancing the likelihood of inducing IL-10 producing regulatory 
cells [discussed in (Sabatos-Peyton et al., 2010)]. Furthermore, if particular delivery 
regimes were found to induce bystander and/or linked suppression, this would also 
be likely to be advantageous to the overall goal of m difying progression of allergic 
disease. 
 
1.9.4.2 HLA variation 
The issue of HLA diversity represents a particular challenge regarding which 
peptides to use in a diverse population, since the expression of MHC II molecules 
varies widely between individuals. MHC diversity means that for any given allergen, 
immunodominant T cell epitopes can vary between indiv duals [discussed in (Larché, 
2008)]. One approach might be to characterise the T c ll immunodominant epitopes 
within an allergen on a personalised basis, but this is unlikely to be feasible in terms 
of practicality and cost. Importantly however, peptides are often promiscuous - 
meaning they can bind to many different MHC II molecules (Friedl et al., 1999, 
Kobayashi et al., 2000). This is partly on account of he non-polymorphic nature of 
the HLA-DR α chain which results in fundamental similarities between different 
HLA-DR molecules. Thus one or several peptides might be capable of inducing 
tolerance in HLA diverse individuals. Furthermore, using multiple overlapping 
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peptides as adopted in some recent studies (Campbell et al., 2009), should also 
promote the induction of T cell tolerance in HLA-mis atched patients.  
 
1.9.4.3 Could PIT induce immunity and not tolerance ? 
The induction of tolerance is associated with peptide presentation by non-activated 
DCs (Hochweller and Anderton, 2005). Therapeutic administration of peptides 
theoretically risks inducing an inflammatory response, rather than a tolerogenic 
response, if DCs are activated. One particular situation where this could be envisaged 
is during illness such as bacterial or viral infection, when PAMPs could activate 
DCs. Currently SIT is contraindicated during acute systemic illness (Zuberbier et al, 
2010), as is also the case for routine vaccinations, a d it would probably also be 
advisable to adopt this approach for PIT. The effects of mild viral infection upon PIT 
are, however, unknown. Exposure to allergen at the im of respiratory viral infection 
can lead to allergic sensitisation, (O'Donnell and Openshaw, 1998) and intranasal 
SIT at the time of influenza virus was found to prevent tolerance and exacerbate AAI 
(Tsitoura et al., 2000). It is, therefore, possible that PIT given via an intranasal route 
at this time, could interfere with tolerance induction or induce an inflammatory 
response. In order to thoroughly address such issues, initially requires the 
development and optimisation of in vivo models of PIT in allergic respiratory 
disease. 
 
1.10 Concluding remarks 
PIT offers promise as an allergen-targeted therapy with the potential not just to 
improve the symptoms of allergic disease, but also to modify disease progression. 
PIT represents a potentially safer alternative to SIT, which is particularly pertinent to 
allergic asthmatics since they have an increased risk of SIT-induced adverse 
reactions. Several clinical trials have shown that PIT can have therapeutic effects in 
allergic respiratory disease. However, there remains uncertainty about the 
mechanisms involved in successful PIT, how these may vary with different PIT 
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regimes and the effects of potential confounding factors such as concurrent viral 
infection. Improved animal models of PIT in allergic disease and AAI should aid our 
understanding of these issues, thus facilitating progression of PIT into the allergy 
clinic.
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1.11 Hypothesis and aims of this project 
The following points influenced the way in which this project was constructed:- 
 
• Further development of models of PIT in allergic sensitisation and allergic 
airways disease are required in order to facilitate further mechanistic 
assessment of the effects of PIT in allergic disease. 
• The model allergen chicken ovalbumin (OVA) is often used in allergic 
models. OVA can induce AAI and transgenic mice are available with CD4+ T 
cells which have OVA-reactive TCRs (Barnden et al.,1998). Congenic 
marking of such cells enables OVA-reactive T cells to be tracked in vivo. 
• The induction of tolerance using SIT has previously been associated with the 
generation of “strong, synchronous and systemic T cell responses” (Janssen et 
al., 2000a) 
• High dose, intravenous PIT using the reported immunodominant epitope of 
OVA (pOVA 323-339) has previously been demonstrated to be capable of 
inducing tolerance of pOVA-reactive T cells via the initial induction of a 
vigorous and widespread T cell response (Hochweller and Anderton, 2005, 
Konkel et al., 2010). 
• The induction of linked suppression is therapeutically desirable. 
 
1.11.1 Hypothesis 
This thesis investigated the hypothesis that strong, systemic T cell responses induced 
by intravenous administration of soluble pOVA 323-339 (pOVA) will induce:-  
 
i) tolerance to pOVA 
ii)  linked suppression to any additional OVA T cell epito es, hence 
improving OVA-induced AAI. 
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1.11.2 Aims 
The aims of this project were to:- 
 
i) Establish a model of OVA-induced AAI in C57BL/6 mice and 
characterise the immune parameters within it. 
ii)  Assess the effects of pOVA PIT, given intravenously and in high dose, on 
the severity of AAI. 
iii)  Assess the effects of pOVA PIT on known, trackable pOVA-reactive 
CD4+ T cells in models of OVA-induced allergic sensitisa on and AAI. 
iv) Assess whether pOVA PIT induces linked suppression to any additional T 
cell epitope(s) within OVA. 
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2 Materials and Methods 
2.1 Mice 
Female C57BL/6J and BALB/c mice were purchased from Charles River (Kent, 
UK). All mice were maintained in specific pathogen-free conditions at the University 
of Edinburgh, UK and fed on OVA-free diets. Age-matched, 6-12 week old female 
mice were used for all experiments. The experimental unit used for statistical 
analysis was individual mice. Each cage consisted of one treatment group, decided at 
random. A colony of OT-II transgenic mice expressing an I-Ab-restricted TCR 
reactive to OVA peptide 323-339 (Barnden et al., 1998), congenically labelled with 
CD45.1 was maintained at the University of Edinburgh, UK. All experiments were 
conducted under UK home office regulations and had local ethical approval. 
 
2.1.1 Phenotyping OT-II mice 
The OT-II mice used were recombination activating gene (RAG) sufficient thus they 
retain the potential for α and β chain rearrangement. However, all OT-II mice were 
screened using flow cytometric analysis of blood taken after weaning to ensure the 
presence of the Vβ5.1 and Vα2 TCR chains on >90% CD4+ cells. The presence of 
the congenic marker CD45.1 and the absence of the C57BL/6 CD45 isoform CD45.2 
was also confirmed (Appendix 1). Splenocytes from rede ived OT-II mice were 
confirmed to proliferate in vitro to OVA and to pOVA (data not shown).  
 
2.2 General reagents 
2.2.1 Wash buffer 
RPMI 1640 (Gibco, Paisley, UK) 
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2.2.2 Tissue culture medium 
RPMI 1640 (Gibco) supplemented with 2mM L-glutamine, 100U/ml penicillin, 
100µg/ml streptomycin (all from PAA, Austria), 50µM 2-β-mercaptoethanol and 5% 
heat-inactivated fetal calf serum [HI-FCS (Gibco)].  
 
2.2.3 Flow cytometry buffer (FACS buffer) 
Phosphate-buffered saline [PBS (Gibco)] supplemented with 1% bovine serum 
albumin (BSA) and 0.05% sodium azide (both from Sigma-Aldrich, Dorset, UK). 
 
2.2.4 MACS buffer 
Hanks Balanced Salt Solution (Gibco) supplemented with 2% HI-FCS (Gibco) and 
2mM EDTA (Sigma-Aldrich). 
 
2.3 Antigens 
Grade V chicken Ovalbumin (OVA) was used for sensitisation (Sigma-Aldrich). 
Chromatographically purified chicken OVA (Worthington Biochemical Corporation, 
Lakewood, USA) was used in vitro and for sensitisation and airway challenges. OVA 
peptide 323-339 (referred to throughout as pOVA) was synthesised by PepLogic, 
Essex, UK. The lipopolysaccharide (LPS) level was quantified using a limulus 
amebocyte lysate (LAL) test (Sigma-Aldrich). 0.6-3.ng/ml LPS was detected in 
OVA (Worthington Biochemical Corporation) at the con entration used for 
intranasal administration (1mg/ml). The LPS concentration for pOVA (PepLogic) 
was undetectable (<0.06EU/ml), however the positive control for this assay did not 
clot completely meaning there is the possibility that an inhibitor of the LAL assay 
may exist within the reconsitituted pOVA. For epitoe mapping experiments, a panel 
of 15mer peptides were synthesised by Peptide 2.0, Chantilly, USA covering the 
amino acid sequence of OVA. Each peptide shifted by 5 amino acids to generate the 
panel shown in Table 1. OVA peptide 263-278 (referrd to throughout as p263-278, 
sequence KLTEWTSSNVMEERKI) was synthesised by Cambridge Research 
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Biochemicals, Cleveland, UK. The peptides in Table 1 were reconstituted in 100µl 
dimethyl sulfoxide [DMSO (Sigma-Aldrich)] and diluted with RPMI 1640 (Gibco) 
to 3mg/ml and stored at -80°C. pOVA and p263-278 were r constituted using sterile 
water only (Sigma-Aldrich) and stored at -80°C. 
 
2.4 CD4+ T cell isolation, polarisation and adoptive transf er 
2.4.1 Positive selection of naïve CD4 + OT-II cells 
Spleens and peripheral lymph nodes from female OT-II mice were harvested and 
disaggregated through gauze to form single cell suspen ions. Spleen cell suspensions 
underwent red cell lysis using 2ml per spleen of red c ll lysis buffer (Sigma-Aldrich) 
for 2 minutes, followed by the addition of 20ml wash medium and centrifugation 
(300xg, 5 minutes). Following red cell lysis, spleen cells were combined with lymph 
node cell suspensions. CD4 (L3T4) MACS Microbeads (Miltenyi Biotec, Surrey, 
UK) were used to positively select for CD4+ cells according to manufacturer’s 
instructions. Briefly, 45µl of MACS buffer and 5 µlCD4 MACS beads were added 
for every 1x107 cells, followed by incubation at 4°C for 15 minutes. Cells were 
washed in MACS buffer, and run through MACS LS columns (Miltenyi Biotec) as 
per manufacturer’s instructions. After washing columns three times with MACS 
buffer, positively selected cells were collected by removing the column from the 
magnet, applying a further 5ml MACS buffer to columns and rapidly flushing with a 
plunger. Cells were washed in PBS, counted and resusp nded in PBS prior to 
adoptive transfer. The purity of positively selected cells was consistently >90%, as 
determined by flow cytometry.  
 
2.4.2 Carboxyfluorescein diacetate succinimidyl est er (CFSE) 
staining of naïve CD4 + cells  
In experiments where OT-II cells were CFSE labelled prior to adoptive transfer, 
5µM CFSE (eBioscience, Hatfield, UK) was added to every 5x107 cells (in a 
concentration of 5x107 cells/ml), mixed well and incubated at 37°C for 5 minutes. 
Cold RPMI (Gibco) containing 10% HI-FCS (Gibco) was dded to cells, prior to 
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centrifugation at 300xg for 5 minutes followed by two additional washes in RPMI 
(Gibco) containing 10% HI-FCS and two washes in PBS (Gibco) prior to counting. 
 
2.4.3 Th2 polarisation of OT-II cells 
Spleen and peripheral lymph node single cell suspensions from female OT-II mice 
were prepared as described in section 2.4.1 and cultured at 4x106 cells/ml in 6 well 
plates (Costar UK Ltd, Buckinghamshire, UK) in tissue culture medium 
supplemented with 40U/ml rIL-2 (Peprotech EC Ltd, London, UK), 4ng/ml rIL-4 
(Peprotech EC Ltd), 5µg/ml anti-IL-12 (BioXcell, New Hampshire, USA) and 
5µg/ml anti-IFNγ (BioXcell) and 10µg/ml pOVA  (PepLogic). At 72 hours, cells 
were split using tissue culture medium containing the same cytokine and antibody 
combination but without further addition of pOVA. Cells were cultured for a total of 
96 hours after which they were harvested, washed and CD4+ cells positively selected 
using CD4 MACS Microbeads (Miltentyi Biotec) as described for naïve CD4+ cell 
selection in section 2.4.1. Supernatants from polarised cells were checked for the 
presence of Th2 cytokines by enzyme-linked immunosorbent assay (ELISA). 
 
2.4.4 Polarising conditions for Th0 and Th1 polaris ation of OT-II 
cells  
In some experiments intracellular cytokine staining was conducted following 
different polarisation regimes. For Th0 polarisation, tissue culture medium was 
supplemented with 20U/ml rIL-2 (Peprotech EC Ltd) and 10µg/ml pOVA 
(PepLogic) only. For Th1 conditions 20U/ml rIL-2 (Peprotech EC Ltd), 25ng/ml 
rIL-12 (Peprotech EC Ltd) and 25ng/ml rIL-18 (Peprotech EC Ltd) together with 
10µg/ml pOVA (PepLogic), were used. Th2 cells were cultured in the conditions 
described above. In these smaller experiments OT-II single cell suspensions were 
cultured at 3 x 106 /ml in 48-well plates (Costar UK Ltd) for 6 days. Cells were split 
after 3 days using antibody/cytokine supplemented tissue culture medium but 
without further addition of pOVA. 
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2.4.5 Adoptive transfer of CD4 + OT-II cells 
Purified CD4+ OT-II cells (either naïve or following Th2 polarisation) were injected 
intravenously into recipient C57BL/6 mice via the tail vein (2-4.5 x 106 cells per 
mouse depending on the experiment).  
 
2.5 Administration of soluble peptides 
500µg pOVA or 500µg p263-278 or 500µg of both peptid s in combination, diluted 
in sterile PBS (Gibco), were given intravenously via the tail vein in a volume of 
200µl. Soluble peptide was given 7 days prior to immunisation with OVA/alum or, 
in the Th2 polarised CD4+ OT-II AAI model, soluble peptide was given 2 days after 
cell transfer and 4 days prior to first intratracheal challenge. 
 
2.6 Allergic airways inflammation (AAI) and sensiti sation models 
2.6.1 Induction of AAI and allergic sensitisation w ithout cell 
transfer 
2.6.1.1 Sensitisation 
Mice were sensitised with two intraperitoneal (i.p) injections of 100µg OVA (grade 
V, Sigma-Aldrich) adsorbed to 2mg aluminium hydroxide [alum, (Alum Imject, 
Pierce, USA)] on days 0 and 14. Controls instead receiv d two i.p injections of 
sterile PBS (Gibco) plus 2mg alum (Pierce). In some experiments only the 
sensitisation injections (either one or two injections) were given and spleen and 
mediastinal lymph nodes harvested 7 days after the last sensitisation.  
 
2.6.1.2 Intranasal airway challenge 
Mice were intranasally challenged under brief isoflurane anaesthesia (Merial Animal 
Health Ltd, Essex, UK) with 30-50µg OVA (Worthington Biochemical Corporation) 
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or sterile PBS (Gibco) as a control on days 28, 29 and 30. Mice were culled on day 
32 for assessment of disease parameters.  
 
2.6.1.3 Intratracheal airway ahallenge 
In later experiments airway challenges were given via intratracheal instillation on 
days 28, 31 and 34. Mice were deeply anaesthetised using i.p medetomidine 
hydrochloride (Pfizer Ltd, Surrey, UK) and ketamine (Fort Dodge Animal Health 
Ltd, Hampshire, UK),  using the protocol in Appendix 2. Mice were supported in a 
frame facing the researcher, the mouth held open and the glottis and vocal cords 
visualized using a cold lamp applied to the neck. A blunt needle attached to a syringe 
was then used to introduce 50µg of OVA directly into the trachea. Anaesthesia was 
reversed using atipamezole hydrochloride (Pfizer Ltd, Surrey, UK) as detailed in 
Appendix 2.  Mice were culled two days after the last intratracheal instillation for 
assessment of disease parameters. 
 
2.6.2 Induction of allergic airways disease using t ransfer of Th2 
polarised OT-II CD4 + T cells 
4-4.5x106 CD4+ Th2 polarised OT-II cells were injected intravenously in a total 
volume of 200µl via the tail vein into C57BL/6 recipients. 1 day later mice received 
the first of three 50µg intratracheal OVA challenges, given every 3 days. Mice were 
culled 2 days after the last airway challenge to asses  the extent of disease. 
 
2.6.3 Assessment of AAI  
2.6.3.1 Invasive plethysmography 
Lung function was assessed 24 hours after the last airway challenge as described 
previously (Glaab et al., 2007) under deep anaesthesia using a FinePointe resistance 
and compliance system (Buxco Research Systems, Winchester, UK). Mice were 
anaesthetised using a combination of ketamine (Fort D dge Animal Health Ltd) and 
xylazine hydrochloride (Bayer Healthcare, Uxbridge, UK) as described in Appendix 
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2. The trachea was surgically exposed and cannulated and the cannula tightly secured 
using elastic. Mice were mechanically ventilated using 120 breaths/minute with a 
maximum tidal volume of 0.25ml. Flow and pressure data in response to nebulised 
PBS alone (Gibco) and to increasing doses of nebulised methacholine [MCh (Sigma-
Aldrich)] were automatically processed using biosystem XA software (Buxco 
Research Systems) to generate values for resistance of the lung (Rl) and dynamic 
compliance (Cdyn) as previously described (Glaab et al., 2007). 
 
2.6.3.2 Bronchoalveolar lavage (BAL) 
The trachea was exposed, canulated and lungs were lavaged with 1ml sterile PBS. 
BAL cells were counted and cytospins prepared using a Shandon Cytospin 3 
centrifuge at 300 rpm for 3 minutes.  Slides were ai  dried for 1 hour, fixed in 100% 
methanol for 20 minutes and stained with Quick-Diff red stain for 1.5 minutes 
followed by Quick-Diff blue stain for 15 seconds (both Gamidor Technical Services, 
UK). Slides were rinsed in water and allowed to air dry. Differential cell counts were 
performed by light microscopy with the researcher blinded to experimental 
conditions. A total of 300 cells were counted per cytospin. 
 
2.6.3.3 Histological scoring 
Lungs were perfused via the heart with sterile PBS (Gibco), inflated and fixed in 
methacarn [60% methanol, 30% chloroform, 10% glacia acetic acid, (all Fisher 
Scientific, Leicestershire, UK)] and embedded in paraffin. Sections were stained 
with hematoxylin and eosin (H+E) or Periodic acid-Schiff (PAS) stains (staining 
provided by on-site histology service). Inflammatory scoring of H+E stained slides 
(1 slide per mouse) was done manually at x200 magnification as previously 
described (Leech et al., 2007a). 10 consecutive fields were scored. To qualify for 
scoring, fields had to contain at minimum one complete bronchiole and a blood 
vessel. Only bronchioles less than half the width of a field (equivalent to less than 
300µm in diameter) were scored. Inflammation scores f 1-4 were applied to the 
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peri-vascular compartment (1 no cells, 2 <20 cells, 3 <100 cells, 4 >100 cells) and 
the peri-bronchiolar compartment (1 no cells, 2 <20 cells, 3 <100 cells, 4 >100 
cells). The percentage of goblet cells in small airw ys (less than half the width of a 
field - equivalent to less than 300µm in diameter) was determined by calculating the 
average percentage of goblet cells within 10 consecutive small airways at x200 
magnification. These percentages were then averaged to give the average percentage 
of goblet cells in small airways for each mouse. The percentage of goblet cells in 
large airways (more than half a field width in diameter i.e. > 300µm) for each mouse 
was calculated in the same way, but since these often numbered less than 10, as 
many large airways as possible (up to a maximum of 10) were scored. All 
histological scoring was carried out blinded to experimental conditions. 
 
2.6.3.4 Detection of OVA-specific IgE, IgG1 and IgG 2a 
Blood was taken via an axillary approach, serum colle ted and frozen at -80°C prior 
to detection of OVA specific IgE. Serum was diluted 1:4 using PBS (Gibco) and 
incubated with fast flow protein G sepharose beads (Sigma-Aldrich) overnight at 4°C 
on a rotator, in order to deplete serum IgG as described previously (Leech et al., 
2007a). High binding EIA/RIA 96-well plates (Costar UK Ltd) were coated 
overnight with 5µg/ml OVA in 0.05M carbonate buffer [0.795g Na2CO3, 1.465g 
NaHCO3 plus 500ml dH2O, pH 9.6, (all Sigma-Aldrich)], 100µl/well. The foll wing 
day plates were blocked with 200µl/well PBS/1% BSA (Gibco/Sigma-Aldrich) for 1 
hour at 37°C. Serum was centrifuged at 14000xg for 5 minutes to remove beads. 
Serum was transferred to a clean eppendorf and centrifuged again to ensure bead 
removal. Recovered serum was diluted further in PBS/1% BSA (Gibco/Sigma-
Aldrich) to a final 1:10 dilution. Serial dilutions of serum were prepared in a 
flexiplate using doubling dilutions in PBS/1% BSA (Gibco/Sigma-Aldrich). OVA-
coated plates were washed 5 times in PBS containing 0.05% Tween [PBS-T, (Sigma-
Aldrich)] and 50µl of pre-diluted serum added in duplicate to wells. Plates were 
incubated at 4°C overnight. The following day plates were washed 5 times with PBS-
T. Biotin conjugated rat anti-mouse IgE antibody (Clone R35-118, BD bioscience) 
was diluted to 2 µg/ml in PBS+1%BSA and 100µl of detection antibody solution 
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added to each well. Plates were incubated for 1 hour at 37°C and washed 5 times in 
PBS-T (Sigma-Aldrich) prior to the addition of 100µl horseradish peroxidase 
labelled streptavidin [(streptavidin-HRP, R+D Systems Ltd, Oxon, UK) diluted 
1:200 in PBS/1% BSA)] per well. Plates were incubated for 1 hour at room 
temperature, washed 6 times in PBS-T (Sigma-Aldrich) and the ELISA was 
developed using 100µl/well 3,3’,5,5’-tetramethylbenzidine [(TMB), Invitrogen Ltd, 
Paisley, UK]. The reaction was stopped using 100µl/wel  2M H2SO4 (Sigma-
Aldrich). As no standard was used, each plate was developed for exactly the same 
time prior to stopping the reaction. Plates were read at a wavelength of 450nm (with 
a wavelength correction set at 630nm) using a Biotek Synergy HT plate reader 
(Biotek, Bedfordshire, UK) and Gen5 software (Biotek).  
 
OVA-specific IgG1 and IgG2a were detected in serum using the same protocol as for 
IgE, without the IgG depletion step. The IgG1 antibody used was biotinylated rat 
anti-mouse IgG1 (clone LO-MG1-2, AbD serotec, Oxfordshire, UK), used at 
0.125µg/ml and the IgG2a antibody used was biotinylated rat anti-mouse IgG2a 
(clone 5.7, BD biosciences) used at 1µg/ml. 
 
2.6.3.5 Isolation of cells from lung tissue 
In some experiments following perfusion and prior to fixation, the left lobe was tied 
off, removed and placed into PBS (Gibco). Lung tissue was finely chopped and 
incubated in collagenase (type I-AS, Sigma-Aldrich) solution (final concentration 
0.23mg/ml collagenase) for 45-60 minutes at 37°C. Tissue was disaggregated using 
rapid flushing through a 20G needle. Cell suspensions were washed twice in PBS 
(all centrifugation steps were carried out at 300xg for 5 minutes) and subjected to red 
cell lysis (2ml/lung for 2 minutes) followed by a further wash in PBS (Gibco). 
Following the final wash, cells were resuspended in PBS (Gibco) and pushed 
through a 40µM cell strainer prior to counting. 
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2.7 Immunisations with OVA/ Complete Freund’s Adjuv ant (CFA) 
Mice were immunised with a total of 100-200µg OVA emulsified in CFA which 
contained 4mg/ml of heat-killed Mycobacterium tuberculosis H37a (Sigma-Aldrich). 
50µl of OVA/CFA was injected subcutaneously into each hind leg. 
 
2.8 Assessing T cell function in vitro 
2.8.1 Ex-vivo recall proliferation assays 
Lymph nodes [mediastinal LN (mLN), or inguinal (iLN) and para-aortic LN, 
dependent upon the experiment] and/or spleens were processed into single cell 
suspensions as described in 2.4.1. Cells were cultured in 96-well flat bottomed plates 
(Costar UK Ltd) at concentrations of 8x105/well for spleen and 6x105/well for LN. 
Cells were cultured in tissue culture medium in the pr sence of OVA (0-11µM) or 
pOVA (0-100µM) or p263-278 (0-30µM) or in equimolar combination (0-30µM 
pOVA plus 0-30µM p263-278). Proliferation was assesed by pulsing cells at 48 
hours with [3H]-thymidine (0.5µCi/well, Amersham Biosciences, Buckinghamshire, 
UK). Incorporation of [3H]-thymidine was assessed using a liquid scintillation β–
counter (Wallac, Turku, Finland) 16 hours later. Cytokines were measured in culture 
supernatants using ELISA. IL-2 was assessed after 48 hours and other cytokines after 
72 hours of culture.  
 
2.8.2 Enzyme-linked Immunosorbent Assay (ELISA) for  cytokines 
Cytokines were detected in culture supernatants and BAL using ELISA. The 
concentrations of antibodies used are shown in Table 2. Capture antibodies were 
diluted in 1 x bicarbonate buffer (10 x bicarbonate buffer comprising 0.15M Na2CO3, 
0.35M NaHCO3 (all Sigma-Aldrich) plus 400ml dH2O, pH 9.6 was made initially 
and subsequently diluted to working concentration in dH2O). High binding EIA/RIA 
96-well plates (Costar UK Ltd) were coated overnight with 50µl/well of capture 
antibody solution. The following day plates were washed twice with PBS-T (Sigma-
Aldrich) and blocked with 200µl/well PBS/1% BSA (Gibco/Sigma-Aldrich) for 1 
hour at 37°C. Plates were washed twice in PBS-T (Sigma-Aldrich) prior to addition 
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of 100µl/well of samples in triplicate. In experiments where samples were diluted 
prior to ELISA, dilutions were carried out in 1%BSA/PBS. A 10 point standard 
curve comprising serial doubling dilutions of standrd (diluted in 1%BSA/PBS) in 
duplicate, and wells containing 1%BSA/PBS (Gibco/Sigma-Aldrich) alone, were 
included on each plate. All standards were obtained from BD Biosciences. Plates 
were incubated at room temperature for 2 hours and washed 4 times with PBS-T 
(Sigma-Aldrich). Biotinylated antibodies were diluted to the concentrations shown in 
Table 2 in PBS/1% BSA (Gibco/Sigma-Aldrich) and 100µl detection antibody 
solution added to each well. Plates were incubated for 1 hour at room temperature 
and washed 6 times in PBS-T prior to the addition of 100µl streptavidin–HRP (R+D 
Systems Ltd) diluted 1:200 in PBS/1% BSA (Gibco/Sigma-Aldrich) per well. Plates 
were incubated for 30 minutes at room temperature, washed 6 times in PBS-T 
(Sigma-Aldrich) and the ELISA developed using 100µl/we l TMB (Invitrogen Ltd). 
The reaction was stopped using 100µl/well 2M H2SO4 (Sigma-Aldrich). Plates were 
read at a wavelength of 450nm (with a wavelength corre tion set at 630nm) using a 
Biotek Synergy HT plate reader and Gen5 software (Biotek, Bedfordshire, UK). 
 
2.9 Generating short term T cell lines 
Mice were immunised with 200µg OVA emulsified in CFA containing 4mg/ml of 
heat-killed Mycobacterium tuberculosis H37a (Sigma-Aldrich) as described in 
section 2.7. 7-10 days after immunisation para-aortic LN and iLN were harvested, 
and a protocol derived from one previously been shown to generate T cell lines 
(Anderton et al., 1998), was used. Briefly, LN cells were cultured at 5x106/well in 
tissue culture medium together with 7µM OVA in 24 well tissue culture plates 
(Costar UK Ltd). Cells were harvested after 72 hours and 2ml of Ficoll (Ficoll-Pague 
Plus, GE Healthcare, Buckinghamshire, UK) laid under 4.5ml of cell suspension in a 
15ml Falcon tube (Beckton Dickinson, UK). Cells were centrifuged at 650xg for 15 
minutes without brake. Cells were removed from the int rface, wash buffer was 
added followed by further centrifugation at 650xg for 5 minutes, without brake. Cells 
were washed twice in wash buffer, counted and resuspended at 4-5x106 cells per well 
in tissue culture medium supplemented with 2.5% rat Con A supernatant as a source 
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of IL-2 [previously generated in the host laboratory by stimulating rat splenocytes 
with concanavalin A (Sigma-Aldrich)]. Cells were incubated at 37°C, 5% CO2 for a 
total of 4 days, splitting as necessary using tissue culture medium supplemented with 
2.5% rat Con A supernatant. 
2.10 In vitro recall assays involving short-term T cell lines 
T cells were cultured at 2x104/well with 5x105/well of irradiated splenocytes 
[exposed to 30Gy of gamma-irradiation (caesium isotope)] and peptide or OVA 
(Worthington Biochemical Corporation) in 96 well flat bottom plates (Costar UK 
Ltd). Proliferation was assessed by pulsing cells at 48 hours with [3H]-thymidine 
(0.5µCi/well, Amersham Biosciences). Incorporation of [3H]-thymidine was assessed 
using a liquid scintillation β–counter (Wallac) 16 hours later. Cytokines were 
measured in culture supernatants after 72 hours of culture, by ELISA.  
 
2.11 Flow cytometry 
2.11.1 Antibodies 
Table 3 lists all antibodies used for flow cytometry. 
 
2.11.2 Staining of surface markers 
Cells to be stained were centrifuged at 300xg for 5 minutes and the supernatant 
removed. Antibodies were diluted in FACS buffer and 50µl added to cell pellets 
which were then mixed well prior to 30 minutes incubation at 4°C in the dark. Cells 
were washed in FACS buffer and resuspended either in a 200µl of FACS buffer and 
collected, or fixed in 200µl of 2% paraformaldehyde (Sigma-Aldrich), kept in the 
dark at 4°C and collected as soon as possible. 
 
2.11.3 Intracellular Foxp3 staining and Intracellul ar staining for 
GATA-3 and cytokines 
For GATA-3 and intracellular cytokine staining (following polarisation) cells were 
harvested, washed in wash medium and restimulated using 50ng/ml of phorbol 
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myristate acetate [PMA (Sigma-Aldrich)], 1µg/ml ionomycin (Sigma-Aldrich) and 
1/1000 dilution of stock brefeldin A (eBioscience) for 4 hours at 37°C.  FoxP3 
staining was carried out without additional stimulation. Cells were surface stained as 
described in section 2.11.2, followed by one wash in FACS buffer. 
Fixation/permeabilisation buffer (eBioscience) was prepared as per manufacturer’s 
instructions, 400µl added to cell pellets and mixed w ll. Cells were incubated in the 
dark at 4°C for 30 minutes or overnight (both approaches having been shown 
previously in the host laboratory to be equally effective). Cells were washed in 
FACS buffer and FoxP3 antibody or isotype control diluted as shown in Table 3 in 
permeabilsation buffer (eBioscience). 50µl of antibody solution was added to cells 
followed by incubation in the dark for 30 minutes at 4°C. Cells were washed with 
FACS buffer, resuspended in 200µl of FACS buffer and acquired as soon as 
possible. 
 
2.11.4 Flow cytometric data analysis 
Flow cytometric data were collected on a FACS Calibur flow cytometer using 
CellQuest (Becton Dickinson) or LSR Fortessa with FACS DIVA (Becton 
Dickinson, UK). Data were analysed using FlowJo software (Treestar, USA). 
 
2.12  Statistical analysis 
Statistical advice was sought from Dr Rob Elton. Statis ical analysis was performed 
using Prism software. Unpaired t-test or Mann-Whitney U tests were used when 
comparing two groups. To compare three or more groups a one-way analysis of 
variance (ANOVA) was used with Tukey’s multiple comparison post test. The 
Kruskal-Wallis test with Dunn’s multiple comparison post test was used to compare 
three or more groups where data were non-parametric. p<0.05 was considered 
significant for all tests.  
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Table 1: Overlapping peptide panel encompassing the sequence of OVA 
Peptide Number Positional Sequence Amino Acid Sequence 
1 1-15 GSIGAASMEFCFDVF 
2 6-20 ASMEFCFDVFKELKV 
3 11-25 CFDVFKELKVHHANE 
4 16-30 KELKVHHANENIFYC 
5 21-35 HHANENIFYCPIAIM 
6 26-40 NIFYCPIAIMSALAM 
7 31-45 PIAIMSALAMVYLGA 
8 36-50 SALAMVYLGAKDSTR 
9 41-55 VYLGAKDSTRTQINK 
10 46-60 KDSTRTQINKVVRFD 
11 51-65 TQINKVVRFDKLPGF 
12 56-70 VVRFDKLPGFGDSIE 
13 61-75 KLPGFGDSIEAQCGT 
14 66-80 CDSIEAQCGTSVNVH 
15 71-85 AQCGTSVNVHSSLRD 
16 76-90 SVNVHSSLRDILNQI 
17 81-95 SSLRDILNQITKPND 
18 86-100 ILNQITKPNDVYSFS 
19 91-105 TKPNDVYSFSLASRL 
20 96-110 VYSFSLASRLYAEER 
21 101-115 LASRLYAEERYPILP 
22 106-120 YAEERYPILPEYLQC 
23 111-125 YPILPEYLQCVKELY 
24 116-130 EYLQCVKELYRGGLE 
25 121-135 VKELYRGGLEPINFQ 
26 126-140 RGGLEPINFQTAADQ 
27 131-145 PINFQTAADQARELI 
28 136-150 TAADQARELINSWVE 
29 141-155 ARELINSWVESQTNG 
30 146-160 NSWVESQTNGIIRNV 
31 151-165 SQTNGIIRNVLQPSS 
32 156-170 IIRNVLQPSSVDSQT 
33 161-175 LQPSSVDSQTAMVLV 
34 166-180 VDSQTAMVLVNAIVF 
35 171-185 AMVLVNAIVFKGLWE 
36 176-190 NAIVFKGLWEKTFKD 
37 181-195 KGLWEKTFKDEDTQA 
38 186-200 KTFKDEDTQAMPFRV 
39 191-205 EDTQAMPFRVTEQES 
40 196-210 MPFRVTEQESKPVQM 
41 201-215 TEQESKPVQMMYQIG 
42 206-220 KPVQMMYQIGLFRVA 
43 211-225 MYQIGFRVASMASE 
44 216-230 LFRVASMASEKMKIL 
45 221-235 SMASEKMKILELPFA 
46 226-240 KMKILELPFASGTMS 
47 231-245 ELPFASGTMSMLVLL 
48 236-250 SGTMSMLVLLPDEVS 
49 241-255 MLVLLPDEVSGLEQL 
50 246-260 PDEVSGLEQLESIIN 
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51 251-265 GLEQLESIINFEKLT 
52 256-270 ESIINFEKLTEWTSS 
53 261-275 FEKLTEWTSSNVMEE 
54 266-280 EWTSSNVMEERKIKV 
55 271-285 NVMEERKIKVYLPRM 
56 276-290 RKIKVYLPRMKMEEK 
57 281-295 YLPRMKMEEKYNLTS 
58 286-300 KMEEKYNLTSVLMAM 
59 291-305 YNLTSVLMAMGITDV 
60 296-310 VLMAMGITDVFSSSA 
61 301-315 GITDVFSSSANLSGI 
62 306-320 FSSSANLSGISSAES 
63 311-325 NLSGISSAESLKISQ 
64 316-330 SSAESLKISQAVHAA 
65 321-335 LKISQAVHAAHAEIN 
66 326-340 AVHAAHAEINEAGRE 
67 331-345 HAEINEAGREVVGSA 
68 336-350 EAGREVVGSAEAGVD 
69 341-355 VVGSAEAGVDAASVS 
70 346-360 EAGVDAASVSEEFRA 
71 351-365 AASVSEEFRADHPFL 
72 356-370 EEFRADHPFLFCIKH 
73 361-375 DHPFLFCIKHIATNA 
74 366-380 FCIKHIATNAVLFFG 
75 371-385 IATNAVLFFGRCVSP 
 Peptides all obtained from Peptide 2.0 
Table 2: Antibodies used for detection of cytokines by ELISA 
Cytokine Detected Antibody Clone Stock Concentration Dilution Used 
Rat anti-mouse 
IL-2* 




JES6-5H4 0.5mg/ml 1:1000 




BVD6-24G2 0.5mg/ml 1:1000 




TRFK4 0.5mg/ml 1:1000 




JES5-2AS 0.5mg/ml 1:1000 
Anti-mouse IFN-γ XMG1.2 0.5mg/ml 1:500 IFN-γ 
Anti-mouse IFN-γ R4-6A2 0.5mg/ml 1:1000 




eBio1316H 0.5mg/ml 1:100 
* indicates antibodies from BD bioscience, all other antibodies are from eBioscience. 
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Table 3: Antibodies used for flow cytometry 
Antibody Conjugate Clone Stock Concentration Dilution  
CD4 AF700 (Invitrogen) MCD0429 0.5mg/ml 1:200 
CD4 APC RM4-5 0.2mg/ml 1:200 
CD45.1 APC A20 0.2mg/ml 1:200 
CD45.1 PercpCy5.5 A20 0.2mg/ml 1:200 
CD45.2 APC 104 0.2mg/ml 1:200 
Vα2 TCR PE B20.1 0.1mg/ml 1:200 
Vβ5.1/5.2 TCR FITC MR9-4 0.5mg/ml 1:200 
CD62L PE (BD) MEL-14 0.2mg/ml 1:200 
CD44 EF450 IM7 0.2mg/ml 1:200 
FoxP3 APC FJK-16a 0.2mg/ml 1:100 
Rat IgG2a isotype 
control 
APC eBR2a 0.2mg/ml 1:100 
IL-13 AF647 ebio13A 0.2mg/ml 1:100 
Rat IgG1 isotype 
control 
AF647 eBRG1 0.2mg/ml 1:200 
IFN-γ FITC XMG1.2 0.5mg/ml 1:100 
Rat IgG1 isotype 
control 
FITC eBRG1 0.2mg/ml 1:40 
GATA-3 PE TWAJ 20ul (0.06µg) /test 1:5 
Rat IgG2b isotype 
control 
PE A95-1 0.2mg/ml 1:333 
All antibodies are from eBioscience unless otherwise stated.
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3 PIT using pOVA 323-339 does not significantly imp rove 
OVA-induced AAI in C57BL/6 mice 
3.1 Introduction 
Many previous AAI studies utilised BALB/c mice, whic  develop strong Th2 
responses (Abbas et al., 1996). AAI protocols for the induction and assessment of 
disease used previously in the Schwarze lab have been ased on BALB/c mice. 
Integral to this project, however, was the intentio t  carry out adoptive transfer 
studies using CD4+ T cells from congenically labelled transgenic OT-II mice. These 
mice are on the C57BL/6 background and their CD4+ T cells express TCRs reactive 
to the p323-339 peptide of OVA (hereafter referred to as pOVA) (Barnden et al., 
1998). A further advantage of studying PIT in the C57BL/6 strain is the extensive 
breadth of transgenic mice available on this background e.g. FoxP3-DTR mice. This 
provides additional flexibility in terms of future mechanistic work based upon 
findings from this project. For these reasons it was decided at an early stage that this 
project would focus upon AAI in C57BL/6 mice.  
 
OVA has been used extensively as a model allergen in murine models of AAI 
(Kearley et al., 2008, Hamelmann et al., 1999a) andwas chosen for this project 
because:- 
 
i) pOVA has previously been described as containing a CD4+ T cell epitope for 
C57BL/6 mice (as well as for BALB/c mice) (Shimonkevitz et al., 1984, 
Llopiz et al., 2008, Barnden et al., 1998). 
 
ii)  of the availability of transgenic OT-II mice possesing CD4+ TCRs reactive 
to pOVA (Barnden et al., 1998).  
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Work from the Anderton lab has previously shown the ability of soluble pOVA to 
tolerise CD4+ OT-II cells (Konkel et al., 2010, Hochweller and Anderton, 2005). In 
those studies CD4+ OT-II cells were adoptively transferred into naïve C57BL/6 mice 
prior to administration of intravenous soluble pOVA. Mice were then immunised 
with pOVA in Complete Freund’s Adjuvant (CFA). In that context, pOVA PIT 
induced tolerance in CD4+ OT-II cells in vivo so they no longer mounted an in vitro 
recall response to pOVA, in contrast to PBS treated controls. These findings were 
taken as a basis for this project. Importantly however, those data were limited 
towards a Th1, CFA-driven setting and to the assessm nt of tolerance following 
pOVA immunisation rather than immunisation with whole protein OVA. In order to 
optimise clinical relevance, it was important that this project assessed the effects of 
PIT on AAI induced with whole protein OVA. This would more accurately model 
allergic asthma in humans, which presumably develops in response to whole protein 
allergen, and would not impair the development of features such as OVA-specific 
IgE (known to develop towards multiple conformational epitopes within OVA) 
(Mine and Yang, 2007).  Prior to the development of an adoptive transfer model 
assessing the effects of pOVA PIT on traceable pOVA-reactive CD4+ OT-II cells in 
AAI, the effects of pOVA PIT on AAI were assessed in wild-type C57BL/6 mice. 
An initial approach assessing the effects of pOVA given intravenously prior to 
induction of AAI was taken; i.e. the same approach s that had previously induced 
OT-II CD4+ T cell tolerance in the Anderton lab (Konkel et al., 2010, Hochweller 
and Anderton, 2005). 
 
3.1.1 Aims 
The aims of the experiments described in this chapter were therefore to:- 
1. Induce AAI in C57BL/6 mice using OVA. 
2. Characterise the disease and immunological readouts f r this model. 
3. Assess the effects of giving soluble pOVA intravenously, prior to OVA 
challenge and sensitisation, on the severity of AAI.  
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3.1.2 Experimental Approach 
A variety of protocols exist for the induction of murine AAI using OVA. These often 
involve a sensitisation phase followed by an airway challenge phase (Takeda and 
Gelfand, 2009), although repeated airway challenges alone can also induce AAI 
(Nials and Uddin, 2008). Sensitisation phases may involve the use of Th2-promoting 
adjuvants such as alum (Nials and Uddin, 2008), but repeated sensitisation injections 
without adjuvant can also be effective (Janssen et al., 1999). Airway challenge 
regimes vary in terms of frequency, dose and route f administration e.g. intranasal, 
inhalation of aerosolised OVA or intratracheal approaches (Trujillo-Vargas et al., 
2005, Hamelmann et al., 1999b). The Schwarze lab has previously induced AAI 
using protocols involving two intraperitoneal sensitisation injections of OVA 
adsorbed to alum followed by three intranasal OVA challenges (Schwarze et al., 
1998). It was decided to follow this approach for the induction of AAI in C57BL/6 
mice. OVA sensitisation with 10µg to 300µg has previously been used by others 
(Vultaggio et al., 2009, de Vries et al., 2009, Hellings et al., 2002) and challenge 
doses can be as high as 100µg (KuoLee et al., 2008). C57BL/6 mice tend to be a 
more difficult strain in which to induce an allergic Th2 phenotype, than for example 
BALB/c mice (Takeda et al., 2001). A dose of 100µg OVA was therefore initially 
chosen for sensitisation and 50µg for intranasal chllenge, both are towards the 
higher end of the dosage spectrum used previously by others. The experimental 
approach taken in this chapter is shown in Figure 3.1. 
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3.2 Results 
3.2.1 Sensitisation with OVA/alum and subsequent ai rway 
challenge induces features of AAI in C57BL/6 mice 
C57BL/6 mice were given two intraperitoneal sensitisation injections of 100µg OVA 
adsorbed to alum, followed by three 50µg OVA intranasal challenges (the approach 
is shown in Figure 3.1). OVA sensitisation and challenge induced inflammatory 
changes in the lungs typical of AAI. Figure 3.2a shows that pulmonary inflammatory 
infiltrates were visible in the peri-vascular and peri-bronchiolar regions of OVA 
sensitised and challenged mice. Inflammatory infiltrates were not seen in mock 
sensitised and OVA challenged, OVA sensitised and PBS challenged or naïve 
controls (Figure 3.2a). Goblet cells were also present in the airways of OVA 
sensitised and challenged mice, and rarely found in co trols (Fig. 3.2c). These 
inflammatory changes were quantified using a previously published inflammation 
scoring system (Leech et al., 2007a). Using this scoring system, Figure 3.2b 
demonstrates significantly increased inflammation scores in OVA sensitised and 
challenged mice, compared to controls. Figure 3.2d shows that, after OVA 
sensitisation and challenge, goblet cells were evident in the small airways and, to a 
greater extent, in the large airways (small and large airways have previously been 
defined in the Materials and Methods).  
 
Total BAL cells were significantly increased in OVA sensitised and challenged mice 
compared to controls (Figure 3.3a). OVA sensitisation and challenge resulted in the 
presence of eosinophils within BAL, accounting for around 60% of total BAL cells 
(Figure 3.3b). Eosinophils were rarely seen in BAL obtained from controls, alveolar 
macrophages constituting the majority of BAL cells in these groups. In addition to a 
substantial increase in total numbers of eosinophils in BAL in OVA sensitised and 
challenged mice compared to controls (Figure 3.3c), lymphocytes were also 
increased compared to mock sensitised controls (Figure 3.3e). There was no 
significant change in the total number of macrophages in BAL between groups 
(Figure 3.3d).  Neutrophils were rarely seen in BAL from any group and, therefore, 
total numbers have been omitted here. 
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3.2.2 mLN cells from OVA sensitised and challenged mice 
produce Th2 cytokines upon in vitro stimulation with OVA 
To assess adaptive immune responses to OVA in this model, mediastinal lymph 
nodes (mLN) were harvested from mock sensitised OVA challenged or OVA 
sensitised and challenged mice, and cultured with increasing concentrations of OVA. 
mLN cells from OVA sensitised and OVA challenged mice, and not from controls, 
proliferated in response to OVA (Figure 3.4a). In a separate experiment, (such 
experiments being limited by the number of cells obtained from mLN), mLN cells 
from OVA sensitised and challenged mice versus naïve controls were cultured with 
increasing concentrations of OVA (Figures 3.4b-d). The presence of cytokines in 
supernatants after 72 hours of culture was determined using ELISA (Figure 3.4b-d). 
mLN cells from OVA sensitised and challenged mice produced the Th2 cytokines 
IL-4, IL-5 and IL-13 in a dose dependent manner in response to OVA, in contrast to 
mLN cells from naïve mice. Interferon-γ was below detection for both groups (data 
not shown). OVA specific-IgE was detected in serum from mice after OVA 
sensitisation and not in serum from mock sensitised controls (Figure 3.4e).  
 
During optimisation of the AAI protocol, the experimental approach shown in Figure 
3.1 was also carried out using 30µg of OVA as the intranasal challenge dose.  
Pulmonary inflammation scores and the presence of goblet cells were similar 
irrespective of whether 30µg or 50µg was used (data not shown). Both doses 
significantly increased the total numbers of BAL cells compared to controls, but the 
increase was greatest using the higher challenge dos and there was a trend for the 
percentage of eosinophils within BAL to be greater in the 50µg challenged group 
(data not shown). 50µg challenge dose was thus used in all subsequent experiments. 
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3.2.3 Induction of AAI in C57BL/6 mice does not res ult in 
measurable changes in lung function in contrast to BALB/c 
mice 
Lung function can be assessed in mice using plethysmography. Invasive and non-
invasive plethysmography techniques are available, however invasive measurements 
are currently the “gold standard” (Glaab et al., 2007). Invasive plethysmography 
enables the determination of resistance of the lung (Rl) and pulmonary dynamic 
compliance (Cdyn). Mice with AAI have been found to have increased Rl and 
reduced Cdyn in response to bronchoconstrictors such as methacholine (MCh), 
compared to non-AAI controls (Hoymann, 2007). 
 
To assess lung function using invasive plethysmography in this model, AAI was 
induced in C57BL/6 mice as shown in Figure 3.1. 24 hours after the final airway 
challenge, mice were terminally anaesthetised, intubated surgically using a cannula 
inserted into the trachea and mechanically ventilated. Rl and Cdyn at baseline and in 
response to inhaled MCh were determined. Much of the lung function data available 
from previous studies on AAI is based on BALB/c mice (Hoymann, 2007). BALB/c 
mice can differ in their plethysmographic responses to MCh compared to C57BL/6 
mice (Adler et al., 2004), therefore AAI was additionally induced in BALB/c mice to 
enable comparison of lung function between the two strains.  
 
Significant changes in Cdyn and Rl were found in BAL /c mice with AAI compared 
to controls at a dose of 6mg/ml MCh (Figure 3.5a,b). Although a similar trend was 
also seen at 12mg/ml MCh, this did not reach significance. This is likely to be due to 
increased variation in Rl in the BALB/c AAI group at the 12mg/ml MCh dose which 
was noted to coincide with increased mucous production, which may have impaired 
air flow. Significant changes in Cdyn were also seen at 12mg/ml of MCh in BALB/c 
mice with AAI compared to naïve controls (Figure 3.5b)  Importantly, no differences 
in either Rl or Cdyn in response to MCh were seen in C57BL/6 mice with AAI 
compared to controls (Figure 3.5c,d). 
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Significant changes in lung function in C57BL/6 mice with AAI are sometimes only 
seen at high MCh doses (Takeda et al., 2001). Invasive plethysmography was 
therefore repeated using OVA sensitised and challenged C57BL/6 mice versus mock 
sensitised controls, this time using MCh doses up to 50mg/ml (Figure 3.6a,b). Again 
no differences in Rl or Cdyn were detected. It was concluded that induction of AAI 
using this model did not induce measurable differences in lung function in C57BL/6 
mice compared to controls; hence lung function was not assessed in later 
experiments. 
 
3.2.4 pOVA PIT given intravenously prior to the ind uction of AAI 
does not improve disease in C57BL/6 mice 
The administration of soluble pOVA was next applied to the AAI model as shown in 
Figure 3.1. The same route (intravenous) and dose (500µg) of soluble pOVA as had 
been successfully used previously in the Anderton lab to induce tolerance of pOVA-
reactive CD4+ OT-II cells (Konkel et al., 2010, Hochweller and Anderton, 2005), 
were chosen. Mice therefore received 500µg pOVA, or PBS as a control, 
intravenously 7 days prior to the induction of AAI. The results are shown in Figures 
3.7 and 3.8.  
 
There was no significant difference in total BAL cells between mice that received 
pOVA PIT and those that did not (Figure 3.7a). There was no significant difference 
in the total number of eosinophils or lymphocytes in the BAL of pOVA PIT treated 
mice compared to PBS treated controls (Figure 3.7c,e). Significantly fewer 
macrophages were present in BAL from mice that receiv d pOVA PIT, compared to 
PBS treated controls (Figure 3.7d). pOVA PIT did not significantly alter levels of 
OVA-specific IgE, IgG1 or IgG2a in serum (data not shown). pOVA PIT did not 
significantly alter lung inflammation scores (Figure 3.8a), nor the percentage of 
goblet cells in small airways (Figure 3.8b). The exp riment described in Figure 3.1 
was carried out twice – in both experiments findings were consistent with those 
shown in Figure 3.7 and 3.8. The only exception wasth t the significant reduction in 
macrophage numbers in BAL from pOVA PIT treated versus PBS treated mice 
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(Figure 3.7d) was not found in the repeat experiment (data not shown). Splenocytes 
from pOVA PIT treated mice versus splenocytes from PBS treated controls were 
cultured with increasing concentrations of OVA. No significant differences in 
proliferation (Figure 3.9a) or the production of IL-5 (Figure 3.9b), measured in 
supernatants by ELISA, were found between the two groups. 
 
3.2.5 Splenocytes from OVA sensitised mice do not m ount a 
measurable proliferative or IL-5 response to pOVA in vitro   
It was unclear from the data described above, whether the lack of improvement in 
AAI seen after pOVA PIT was because tolerance of pOVA-reactive CD4+ T cells 
was not being induced. So far, in vitro recall responses had only been assessed to 
OVA and not to pOVA. This meant it was possible that CD4+ T cells responding to 
other potential epitope(s) within OVA were still capable of driving OVA-induced 
AAI in this model, despite tolerance being induced to pOVA. The experimental 
protocol in Figure 3.1 is 39 days long. In order to try to assess whether or not 
tolerance to pOVA was being achieved it was decided to examine in vitro recall 
responses of splenocytes after OVA sensitisation but prior to challenge, thus 
reducing the length of experiments. Mice were given either pOVA PIT or PBS 
intravenously 7 days before OVA sensitisation. 7 days fter sensitisation, splenocytes 
were cultured with increasing concentrations of pOVA or OVA and proliferation and 
IL-5 production were assessed. Multiple experiments were conducted involving 
either one or two OVA sensitisations. Importantly, although splenocytes from mice 
that had been sensitised using OVA/alum (+/- PIT), proliferated to OVA (Figure 
3.10), as found previously following OVA challenge (Figure 3.9), proliferation could 
not reliably be detected in response to pOVA, regardless of whether mice had 
received pOVA PIT or PBS (Figure 3.10). In addition, while IL-5 was produced by 
splenocytes from pOVA PIT treated and PBS treated mice in response to OVA 
(Figure 3.11a), no IL-5 was produced by splenocytes from either group in response 
to pOVA (Figure 3.11b). Hence, because no i  vitro recall response to pOVA could 
be detected after OVA sensitisation, no conclusion c uld be drawn as to whether or 
not pOVA PIT had induced tolerance of pOVA-reactive CD4+ T cells. 
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Figure 3-1: Experimental approach for the experiments described in Chapter 3
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Figure 3-2: OVA sensitisation and challenge induces pulmonary inflammation consistent with 
AAI
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Figure 3-3: OVA sensitisation and challenge induce changes in BAL consistent with AAI
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Figure 3-4: Effects of OVA sensitisation and challenge on mLN recall responses and serum 
OVA-specific IgE 
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Figure 3-5: Comparison of BALB/c and C57BL/6 lung function responses to MCh using invasive 
plethysmography 
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Figure 3-6: No significant differences in lung function are detected in C57BL/6 mice with AAI 
even at high doses of MCh
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Figure 3-7: pOVA PIT prior to induction of AAI does  not significantly alter BAL readouts
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Figure 3-8: pOVA PIT prior to induction of AAI does  not significantly alter pulmonary 
inflammation
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Figure 3-9: pOVA PIT does not significantly alter in vitro recall responses of splenocytes to 
OVA on D32
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Figure 3-10: Following OVA sensitisation, proliferation was detectable in splenocytes in 
response to OVA but not to pOVA, irrespective of pOVA PIT treatment
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Figure 3-11: Following OVA sensitisation, splenocytes produce IL-5 in response to OVA but not 
to pOVA, irrespective of pOVA PIT treatment
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3.3 Discussion 
3.3.1 How does this AAI model compare to others? 
3.3.1.1 Histological and immunological readouts 
The histological findings shown in Figure 3.2a-d both in terms of cellular infiltrate 
into the lungs and the presence of goblet cells, are consistent with other AAI models 
(Finkelman and Wills-Karp, 2008). The total numbers of BAL cells after OVA 
sensitisation and challenge (Figure 3.3a) and the concentrations of Th2 cytokines 
produced upon in vitro recall of mLN cells to OVA (Figure 3.4) are within the ranges 
seen by previously by others (Leech et al., 2007a, Takeda et al., 2001, Zhou Y et al., 
2001). The percentage of eosinophils within BAL (Figure 3.3b) is high, but similar to 
some other studies in C57BL/6 mice (Hamelmann et al., 1999b), which have a 
tendency for greater eosinophilia within BAL after induction of AAI compared to 
BALB/c mice (Wilder et al., 1999, Takeda et al., 2001). Indeed, numbers of BAL 
eosinophils have been reported to be up to 10 times greater in C57BL/6 mice than in 
BALB/c mice after OVA sensitisation and challenge (Morokata et al., 1999).  
 
3.3.1.2 Lung function measurements 
Non-invasive whole body plethysmography in which pressure changes and timing of 
respiration are used to derive the “enhanced pause” parameter known as PenH (Adler 
et al., 2004, Glaab et al., 2007), can be used as a measure of lung function in mice. 
However, although PenH changes can be significantly i creased after induction of 
AAI (Takeda et al., 1997), concerns have been raised surrounding its use. Adler et al 
found that PenH changes do not necessarily correlate with changes in pulmonary 
resistance detected using invasive plethysmography (Adler et al., 2004), particularly 
in the case of C57BL/6 mice. Strain-specific differences in reflex responses to 
irritants such as MCh and how these alter breathing patterns are also likely to play a 
role in differences in PenH readings between strains (Adler et al., 2004). For these 
reasons, invasive plethysmography is currently the “gold-standard” approach to lung 
function testing in mice and was therefore chosen for use in this project. 
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During invasive plethysmography, resistance of the lung (Rl) and dynamic 
compliance (Cdyn) are derived from pressure, flow and volume measurements 
during mechanical ventilation of anaesthetised, intuba ed mice (Glaab et al., 2007). 
Rl indicates airway narrowing and/or resistance within the lung parenchyma and 
Cdyn indicates the elasticity of the lung tissue (Glaab et al., 2007). A feature of 
allergic asthma in humans is AHR - increased constriction of the airways upon 
encountering non-specific stimuli such as bronchoconstrictive agents (Cohn et al., 
2004). The induction of AAI in mice can also induce AHR in response to 
bronchoconstrictive agents such as MCh, causing Rl to increase and Cdyn to 
decrease (Glaab et al., 2007, Zhang et al., 2009). Consistent with this, significant 
changes were found in Rl and Cdyn in OVA sensitised an  challenged BALB/c mice 
at relatively low MCh doses (Figure 3.5a,b). However, no changes in Rl or Cdyn 
were detected in OVA sensitised and challenged C57BL/6 mice (Figure 3.5c,d). 
These data are similar to those of Wilder et al who als  found significant differences 
in Rl in response to MCh in OVA sensitised and challenged BALB/c mice but not in 
C57BL/6 mice (Wilder et al., 1999). Others have also found no difference between 
Rl in C57BL/6 mice with AAI versus controls (Zhou et al., 2008). C57BL/6 mice 
have previously been described as hyporeactive to bronchial provocation (Levitt et 
al., 1990), although in Figure 3.5 both naïve C57BL/6 mice and those with AAI do 
display Rl and Cdyn changes in response to MCh, there is just no significant change 
in the AAI group compared to controls. However, changes in Rl and Cdyn have been 
found in some AAI models in C57BL/6 mice (Albertine et al., 2002). Takeda et al 
found that significant changes in Cdyn and Rl in C57BL/6 mice with AAI only 
occurred at high doses of MCh (Takeda et al., 2001), but this was not found here 
(Figure 3.6). 
 
It is seems clear that strain differences exist betwe n C57BL/6 and BALB/c mice in 
terms of lung function changes in AAI, and the data found here are consistent with 
this (Figure 3.5). It is interesting that the lack of change seen in Rl and Cdyn in 
C57BL/6 mice with AAI compared to controls occurs despite significant pulmonary 
Chapter 3 Results 
 93 
inflammation and eosinophilia within the BAL (Figure 3.2 and 3.3). The requirement 
for eosinophils for AHR in mouse AAI models remains unclear (Akuthota et al., 
2011). AHR can develop in eosinophil deficient BALB/c mice with AAI (Humbles et 
al., 2004), however the number of eosinophils in BAL has been found to correlate 
with MCh induced changes in Rl and Cdyn in BALB/c mice but not in C57BL/6 
mice (Takeda et al., 2001). Takeda et al found thate distribution of eosinophils 
within lung tissue after induction of AAI differed between strains and hypothesised 
that the relative paucity of eosinophils in peri-bronchial regions in C57BL/6 mice 
compared to BALB/c mice may be implicated in the less severe lung function 
changes seen in this strain (Takeda et al., 2001). 
 
Inter-strain differences in lung function are also ikely to reflect differences in lung 
structure, composition and baseline lung function. Differences in elastic recoil of the 
lungs between strains could affect Cdyn (Takeda et l., 2001) and differences in 
baseline physiological readings such as respiratory rate have been demonstrated 
between strains (Flandre et al., 2003). Recently, Thiesse et al used micro- 
computerised tomography to elegantly demonstrate variations in the structure of the 
lung in different mouse strains (Thiesse et al., 2010). Airways at certain points within 
the bronchial tree were found to be wider in C57BL/6 mice compared to BALB/c 
mice. Additonally, certain airways were noted to display bulging in C57BL/6 mice 
which was not seen in BALB/c mice, leading the authors to hypothesise that reduced 
elasticity of the C57BL/6 lungs may partly account for this. Therefore, it may be that 
current methods of measuring lung function, predominantly developed using 
BALB/c mice, are less able to detect AHR in C57BL/6 mice on account of factors 
such as differences in lung structure and composition.  
 
3.3.2 Why does pOVA PIT not improve disease in this  model? 
The results presented in Figures 3.7 and 3.8 demonstrate that pOVA PIT given prior 
to OVA sensitisation and challenge does not improve AAI.  So how can these results 
be accounted for? Only a few previous studies have examined the effects of pOVA 
PIT in OVA-induced AAI (Janssen et al., 1999, Jansse  et al., 2000a, Janssen et al., 
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2000b, Barbey et al., 2004) and it is valuable to discuss these in the context of the 
data shown in this chapter. 
 
The findings of Janssen et al have similarities to those in Figure 3.7. They showed, in 
a model utilising BALB/c mice, that administering pOVA PIT subcutaneously after 
OVA sensitisation and prior to OVA challenge, led to more severe AAI compared to 
PBS treated controls (Janssen et al., 1999). In particular, AHR and the number of 
eosinophils in the BAL were increased in mice given pOVA PIT. Despite the results 
from the Janssen et al study, it was still possible that applying pOVA as shown in 
Figure 3.1 could improve disease because of several k y differences in approach.  
 
Firstly, Janssen et al administered pOVA PIT subcutaneously rather than 
intravenously. pOVA PIT exacerbated AHR and BAL eosin philia (Janssen et al., 
1999). In contrast, treatment with subcutaneous OVA (in the absence of adjuvant) 
reduced the severity of AAI. Furthermore, administer ng OVA intranasally increased 
the severity of AAI, whereas intranasal pOVA PIT did not alter disease severity 
(Janssen et al., 2000a). In that study Janssen et al found, using adoptive transfer of 
OVA-reactive T cells, that subcutaneous OVA induced a strong CD4+ OVA-reactive 
T cell response which quickly occurred within peripheral lymph nodes and spleen, 
whereas subcutaneous pOVA, intranasal OVA or intranas l pOVA all led to slower, 
more localised OVA-reactive CD4+ T cell responses (Janssen et al., 2000a). This led 
them to conclude that tolerance induction was favoured by a “strong, synchronized 
and systemic T cell response” (Janssen et al., 2000a), consistent with findings from 
others (Kearney et al., 1994). Since intravenous administration of soluble pOVA has 
previously been shown to induce rapid, systemic pOVA-reactive CD4+ T cell 
responses (Kearney et al., 1994), and to induce tolrance prior to pOVA/CFA 
immunisation (Konkel et al., 2010, Hochweller and Anderton, 2005), this implied 
that administering pOVA intravenously prior to induction of AAI as in Figure 3.1, 
would induce a systemic pOVA-reactive CD4+ T cell response and improve disease, 
but this was not found to be the case (Figures 3.7, .8). Thus, administration of 
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soluble pOVA, in a dose and route known to induce rapid and systemic activation of 
pOVA-reactive CD4+ T cells, did not improve AAI.  
 
Yet, induction of systemic T cell responses to soluble peptide does not always result 
in tolerance - Barbey et al, in a model utilising BALB/c mice, found that intranasal 
administration of pOVA and subsequent subcutaneous OVA/alum sensitisation, did 
not induce tolerance (assessed using in vitro recall responses to OVA), whereas 
treatment with intranasal OVA did induce tolerance (Barbey et al., 2004). In contrast 
to the findings of Janssen et al, they found that tolerance induced by intranasal OVA 
induced OVA-reactive CD4+ T cell responses primarily in draining lymph nodes, 
whereas intranasal pOVA induced a systemic response but did not induce tolerance 
to OVA (Barbey et al., 2004).  
 
A second important difference between the approach used in the Janssen et al study 
and that shown in Figure 3.1, is the nature of the CD4+ T cells that are being 
targeted. Janssen et al chose to give pOVA PIT after mice had been sensitised to 
OVA and prior to OVA challenge, rather than prior t sensitisation as here. Much of 
the evidence demonstrating the ability of soluble peptides to induce CD4+ T cell 
tolerance involves giving peptide prior to immunisation/sensitisation (Hochweller et 
al., 2006b). Hence, the majority of CD4+ T cells encountering peptide will be 
encountering antigen for the first time – i.e. they will be naïve. Some evidence 
suggests that it may be easier to tolerise naïve CD4+ T cells using peptide than to 
tolerise effector or memory T cells that have already responded to antigen (Liu and 
Wraith, 1995, Kurts, 2010). The heightened disease in the Janssen et al study may 
have been on account of pOVA activating effector/memory pOVA-reactive CD4+ T 
cells rather than tolerising them. Administering pOVA PIT prior to OVA 
sensitisation as in Figure 3.1 might then have been pr dicted to induce tolerance on 
account of the naïve status of the pOVA-reactive CD4+ T cells. However despite this, 
no improvement in AAI was seen here (Figure 3.7,3.8). 
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A third difference between the Janssen et al study and the experiments shown in 
Figure 3.7-3.9 are differences in mouse strains, sice BALB/c mice were used in that 
study, in contrast to the C57BL/6 mice used here. It was possible that the 
predominance of eosinophils seen after pOVA may have been influenced by the 
tendency of BALB/c mice to skew towards Th2 responses (Abbas et al., 1996), and 
therefore might not be replicated in C57BL/6 mice. However, Figure 3.7 shows that 
despite the use of C57BL/6 mice in this study, there was no improvement in AAI 
disease readouts, including eosinophilia in BAL, following PIT.  
 
Janssen et al found that maximal in vitro recall responses of  lung draining LN from 
OVA sensitised and challenged BALB/c mice were 30% lower to pOVA than to 
OVA (Janssen et al., 1999). Interestingly, while IL-5 and IL-4 were found in OVA 
stimulated cultures, only IL-5 was detected from pOVA stimulated cultures, leading 
them to conclude that this might be implicated in the increased BAL eosinophilia in 
pOVA treated mice. In initial in vitro recall experiments (such as the ones shown in 
Figure 3.4 and Figure 3.9), responses were only assessed to OVA and not to pOVA. 
In Figure 3.10 and 3.11, however, no proliferative or IL-5 recall response to pOVA 
could be elicited from splenocytes from OVA sensitised mice (regardless of whether 
or not they had received pOVA PIT). This meant that no conclusions as to whether 
or not pOVA PIT had reduced the pOVA-reactive CD4+ T cell response could be 
drawn. The lack of an in vitro response of splenocytes to pOVA may have been 
because in these experiments, mice were only sensitised to OVA and not challenged 
prior to assessment of pOVA recall responses (with the aim of shortening 
experimental time courses). Yet, Sun et al were similarly unable to demonstrate 
pOVA recall responses from splenocytes of OVA sensitised and challenged BALB/c 
mice (Sun et al., 2010).  
 
The lack of a demonstrable pOVA recall response following sensitisation with OVA 
implied that epitopes other than, or in addition to, pOVA might be important in the 
overall OVA-driven response in this model. A recent study by Yang et al gave 
support to this. In a model of OVA-induced food allergy in BALB/c mice, they 
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found that pOVA PIT given subcutaneously (using a multi-dose regime) at time-
points after oral OVA sensitisation, led to worse anaphylaxis scores and increased 
histamine release upon oral OVA challenge, compared to mice that did not receive 
pOVA PIT (Yang et al., 2010). However, the same group have also recently 
identified three further potential CD4+ T cell epitopes within OVA in addition to the 
epitope contained in pOVA, in the context of BALB/c mice (Yang and Mine, 2009). 
Treating mice with a combination of two of these peptides together with pOVA, 
significantly reduced anaphylaxis scores and histamine release upon subsequent oral 
OVA challenge (Yang et al., 2010).  
 
In summary, there are several possibilities as to why pOVA PIT did not improve 
AAI in this model:-  
 
i) Tolerance of pOVA-reactive T cells might not have ben achieved in this 
model. The failure to detect pOVA recall responses from splenocytes of OVA 
sensitised mice means that this cannot be ruled out. 
ii)  An inherent property of the response to soluble pOVA is a (Th2) 
inflammatory response to OVA which can lead to enhanced disease.  
iii)  Additional OVA CD4+ T cell epitopes might be important in driving OVA 
responses in C57BL/6 mice. Such epitopes are however likely to be different 
to those described by Yang et al since CD4+ T cells in C57BL/6 mice will 
recognise peptide in the context of I-Ab MHC class II molecules rather than I-
Ad as for BALB/c mice. 
 
3.3.3 Concluding remarks 
The findings in this chapter demonstrated that:- 
 
• a model of OVA-induced AAI in C57BL/6 mice has been established. 
• high dose pOVA PIT given intravenously prior to induction of AAI, did not 
reduce the severity of AAI.   
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The experiments described in subsequent chapters threfore sought to address:- 
 
i) whether tolerance of pOVA-reactive CD4+ T cells was being achieved 
(Chapter 4). 
ii)  whether additional CD4+ T cell OVA epitope(s) are implicated in driving 
OVA-induced AAI in C57BL/6 mice  and, if so, whether these are capable of 
improving AAI when given in the form of PIT (Chapter 5). 
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4 The effects of pOVA PIT on traceable pOVA-reactiv e CD4+ 
T cells (OT-II cells) in models of Th2 sensitisatio n and AAI 
 
4.1 Introduction 
The data in Chapter 3 demonstrated that soluble pOVA given intravenously prior to 
the induction of OVA-induced AAI, did not improve disease (Figure 3.7,3.8). Since 
no measurable in vitro recall response to pOVA could reliably be elicited from 
splenocytes from OVA sensitised mice (Figure 3.10, 3.11), it was not possible to say 
from those experiments whether or not pOVA PIT had tolerised pOVA-reactive 
CD4+ T cells. Yet the same application of soluble pOVA has previously induced 
tolerance of pOVA-reactive CD4+ OT-II cells prior to immunisation with pOVA in 
CFA (Konkel et al., 2010, Hochweller and Anderton, 2005). It was thus important to 
determine whether or not pOVA PIT was inducing tolerance of pOVA-reactive CD4+ 
T cells, as it was perhaps possible that pOVA-reactive CD4+ T cells were less 
susceptible to tolerance induction in a Th2, compared to a Th1, setting.  
 
Incorporating adoptive transfer of trackable CD4+ OT-II cells (which have TCRs 
reactive towards pOVA), into models of OVA-driven AAI and allergic sensitisation, 
would enable direct assessment of the tolerising capa ity of soluble pOVA on these 
cells in the context of Th2 mediated, OVA-driven disease. This would serve two 
main purposes. Firstly, if pOVA PIT was found to induce tolerance in such models, 
these would then provide a platform for mechanistic work involving PIT in allergic 
and AAI settings, based on the trackable nature of the OT-II cells. Secondly, if 
pOVA PIT was found to be capable of inducing tolerance of pOVA-reactive CD4+ T 
cells in an allergic setting, this could imply that other OVA epitope(s), in addition to 
pOVA, were implicated in driving OVA-induced AAI; this could perhaps then 
account for the lack of therapeutic effect of pOVA PIT in OVA-induced AAI, seen in 
Chapter 3.  
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4.1.1 Aims 
The experiments described in this chapter therefore aim d to: 
 
i) Develop models of Th2 sensitisation and AAI which incorporated adoptive 
transfer of trackable pOVA-reactive (OT-II) CD4+ T cells. 
ii)  Assess the ability of pOVA PIT to induce tolerance in pOVA-reactive (OT-
II) CD4+ T cells in settings of Th2 sensitisation and AAI. 
 
4.1.2 Approach  
Initially an approach involving adoptive transfer of naïve CD4+ OT-II cells followed 
by pOVA PIT then OVA/alum sensitisation, was taken to examine the effects of 
pOVA PIT on pOVA-reactive CD4+ T cells in the context of Th2 sensitisation. This 
model was then extended to include airway challenge, to assess the effects of pOVA 
PIT on pOVA-reactive CD4+ cells in the context of AAI. But, as discussed below, 
problems in tracking naïve OT-II cells over long periods of time also necessitated the 
development of an alternative approach. This involved the adoptive transfer of Th2 
polarised CD4+ OT-II cells followed by OVA challenge. This model nabled the 
effects of pOVA PIT in the context of AAI driven by Th2 polarised OT-II cells, to be 
assessed.  
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4.2 Results 
4.2.1 Adoptively transferred CD4 + OT-II cells increase in 
frequency and become activated following OVA/alum 
sensitisation 
The first step was to assess the ability to track adoptively transferred CD4+ OT-II 
cells and assess their responses to in vivo OVA/alum sensitisation. The approach is 
shown in Figure 4.1a. Following intravenous transfer of 2x106 CD4+ OT-II cells into 
C57BL/6 recipients, mice received either one or two OVA/alum sensitisations or 
PBS/alum as a control. 7 days after the first or second sensitisation, spleen and mLN 
were harvested and numbers and phenotype of OT-II cells were determined by flow 
cytometry.  
 
The percentage of OT-II cells in the CD4+ population (Figure 4.1b) and total CD4+ 
OT-II cells (Figure 4.1c) in the spleen, were significantly increased seven days after 
either one [day 7 (D7)] or two [day 14 (D14)] OVA/alum sensitisations, compared to 
mock sensitised controls. Although OT-II cells were still significantly increased after 
two OVA sensitisations compared to mock sensitised controls, percentages and total 
numbers of OT-II cells were reduced by around 50% compared to after only one 
sensitisation (Figure 4.1b,c).  
 
OT-II expression of CD62L (a cell surface molecule highly expressed on naïve and 
memory T cells) and CD44 (highly expressed on effector and memory T cells), was 
assessed (Figure 4.2a).  The majority of CD4+ OT-II cells prior to adoptive transfer 
were CD62LhiCD44lo - indicating a naïve phenotype (Figure 4.2b). Numbers of OT-
II cells from spleens of mock sensitised mice were too low to accurately assess 
CD62L and CD44 expression. However, following OVA sen itisation, two 
populations of OT-II cells were identified encompassing CD62LloCD44hi (associated 
with effector T cells) and CD62LhiCD44hi (associated with memory T cells) (Figure 
4.2c-e). The frequency of these populations was not altered by the number of OVA 
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sensitisations (Figure 4.2d,e). mLN data mimicked those seen in the spleen at both 
time points (data not shown).   
 
4.2.2 pOVA PIT prior to OVA/alum sensitisation redu ces the 
frequency of CD4 + OT-II cells in spleen and mLN following 
sensitisation 
The effect of pOVA PIT on CD4+ OT-II cells in the context of OVA/alum 
sensitisation was assessed. Figure 4.3 shows the experimental approach. In order to 
maximise detection of OT-II cells a short protocol was initially chosen involving 
only one OVA/alum sensitisation. Soluble pOVA or PBS as a control was given one 
day after adoptive transfer of CD4+ OT-II cells. Mice received one OVA/alum 
sensitisation on D0. OT-II cells were assessed in spleen and mLN on D7 (Figure 
4.4). Since OVA/alum is given via intraperitoneal injection, there was the possibility 
that OT-II cells may accumulate in the peritoneal cvity. To assess this, peritoneal 
wash-outs were also performed and the presence of CD4+ OT-II cells assessed in 
wash-out fluid (Figure 4.4e,f). pOVA PIT significantly reduced the percentage of 
OT-II cells in the CD4+ population and total numbers of CD4+ OT-II cells in spleen 
and mLN, compared to mice that received PBS (Figure 4.4a-d). Although OT-II cells 
were found in the peritoneal cavity, these were also reduced in the pOVA PIT group 
(Figure 4.4e,f).   
  
4.2.3 pOVA PIT prior to OVA sensitisation abrogates  the in vitro 
recall response to pOVA with limited impact on the 
response to whole OVA 
Functional responses of splenocytes following pOVA PIT were determined. 
Splenocytes were cultured with increasing doses of pOVA or OVA and the 
concentration of IL-2 measured in supernatants after 48 hours (Figure 4.5). No 
significant difference in the concentration of IL-2 was detected between pOVA 
treated or PBS treated groups in response to OVA (Figure 4.5a). High concentrations 
of IL-2 were detected after culturing splenocytes from PBS treated mice with pOVA 
(Figure 4.5b). This is likely to predominantly be due to responses of CD4+ OT-II 
cells in the spleen (quantified previously in Figure 4.4b), responding to pOVA, since 
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previously no pOVA-induced proliferative response of splenocytes had been detected 
in OVA sensitised mice in the absence OT-II adoptive ransfer (discussed in Chapter 
3).  Importantly, the IL-2 response to pOVA was abrogated in the pOVA PIT group 
(Figure 4.5b). This implied that pOVA PIT had induced tolerance of pOVA-reactive 
CD4+ OT-II cells, abrogating their IL-2 response to pOVA. However, the effect on 
the OVA response was limited and not significantly different to PBS treated controls. 
This implied that host CD4+ T cell responses to epitope(s) other than pOVA had 
been induced by OVA sensitisation.  
 
Culture supernatants after 72 hours were also assessed for Th2 cytokines such as IL-
5 – however these were below the limit of reliable detection (data not shown). A 
factor in this is likely to be that mice only receiv d one OVA sensitisation in these 
experiments.  
 
No significant differences in serum OVA-specific IgE were detected between pOVA 
PIT or PBS treated mice, although there was wide inter-group variation (Figure 4.6). 
 
4.2.4 Tolerance of CD4 + OT-II cells induced by pOVA PIT prior to 
sensitisation is likely to be primarily effected vi a deletion 
Previous work in the Anderton lab had demonstrated that soluble pOVA effected 
tolerance of CD4+ OT-II cells by inducing a rapid proliferative response followed by 
deletion (Hochweller and Anderton, 2005).  It was important to assess whether 
pOVA PIT was also inducing tolerance via deletion of OT-II cells in this setting, 
particularly as the experiments described here were conducted in different animal 
facilities to those previously used by Hochweller et al.  
 
The approach shown in Figure 4.7 was taken in order to assess OT-II cells over a 
time course following pOVA PIT. CD4+ OT-II cells were labelled with CFSE prior 
to adoptive transfer to examine in vivo proliferation. Two and a half days after pOVA 
administration, CD4+ OT-II cells in spleen had already undergone proliferation as 
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indicated by the reduction in CFSE intensity (Figure 4.8a). There was evidence of 
further rounds of proliferation having taken place by D5 and D10 (Figure 4.8a). The 
percentage of CD4+ OT-II cells in the CD4+ population (Figure 4.8b) and the total 
number of CD4+ OT-II cells in spleen (Figure 4.8c) were significantly increased on 
D2.5 in the pOVA PIT group compared to the PBS treated group. CD4+ OT-II cells 
in spleens of pOVA PIT treated mice subsequently declin d on D5 and D10 - 
indicating deletion, consistent with the findings of Hochweller et al (Hochweller and 
Anderton, 2005). Interestingly however, the total number of CD4+ OT-II cells in 
spleen on D10 were still significantly raised in the pOVA PIT group compared to 
PBS treated controls (Figure 4.8c). 
 
Results from iLN were also assessed (Figure 4.9a-c). Data were consistent with 
findings from spleen, with the exception that by D10 there was no significant 
difference in the total number of CD4+ OT-II cells in pOVA PIT and PBS treated 
groups (Figure 4.9c). 
 
On D2.5, splenocytes from pOVA PIT treated mice proliferated strongly to all 
concentrations of pOVA tested (although this was still a pOVA dependent response, 
as culturing splenocytes with medium alone resulted in low levels of proliferation) 
(Figure 4.10a). Splenocytes from PBS treated mice dd not proliferate to pOVA 
(Figure 4.10a). On D5 the proliferative response to pOVA in the pOVA PIT treated 
group had diminished and was equivalent to background levels by D10 (Figure 
4.10a). A similar but less strong proliferative response pattern to OVA was also seen 
(Figure 4.10b). 
 
Overall, these data indicate that, consistent with previous data from the Anderton lab 
(Hochweller and Anderton, 2005), CD4+ OT-II cells undergo a proliferative burst 
shortly after pOVA administration (seen here both in iLN and spleen), followed by a 
contraction phase. OT-II cells were evaluated here in spleen and iLN only, therefore 
there is a possibility that OT-II cells could be present in non-lymphoid organs. This 
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has been found previously following OT-II transfer by Reinhardt et al (Reinhardt et 
al., 2001). However, in that study it was shown that following soluble pOVA 
administration deletion of OT-II cells in lymphoid tissues was mimicked in non-
lymphoid tissues (Reinhardt et al., 2001). This is, therefore, also likely to be the case 
in the experiments shown here, although non-lymphoid tissues were not formally 
examined. These findings would therefore be consistent with the deletional paradigm 
of tolerance induction that has previously been proposed to predominant following 
high dose pOVA PIT (Hochweller and Anderton, 2005, Kearney et al., 1994). 
 
4.2.5 FoxP3 expression in CD4 + OT-II cells does not increase 
following pOVA PIT 
Typically, 3-5% of CD4+ OT-II cells were found to be FoxP3+ prior to adoptive 
transfer (as shown in the example in Figure 4.11a). The percentage of host CD4+ 
cells and CD4+ OT-II cells were assessed on D2.5, D5 and D10 following pOVA PIT 
(Figure 4.11b). The number of OT-II cells in the group that received PBS was too 
low to accurately assess the percentage of FoxP3+ OT-II cells (data not shown). 
Following pOVA PIT, the percentage of CD4+ OT-II cells that were FoxP3+ was 
lower on D2.5 than seen pre-transfer and did not increase thereafter (Figure 4.11c). 
Total numbers of FoxP3+ CD4+ OT-II cells fell from D2 to D10 (Figure 4.11d), 
reflecting the overall reduction in total CD4+ OT-II cell numbers. The percentage of 
FoxP3+ cells in the host CD4+ population was not altered following pOVA PIT (data 
not shown). 
 
4.2.6 CD4+ OT-II cells are difficult to track over the time r equired 
for the full AAI model  
So far, the tolerogenic effects of pOVA PIT on CD4+ OT-II cells had only been 
demonstrated in the context of one OVA sensitisation. To extend this in order to 
examine the effects of pOVA PIT in the context of AAI, the approach shown in 
Figure 4.12 was taken. CD4+ OT-II cells were transferred one day prior to soluble 
pOVA or PBS, and this was followed by the same protoc l that had been used to 
induce AAI in wild type mice (without OT-II cell transfer) in Chapter 3. Very few 
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CD4+ OT-II cells were detectable in mLN in either group (Figure 4.13a,b). In several 
mice from each group no OT-II cells were detectable in mLN (Figure 4.13a,b). There 
was no significant difference in lung inflammation scores (Figure 4.13c), the 
percentage of goblet cells in the airways (Figure 4.13d) or OVA-specific IgE (4.13e) 
between pOVA PIT or PBS treated groups. BAL readouts were not significantly 
different between the groups (Figure 4.14a-e)  
 
Poor OT-II cell viability over the 40 day experiment described above most likely 
accounted for the low (even absent) numbers of OT-II cells in mLN even in some 
PBS treated mice. Different approaches were therefore taken to reduce the 
experimental length. The seven day period between pOVA PIT administration or 
PBS was kept constant. In two different experiments two OVA sensitisations were 
given either 7 or 14 days apart. CD4+ OT-II cells in spleen were assessed 7 days after 
the last sensitisation. In both experiments however, OT-II cells could not consistently 
be detected and were often undetectable even in PBS treated groups (data not 
shown).  
 
4.2.7 Adoptive transfer of CD4 + OT-II cells, one OVA sensitisation 
followed by OVA challenge does not lead to an OT-II  driven 
AAI phenotype 
It therefore appeared that OT-II cells could not be reliably detected in the context of 
pOVA PIT or PBS followed by two OVA sensitisations. Data in Figure 4.1b,c had 
indicated that CD4+ OT-II cell numbers were higher after one sensitisat on compared 
to after two sensitisations. It was therefore postulated that adoptive transfer of CD4+ 
OT-II cells followed by only one OVA sensitisation a d then airway challenge may 
be sufficient to induce AAI and improve OT-II detection (this approach is shown in 
Figure 4.15). It was anticipated that an increased fr quency of CD4+ OT-II cells at 
the time of OVA airway challenge would lead to more severe AAI in comparison to 
mice that did not receive OT-II cell transfer. If so, then this CD4+ OT-II driven AAI 
phenotype could then be utilised to assess the effects of pOVA PIT on CD4+ OT-II 
cells in the context of AAI.  
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In previous experiments airway challenges were given ntranasally. It was therefore 
possible that i) the exact dose of OVA reaching the lungs following intranasal 
challenge may vary between mice and ii) that OT-II cells were likely to track to nasal 
tissues as well as to the lung. To bypass these issues, it was decided to use an 
intratracheal approach in this, and all subsequent experiments. This more invasive 
approach meant that intratracheal challenges were given once every three days (see 
approach in Figure 4.15), compared to the consecutive intranasal challenges used 
previously. Importantly however, mice continued to receive a total of three airway 
challenges. 
 
Previous experiments had also only assessed CD4+ OT-II cells within mLN and 
spleen and not within lung tissue. Difficulties in detecting OT-II cells may therefore 
have been because they were mainly within the lung following OVA challenge. In 
this experiment, therefore, the left lung lobe was digested and OT-II cells detected 
using flow cytometry. The remaining lung was assessed histologically. Few CD4+ 
OT-II cells were found in the left lung lobe or mLN after PBS challenge, whereas 
significant numbers were present in both tissues following OVA challenge (Figure 
4.16a-d). Total numbers of CD4+ OT-II cells in the spleen were not significantly 
different regardless of whether mice were challenged with PBS or OVA (Figure 
4.16e,f). 
 
BAL data from the same experiment are shown in Figure 4.17a,b. Importantly, very 
few eosinophils were detected in mice that received CD4+ OT-II cells and OVA 
challenge (Figure 4.17b). In contrast, a higher percentage of eosinophils were 
detected in BAL from mice that had had OVA challeng in the absence of OT-II 
transfer (Figure 4.17b). Of note, the percentage of osinophils in BAL in mice that 
did not receive CD4+ OT-II cells constituted around 10% of total BAL cells - 
substantially lower than the percentage of eosinophils seen after two OVA 
sensitisations followed by OVA challenge in Chapter 3 (Figure 3.3b). Lung 
inflammation scores were low in all groups (Figure 4.17c) – similar inflammation 
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scores were found in OVA challenged mice regardless of whether or not they had 
had OT-II cell transfer.  
 
These data indicated that although many CD4+ OT-II cells were present in the lung 
following OVA challenge, they did not appear to be g nerating a Th2 effector 
response. Since significant eosinophilia was only detected in BAL from mice that 
had OVA challenge in the absence of OT-II cell transfer, this implied that the OT-II 
response to OVA was likely to be counteracting the host CD4+ Th2 responses to 
OVA. One OVA sensitisation did not therefore appear to induce strong and/or stable 
Th2 polarisation of CD4+ OT-II cells. 
 
 
4.2.8 CD4+ OT-II cells can be polarised to a Th2 phenotype in vitro 
and their phenotype is comparable to Th2 polarised DO11.10 
CD4+ cells 
It was therefore important to examine whether OT-II cells could be polarised to a 
Th2 phenotype in vitro. The approach shown in Figure 4.18a was taken. CD4+ cells 
from transgenic DO11.10 mice, which also have TCRs reactive to pOVA 323-339 
but are on the BALB/c background, were included as a comparison.  
 
Supernatants from OT-II and DO11.10 Th2 polarisation cultures both contained high 
concentrations of IL-13 (Figure 4.18b). IL-5 was present in supernatants from 
DO11.10 and OT-II cultures but a much higher concentration was detected in 
supernatants from DO11.10 cell cultures (Figure 4.18b). 
 
CD4+ cells were isolated after Th2 polarisation, rested for three days in IL-2, then 
cultured with irradiated strain-matched splenocytes and OVA or pOVA. Freshly 
isolated CD4+ cells from naïve DO11.10 or OT-II mice were also cultured. Th2 
polarised CD4+ OT-II cells produced the most IL-2 upon culture with OVA, naïve 
OT-II cells had the second highest IL-2 response (Figure 4.18c). Th2 polarised and 
Chapter 4 Results 
 109 
naïve DO11.10 CD4+ cells had similar IL-2 responses to OVA (Figure 4.18c). 
Concentrations of IL-2 produced in response to pOVA were above the limit of 
detection for all groups (data not shown). 
 
IL-13 and IL-5 were produced by Th2 polarised OT-II and DO11.10 CD4+ cells in a 
dose dependent manner to OVA (Figure 4.18d,e). In co trast to the lower IL-5 
concentration in supernatant from OT-II Th2 polaristion cultures compared to 
DO11.10 Th2 polarisation cultures (Figure 4.18b), upon recall to OVA there was no 
inability of Th2 polarised CD4+ OT-II cells to produce IL-5, compared to Th2 
polarised DO11.10 CD4+ cells (Figure 4.18e). IL-13 and IL-5 in Th2 DO11.10 and 
OT-II cultures were above limits of detection for all doses of pOVA tested (Figure 
4.18 f,g). Naïve CD4+ T cells from either OT-II or DO11.10 mice produced IL-13 
more efficiently in response to pOVA than to OVA (Figure 4.18d,f). 
 
Intracellular cytokine staining for Th2 cytokines was performed numerous times on 
CD4+ T cells after 4 days of culture in Th2 polarising conditions. However, IL-5, IL-
13 or IL-4 were not detected intracellularly (data not shown). However, IL-13 was 
detected intracellularly in CD4+ OT-II cells after 6 days of culture in Th2 polarising 
conditions and not in cells cultured in Th1 or Th0 conditions (Figure 4.19a,b). There 
was also increased expression of the Th2-associated transcription factor GATA-3 in 
CD4+ OT-II cells after 6 days of culture in Th2 polarising conditions (Figure 4.19c). 
GATA-3 expression was greater in the Th2 CD4+ OT-II cells when compared to 
either Th0 or Th1 polarised CD4+ OT-II cells, as evidenced by the increase in mean 
fluorescence intensity (Figure 4.19c). No IL-4 or IL-5 was detected in Th2 polarised 
CD4+ OT-II cells by intracellular staining after 6 days of culture (data not shown). 
 
In summary, naïve OT-II cells could be effectively polarised to a Th2 phenotype in 
vitro. Following Th2 polarisation CD4+ OT-II cells produced more IL-2 in response 
to OVA compared to that produced by naïve CD4+ cells, and in vitro recall responses 
to OVA and to pOVA were associated with the production of Th2 cytokines. 
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4.2.9 Adoptive transfer of Th2 polarised CD4 + OT-II cells induces 
AAI following OVA airway challenge 
Previous studies have shown that adoptive transfer of Th2 polarised pOVA-reactive  
CD4+ cells followed by airway challenge induces features of AAI (Cohn et al., 1997, 
Jacobsen et al., 2008, Hansen et al., 1999) The appro ch shown in Figure 4.20 was 
used to assess whether OT-II Th2 cells, generated as shown in Figure 4.18, were 
capable of inducing AAI. 4.5x106 OT-II cells were transferred, consistent with some 
other studies (Cohn et al., 1997). 
 
Adoptive transfer of Th2 polarised CD4+ OT-II cells followed by OVA challenge 
induced pulmonary inflammation (Figure 4.21a,b). Peri-vascular inflammation 
scores were significantly increased in the group that received Th2 polarised CD4+ 
OT-II cells followed by OVA challenge compared to mice that received naïve CD4+ 
OT-II cells and PBS challenge (Figure 4.21b). Regarding peri-bronchiolar 
inflammation, this was significantly increased in the group that received Th2 
polarised CD4+ OT-II cells followed by OVA challenge compared to the group that 
received Th2 polarised CD4+ OT-II cells and PBS challenge (Figure 4.21b). No 
significant difference was found between the inflammation scores of mice that 
received Th2 polarised CD4+ OT-II cells followed by OVA challenge compared to 
mice that received naïve CD4+ OT-II cells and OVA challenge, although it would be
interesting to assess whether this was still the case if the experiment was repeated 
with larger group sizes. Inflammation scores were higher than those seen previously 
in AAI induced without OT-II transfer (Figure 3.2b). Interestingly, transfer of 
4.5x106 naïve CD4+ OT-II cells followed by OVA challenge also induced some 
pulmonary inflammation (Figure 4.21a,b). Goblet cells were seen in both groups that 
received OVA challenge regardless of whether the CD4+ cells transferred were naïve 
or Th2 polarised (Figure 4.21 c,d). However, total BAL cells and the percentage and 
total numbers of eosinophils in BAL were only significantly raised following Th2 
CD4+ OT-II transfer and OVA challenge (Figure 4.22a-e). These data are compatible 
with some IL-13 but little IL-5 previously detected in supernatants from naïve CD4+ 
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OT-II cells after in vitro culture with OVA (Figure 4.18d,e). OVA-specific IgE was 
detectable in mice that received Th2 polarised CD4+ OT-II cells and OVA challenge 
OVA, but not in controls (Figure 4.22f). This was surprising given the short 
timeframe of this experiment. However, OVA-specific IgE was not detected in 
subsequent similar experiments.  
 
CD4+ OT-II cells in the left lung lobe were significantly increased in the group that 
received Th2 CD4+ OT-II and OVA challenge compared to all other groups (Figure 
4.23a,b). The percentage of OT-II cells in the CD4+ population in the left lung lobe 
was not significantly different between mice that received naive CD4+ OT-II cells 
and OVA challenge versus mice that received Th2 CD4+ OT-II cells and PBS 
challenge (Figure 4.23a).  
 
4.2.10 pOVA PIT prior to OVA challenge significantl y improves 
Th2 CD4+ OT-II driven AAI 
The effects of pOVA PIT on Th2 polarised CD4+ OT-II driven AAI were examined 
using the approach in Figure 4.24. pOVA PIT prior t OVA challenge resulted in  
lower pulmonary inflammation scores (Figure 4.25a,b) and a lower percentage of 
goblet cells in small airways (Figure 4.25c,d) compared to PBS treated, OVA 
challenged controls. There were significantly fewer total BAL cells and significantly 
fewer eosinophils in BAL from pOVA PIT treated OVA challenged mice compared 
to PBS treated OVA challenged controls (Figure 4.26a-d). Examples of BAL 
cytospins from pOVA treated versus PBS treated OVA challenged mice are shown in 
Figure 4.26c where the reduction in the frequency of eosinophils in BAL following 
pOVA PIT can be seen. Total lymphocytes in BAL were also significantly reduced 
in the pOVA PIT treated OVA challenged group compared to the PBS treated OVA 
challenged group (Figure 4.26f). There was no significant difference in the total 
number of macrophages in BAL between groups (Figure 4.26e). 
 
Reduced AAI severity was associated with a significant reduction in CD4+ OT-II 
cells in the lung in pOVA PIT treated OVA challenged mice compared to PBS 
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treated OVA challenged mice (Figure 4.27a,b). Total CD4+ cells in the lungs of PBS 
treated OVA challenged mice were also increased, an were greater than the total 
number of lung CD4+ OT-II cells, indicating an infiltration of host CD4+ cells into 
the inflamed lung (Figure 4.27c). The percentage of OT-II cells in the CD4+ 
population and the total number of OT-II cells in the lung in the pOVA PIT treated 
group were not significantly different to PBS challenged controls (Figure 4.27a,b). 
There was no significant reduction in CD4+ OT-II cells in the mLN of pOVA PIT 
treated OVA challenged mice compared to PBS treated OVA challenged mice 
(Figure 4.27d,e). There was no significant difference in the percentages or total 
numbers of OT-II cells in the spleen between groups (Figure 4.27g,h). Hence, 
improvements in disease in the pOVA PIT group were associated with a marked 
reduction in total CD4+ OT-II cells in the lung, but no significant difference was 
found in total CD4+ OT-II cells in the mLN and spleen between the two gr ups.  
 
Prior to adoptive transfer, Th2 polarised CD4+ OT-II cells consisted of a mixture of 
CD62LloCD44hi (associated with effector cells) and CD62LhiCD44hi (associated with 
memory cells) populations (Figure 4.28a). On D8, the majority of CD4+ OT-II cells 
in the left lung lobe displayed an effector phenotype in all groups (Figure 4.28b,c). 
There was no significant difference in the percentages of effector or memory cells in 
the CD4+ OT-II population in lung, mLN or spleen between pOVA PIT treated OVA 
challenged or PBS treated OVA challenged mice (Figure 4.28b-g). 
 
The concentration of IL-10 in BAL fluid was very low and did not differ 
significantly between groups (data not shown). In addition, in these experiments, 
OVA-specific IgE was not detected in any group (data not shown). 
  
4.2.11 pOVA PIT does not induce FoxP3 expression in  CD4+ OT-II 
cells in Th2 CD4 + OT-II driven AAI 
FoxP3 expression in Th2 polarised CD4+ OT-II cells was low (typically around 
0.5%) at the time of adoptive transfer (Figure 4.29a). FoxP3 expression in CD4+ OT-
II cells in the lung remained low on D8 and was notsignificantly altered following 
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pOVA PIT with or without OVA challenge (Figure 4.29b,c). The expression of 
FoxP3 in host CD4+ T cells was also unaffected (Figure 4.29d).  
 
4.2.12 CD4+ OT-II cells are increased in pOVA PIT treated mice  
compared to PBS treated mice prior to first challen ge in Th2 
OT-II driven AAI 
The percentage of OT-II cells in the CD4+ population in peripheral blood was 
assessed on D-1 i.e. one day prior to OVA challenge, and was significantly increased 
in pOVA PIT treated mice compared to PBS treated controls (Figure 4.30). It was 
possible that CD4+ OT-II cells within peripheral LNs and spleen were at a lower 
frequency than seen in blood at this time point and lso that the percentage of CD4+ 
OT-II cells may have reduced (i.e. as a consequence of deletion) in the 24 hours 
before the first OVA challenge on D0. A separate experiment was therefore carried 
out to assess CD4+ OT-II cells in blood, peripheral LNs and spleen and their 
functional responses on D0 prior to OVA challenge (s e approach Figure 4.31).  
 
The percentage of OT-II cells in the CD4+ population in peripheral blood was still 
significantly higher in the pOVA PIT group compared to PBS treated controls on D0 
(Figure 4.32a) and higher than seen on D-1 in the previous experiment (Figure 4.30). 
Percentages and total numbers of CD4+ OT-II cells were also increased in iLN and 
spleen (Figure 4.32b-e). 
 
Concentrations of IL-2 in supernatants from in vitro splenocyte cultures were very 
high in both groups, even in the absence of antigen (Figure 4.33a,b). Overall, more 
IL-2 was produced by splenocytes from PBS treated mice, although a dose dependent 
response to antigen was only seen in response to pOVA (Figure 4.33b). IL-5 
production was similar in both groups, although again this was not solely an antigen 
dependent response (Figure 4.33c,d). Therefore, despite around five times as many 
CD4+ OT-II cells present in spleens of pOVA PIT treated mice (Figure 4.32e), IL-2 
and IL-5 production from splenocytes was not higher than from splenocytes from 
PBS treated mice (Figure 4.33a-d). Notably, IL-10 was produced by splenocytes 
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from pOVA PIT treated mice in a dose-dependent manner to pOVA (Figure 4.33f). 
This was not seen in cultures derived from PBS treated controls (Figure 4.33f). 
Whether this was on account of the greater frequency of OT-II cells in the pOVA 
PIT group, or the induction of, or a skewing towards IL-10 production by OT-II 
cells, is unclear from these experiments. No dose dependent IL-10 response to OVA 
was seen in either group (Figure 4.33e). 
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Figure 4-1: Adoptively transferred CD4+ OT-II cells are increased after OVA sensitisation
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Figure 4-2: Adoptively transferred CD4+ OT-II cells become activated after OVA sensitisation
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Figure 4-3: Experimental approach to assess OT-II cells after one OVA sensitisation +/- pOVA 
PIT
Chapter 4 Results 
 118 
Figure 4-4: pOVA PIT prior to OVA sensitisation reduces the number of OT-II cells in spleen 
and mLN
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Figure 4-5: pOVA PIT prior to OVA sensitisation abrogates the recall response to pOVA with 
limited impact on the IL-2 responsess to OVA
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Figure 4-6: pOVA PIT prior to OVA sensitisation does not significantly alter OVA-specific IgE
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Figure 4-7: Experimental approach to assess the fate of OT-II cells following pOVA PIT
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Figure 4-8: pOVA PIT induces proliferation of OT-II  cells in the spleen followed by deletion
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Figure 4-9: pOVA PIT induces proliferation of OT-II  cells followed by deletion in peripheral 
LN
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Figure 4-10: Time course of OVA and pOVA proliferative recall responses following pOVA PIT
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Figure 4-11: pOVA PIT does not increase FoxP3 expression in CD4+ OT-II cells
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Figure 4-12: Experimental approach for incorporating CD4+ OT-II transfer into the AAI model 
+/- pOVA PIT
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Figure 4-13: Difficulties in tracking adoptively transferred CD4+ OT-II cells to D32
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Figure 4-14: Adoptive transfer of naïve CD4+ OT-II cells followed by pOVA PIT and induction 
of AAI does not alter BAL readouts on D32
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Figure 4-15: Experimental approach examining the effects of naïve CD4+ OT-II cell transfer, 
one OVA sensitisation and OVA challenge
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Figure 4-16: CD4+ OT-II cells are present in the lung after one sensitisation and OVA challenge
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Figure 4-17: Adoptive transfer of CD4+ OT-II cells, one OVA sensitisation followed by OVA 
challenge does not induce an OT-II driven AAI phenotype
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Figure 4-18: CD4+ OT-II cells can be polarised to a Th2 phenotype in vitro
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Figure 4-19: IL-13 and GATA-3 are detectable intracellularly in CD4 + OT-II cells after 6 days 
of culture in Th2 polarising conditions
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Figure 4-20: Experimental approach for experiments examining the potential of Th2 polarised 
CD4+ OT-II cells to induce AAI
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Figure 4-21: Adoptively transferred Th2 polarised CD4+ OT-II cells induce pulmonary 
inflammation consistent with AAI upon OVA airway challenge
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Figure 4-22: Adoptive transfer of Th2 polarised CD4+ OT-II cells followed by OVA challenge 
induces BAL changes consistent with AAI and can also induce OVA-specific IgE
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Figure 4-23: Induction of AAI following adoptive transfer of Th2 OT-II cells is associated with 
increased CD4+ OT-II cells in the lung
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Figure 4-24: Experimental approach to examine the effects of pOVA PIT on Th2 OT-II driven 
AAI
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Figure 4-25: pOVA PIT prior to OVA challenge improves pulmonary inflammation in Th2 OT-
II driven AAI
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Figure 4-26: pOVA IT prior to OVA challenge improves BAL readouts in Th2 OT-II driven 
AAI
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Figure 4-27: Therapeutic effects of pOVA PIT in Th2 OT-II driven AAI are associated with 
fewer CD4+ OT-II cells in the lung on D8
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Figure 4-28: Assessing activation status of CD4+ OT-II cells in the context of pOVA PIT in Th2 
OT-II driven AAI
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Figure 4-29: Characterisation of FoxP3 expression of CD4+ OT-II and host cells after pOVA 
PIT in Th2 OT-II driven AAI
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Figure 4-30: The percentage of OT-II cells in the CD4+ population in blood is increased in 
pOVA PIT treated mice on D-1
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Figure 4-31: Experimental approach for functional assessment of Th2 polarised CD4+  OT-II 
cells 4 days after pOVA PIT
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Figure 4-32: CD4+ OT-II cells are elevated in blood, spleen and peripheral LN on D0 following 
pOVA PIT
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Figure 4-33: Splenocytes harvested 4 days following pOVA PIT produce IL-10 in response to 
pOVA in vitro
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Figure 4-34: Overview of the outcomes from the OT-II adoptive transfer models described in 
Chapter 4
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4.3 Discussion 
4.3.1 Overview of the experimental findings in this  chapter 
Figure 4.34a-d summarises the outcomes of the experiments involving adoptive 
transfer of naïve CD4+ OT-II cells in this chapter. Although pOVA PIT induced 
tolerance of naïve CD4+ OT-II cells in the context of one OVA/alum sensitisation, 
one sensitisation was insufficient to induce a reliable Th2 recall response (Figure 
4.34a). However, OT-II cells were difficult to track in longer models (Figure 
4.34b,c). It is probable that poor viability of naïve CD4+ OT-II cells over the course 
of these experiments was a major contributory factor to these difficulties. Indeed, 
rapid attrition of naïve CD4+ T cells has been reported by others, using a different 
transgenic system (Hu et al., 2001). Such problems are not associated with 
previously published models examining pOVA PIT after adoptive transfer of naïve 
OT-II or DO11.10 cells, because pOVA/CFA immunisations in these studies 
generate a strongly polarised immune response after only one immunisation 
(Kearney et al., 1994, Konkel et al., 2010).  Furthe more, although the shortened 
approach shown in Figure 4.34d, consisting of one sensitisation and three challenges, 
enabled detection of OT-II cells in lung, LN and spleen; AAI was not induced, 
suggesting insufficient or unstable polarisation to a pathogenic Th2 phenotype. In 
contrast, in the model shown in Figure 4.34e, which in orporated Th2 polarised OT-
II cells, AAI was induced, OT-II cells were easily trackable and pOVA PIT was 
found to reduce the severity of AAI. 
 
A further outcome from the experiments in this chapter was that in the OVA/CFA 
setting, pOVA PIT tolerised the pOVA response with l mited impact on the overall 
response to OVA (Figure 4.5). This suggested that other T cell epitope(s) in addition 
to pOVA were likely to be involved in the overall response to OVA. 
 
This discussion will focus on the effects of pOVA PIT in the experiments involving 
the adoptive transfer of i) naïve CD4+ OT-II  cells, ii) Th2 OT-II cells, and then 
discuss the issues surrounding the potential for additional OVA T cell epitope(s). 
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4.3.2 Mechanisms of tolerance induction of naïve CD 4+ OT-II cells 
using pOVA PIT in the context of one OVA/alum 
sensitisation 
Figures 4.3-4.5 indicate that pOVA PIT prior to one OVA/alum sensitisation induced 
tolerance of pOVA-reactive CD4+ OT-II cells. This is evident from the reduction in 
CD4+ OT-II cells in spleen and peripheral LN seven days fter OVA sensitisation 
(Figure 4.4a-d), together with the abrogation of in vitro IL-2 production by 
splenocytes in response to pOVA (Figure 4.5b). These findings are consistent with 
previous data from the Anderton lab demonstrating the ability of pOVA PIT to 
induce tolerance of naïve CD4+ OT-II cells prior to pOVA/CFA immunisation 
(Konkel et al., 2010, Hochweller and Anderton, 2005).  
 
Previous studies using adoptive transfer of transgeic pOVA-reactive CD4+ T cells 
(both DO11.10 cells into BALB/c mice as well as OT-II cells into C57BL/6 mice), 
have shown that intravenous pOVA PIT induces rapid roliferation of pOVA-
reactive CD4+ cells (Kearney et al., 1994, Hochweller and Anderton, 2005). The total 
number of the pOVA-reactive T cells tends to peak three days after pOVA PIT and 
this peak is followed by a contraction phase, most rapid 3-5 days after pOVA PIT 
(Kearney et al., 1994, Hochweller and Anderton, 2005). This has been proposed to 
occur due to the wholesale deletion of pOVA-reactive CD4+ cells, as a consequence 
of insufficient upregulation of the costimulatory molecule CD40 on DCs, in 
conditions promoting tolerance (Hochweller and Anderton, 2005). Hence, although 
OT-II cells do upregulate the CD40 ligand (CD154) in response to the efficient TCR 
ligation provided by pOVA PIT, the lack of strong CD40-CD154 ligation results in a 
failure of OX40L upregulation on the DC (Hochweller and Anderton, 2005). This 
prevents the upregulation of the anti-apoptotic proteins Bcl-2 and Bcl-xL by the 
responding T cell, which is known to occur upon OX40L on the DC ligating to 
OX40 on the T cell (Hochweller et al., 2006a, Hochweller and Anderton, 2005, 
Rogers et al., 2001). Indeed, administering an OX40 agonist antibody 2 days after 
high-dose PIT has been found to prevent tolerance iduction and inhibits the 
contraction phase, in a model utilising transgenic CD4+ T cells reactive to 
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cytochrome c (Bansal-Pakala et al., 2001). The datain Figures 4.7-4.9 are consistent 
with a proliferative phase followed by a contraction phase. In the spleen, loss of 
CD4+ OT-II cells had evidently begun by day 5 after pOVA PIT (Figure 4.8b,c). In 
the iLN however, such loss appeared to occur predominantly after day 5 and prior to 
day 10 (Figure 4.9b,c).  
 
Despite this evidence supporting the deletional tolerance paradigm, total numbers of 
CD4+ OT-II cells were still higher in the spleen 10 days after pOVA PIT compared 
to PBS treated mice (Figure 4.8c).  By extrapolation, this means that the number of 
CD4+ OT-II cells in spleens of pOVA PIT treated mice would also be raised 
compared to PBS treated controls on the day of OVA/alum sensitisation for the 
experiments shown in Figure 4.3-4.6. Therefore, in the pOVA PIT group, the 
reduction in the total number of CD4+ OT-II cells seven days after OVA sensitisation 
and the abrogation of IL-2 response to pOVA (Figure 4.4b,d and Figure 4.5), occurs 
despite an increased number of CD4+ OT-II cells in spleen at the time of OVA 
sensitisation. So why is this the case? 
 
The de novo expression of FoxP3 by naïve CD4+ T cells has been associated with 
tolerance induction in OVA-reactive (DO11.10) CD4+ T cells when OVA is 
expressed as a self-antigen in recipient mice (Thomps n et al., 2011), and after 
continuous delivery of very low dose peptide (Verginis et al., 2008).  Importantly 
here, the percentage of CD4+ OT-II cells that were FoxP3+ did not change in 
response to pOVA PIT (Figure 4.11), indicating that OT-II cells are not converting to 
FoxP3+ T regulatory cells following pOVA PIT. Pape et al have, however, 
previously shown that a small population of pOVA-reactive CD4+ T cells, (DO11.10 
cells in that study), do escape deletion following pOVA PIT, but remain in a state of 
anergy (Pape et al., 1998). Such cells had a reduced, but not abrogated, capacity to 
proliferate in vivo following pOVA/CFA immunisation (Pape et al., 1998). pOVA-
reactive CD4+ T cells that escaped deletion following pOVA PIT also displayed a 
reduced ability to produce IL-2 and TNF-α in response to pOVA stimulation i vitro 
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12 days after pOVA PIT (Pape et al., 1998). A similar anergic phenotype has also 
been found by others in similar studies (London et al., 2000).  
 
In summary, the data in Figures 4.3-4.10 are consistent with pOVA PIT inducing a 
proliferative burst in naïve CD4+ OT-II cells, followed by an extensive contraction 
phase. A population of CD4+ OT-II cells escape deletion and are most likely to be in 
a state of anergy, consistent with previous studies.  
 
4.3.3 Issues related to inducing tolerance of antig en-experienced 
T cells 
One reason why the Th2 OT-II approach was not favoured initially was because 
recently activated or memory T cells are often thought to be more resistant to 
tolerance induction, compared to naïve T cells (Liu and Wraith, 1995, Kurts, 2010). 
Previously activated cells, particularly memory cells, can proliferate in response to 
low concentrations of antigen i vitro (London et al., 2000). Memory T cells also 
rely less on costimulation. For example, London et al found that in vitro proliferation 
of memory CD4+ DO11.10 cells was unaffected when APC lacked CD40, and was 
only minimally reduced when APC lacked CD80 and CD86 (London et al., 2000). 
Memory and effector CD4+ T cells, in contrast to naïve CD4+ T cells, have also been 
found capable of responding to antigen presented by APC with low costimulatory 
ability, such as non-activated B cells (Croft et al., 1994). Hence, these reduced 
costimulatory requirements and heightened antigen sensitivity, may mean that PIT is 
less likely to induce tolerance of effector/memory T cells. Indeed, several studies 
have been unable to induce tolerance in predominantly memory T cell populations 
using OVA protein orally (Chung et al., 1999), intravenous high dose pOVA  
(London et al., 2000) or, perhaps unsurprisingly given the apparent lack of 
dependence on costimulation via CD40L, using CD40L blockade (Chen et al., 2004). 
Interestingly, other studies have been able to demonstrate tolerance in effector and/or 
memory populations. Nasreen et al found that transferring memory CD4+ OT-II cells 
(generated in vitro after 7 days of culture with pOVA), into transgenic mice in which 
steady-state DCs expressed OVA, led to tolerance (Nasreen et al., 2010). In that 
Chapter 4 Results 
 162 
study, an initial proliferation phase was followed by a contraction phase, similar to 
that described here in respect to the response of naïve OT-II cells to soluble pOVA 
(Nasreen et al., 2010). Furthermore, Higgins et al found that high dose intravenous 
PIT induced tolerance of hemagglutinin (HA)-reactive transgenic CD4+ cells, 6 days 
after infection with vaccinia virus expressing HA, i.e. when cells were likely to be of 
an effector phenotype (Higgins et al., 2002). Campbell et al were also able to 
demonstrate therapeutic improvement using PIT, given only one day after allergen 
airway challenge; again when many allergen-reactive eff ctor T cells were likely to 
be present (Campbell et al., 2009). Therefore, althoug  it may be more difficult, it is 
still possible to induce tolerance of antigen-experienced T cells, as found here in the 
experiments shown in Figure 4.25-4.26. 
 
In summary, while pOVA PIT did not improve OVA-induced AAI in Chapter 3, 
pOVA PIT did improve disease when AAI was solely driven by Th2 polarised 
pOVA-reactive CD4+ cells, even though these cells were antigen-experienced. A key 
question is whether tolerance induced by pOVA PIT in the Th2 transfer model is 
effected by the same mechanisms that are thought to be responsible for inducing 
tolerance of naïve CD4+ OT-II cells i.e. predominantly deletional? To address this 
requires further discussion of the nature of the transferred Th2 cells in this model. 
 
 
4.3.4 What is the activation status of the Th2 pola rised OT-II cells 
upon transfer? 
It is not possible from the experiments conducted in th s chapter to specify the exact 
effector/memory status of the transferred Th2 OT-II population.  However, the pre-
transfer Th2 polarised OT-II population was CD44hi with a mixture of CD62Llo and 
CD62Lhi expressing cells (Figure 4.28a). This could indicate a mixed 
effector/memory population (MacLeod et al., 2009, Sprent and Surh, 2002). The 
findings of Hu et al are particularly relevant here. They used a similar protocol to 
polarise transgenic CD4+ T cells reactive to cytochrome c, to a Th2 phenotype (Hu et 
al., 2001). Cells were then adoptively transferred into MHC II-/- mice or rested for a 
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further 3 days in medium alone and then transferred (Hu et al., 2001).  On the day of 
transfer, 57% of non-rested Th2 CD4+ cells were actively proliferating compared to 
only 6% of cells after resting (Hu et al., 2001). Adoptive transfer of non-rested Th2 
CD4+ cells led to an expansion phase followed by a contraction phase, resulting in a 
long-lived population (Hu et al., 2001). In contras, although transfer of rested Th2 
CD4+ cells also resulted in a long-lived population, this occurred in the absence of a 
proliferation/contraction phase (Hu et al., 2001).  
 
The findings of Hu et al, together with the CD44/CD62L expression of the Th2 cells 
pre-transfer shown in Figure 4.28a, imply that:- 
 
i) it is likely that the Th2 OT-II cells transferred here contained a mixture of 
effector and memory T cells, or at least cells that were capable of 
becoming memory T cells. 
 
ii)  Th2 OT-II cells were likely to have proliferated init ally following 
transfer since no rest period was included in these experiments. This may 
be implicated in the high cytokine concentrations detected in cultures in 
the absence of antigen, 4 days after adoptive transfer (Figure 4.33).  
 
4.3.5 How might the therapeutic effects of pOVA PIT  in Th2 OT-II 
driven AAI be mediated? 
It is important to note that OT-II mice used in this project were RAG sufficient and 
therefore could express endogenous TCR α and/or β chains. This could allow for the 
generation of pOVA-reactive TCRs with subtly different requirements for 
recognition of the pOVA I-Ab peptide-MHC complex. On this point it is worth 
considering the existence of so-called type B cells (cells that respond to exogenous 
peptide only and not to the same peptide derived from naturally processed protein) 
(Viner et al., 1996). In contrast, type A T cells can respond to their epitope either 
when processed from whole protein or when delivered in peptide form. Since OT-II 
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mice were originally derived following OVA immunisation this means that OT-II 
CD4+ cells were originally type A cells (Barnden et al., 1998). 
 
In the experiments shown in Figure 4.18-4.33 OT-II cells were polarised to a Th2 
phenotype using pOVA, and not OVA, stimulation. It is herefore possible that under 
these conditions T cells expressing variant TCRs able to respond in a type B manner 
(i.e. to peptide but not protein) could have been preferentially expanded. In this 
project every OT-II mouse was screened for the appropriate Vα and Vβ TCR chains 
prior to use and both chains were found on around 90% of CD4+ T cells (Appendix 
8.1). While the remaining 10% of CD4+ cells may recognize pOVA in a 
conformation different to that found after natural processing of OVA (as a 
consequence of α or β chain rearrangement), it seems unlikely that such cells would 
constitute a large proportion of the remaining 10% of CD4+ T cells. The effect this 
may have on the type A/type B ratio of OT-II cells post polarization is thus likely to 
be small.  
 
Perhaps most pertinently, it is clear from the experim nts in this chapter that Th2 
OT-II cells polarised using pOVA are capable of responding to OVA (as shown in 
Figure 4.18 in vitro and that disease is induced following OVA challenge in Figures 
4.21-4.26). Thus, the polarised population is likely to contain a substantial population 
of type A cells (Viner et al., 1996).  
 
The reduced severity of AAI in the pOVA PIT group was associated with a 
significant reduction in the total number of CD4+ OT-II cells in the lung (Figure 
4.27b). Interestingly, there was no significant difference in total number of CD4+ 
OT-II cells in mLN (Figure 4.27e). These lung data would be compatible with pOVA 
PIT inducing deletion of CD4+ OT-II cells (as proposed in the case of pOVA PIT and
naïve OT-II cells), however the mLN findings would fit less well with this 
conclusion. Again, there was no evidence that effector ells were converting to 
FoxP3+ cells following pOVA PIT (Figure 4.29).  
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The stark reduction in total CD4+ OT-II cells seen in the lung and not in the mLN in 
the pOVA PIT group could also suggest:- 
 
i) that pOVA PIT affects the ability of Th2 OT-II cells to migrate to the lung 
upon OVA challenge 
 and/or  
ii)  that pOVA PIT induces apoptosis of Th2 OT-II cells upon encountering 
OVA in lung.  
 
These possibilities are further discussed below. 
 
4.3.6 Does pOVA PIT inhibit the homing of Th2 CD4 + OT-II cells to 
the lung during OVA challenge? 
The data in Figure 4.27a,b indicate that Th2 OT-II cells are found within the lung 
even in mice that only received PBS challenge. The lungs were perfused with PBS 
via the heart prior to digestion so it is unlikely that this represents OT-II cells that 
were present in the blood. Furthermore, Figure 4.23a,b shows that following adoptive 
transfer of naïve OT-II cells and PBS challenge, very f w OT-II cells were present in 
the lung. Data from Harris et al suggest that this could be the result of differences in 
CD62L expression between the transferred populations. I  that study, transgenic 
CD4+ T cells reactive towards cytochrome c were activated and polarised in vitro for 
5-6 days which, similar to the findings shown in Figure 4.28a, induced 
CD44hiCD62Llo/med and CD44hiCD62Lhi populations (Harris et al., 2002). 5 days after 
adoptive transfer (in the absence of airway challenge), transferred cells were found in 
lung and mLN (Harris et al., 2002). In the LN these were predominantly 
CD44hiCD62Lhi, whereas those in the lung were predominantly CD44hiCD62Llo/med 
(Harris et al., 2002). By labelling transferred cells with CFSE in that study, there was 
also evidence that airway challenge with moth cytochr me c induced proliferation of 
cytochrome c-reactive T cells present in the LN, but not in the lung (Harris et al., 
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2002). However, both populations produced effector ytokines (Harris et al., 2002). 
A subsequent increase in T cells into the lungs following airway challenge, occurred 
as a result of cytochrome c-reactive T cells proliferating in draining LN and 
migrating to the lung, rather than proliferation of the cells that had initially homed to 
the lung following adoptive transfer (Harris et al., 2002).  
 
Consistent with the findings of Harris et al, some Th2 OT-II cells appear to home to 
the lung following adoptive transfer prior to OVA challenge (Figure 4.27a,b). Thus, 
if pOVA PIT affected the migration of Th2 OT-II cells from the mLN to the lung, 
this could account for the findings in Figure 4.25-4.27, particularly since the 
percentage, and total number, of OT-II cells in thelung in the pOVA PIT OVA 
challenge group is very similar to the PBS challenged roups (Figure 4.27a,b). These 
findings are similar to the previously discussed Campbell et al study where PIT led 
to reduced numbers of Th2 CD4+ cells in the lung, while the number of Th2 CD4+ 
cells in mLN was not significantly different to controls (Campbell et al., 2009). It is 
very difficult to identify potential mechanisms tha could inhibit Th2 cell migration 
from the mLN to the lung, because a multitude of chemokine-chemokine receptor 
interactions are implicated in the homing of Th2 cells to the lung (Medoff et al., 
2008). There is also evidence of substantial redundancy in these mechanisms 
(Medoff et al., 2008), which appear to vary according to the activation status of the T 
cell (Tager et al., 2003). Two prime candidates are the chemokine receptors CCR4 
and CCR8, both of which are induced upon Th2 differentiation (Medoff et al., 2008); 
however, the role of these in AAI is unclear. Some studies have found no absolute 
requirement for either CCR4 or CCR8 for homing of Th2 cells to the lungs and the 
development of AAI (Conroy et al., 2003, Mikhak et al., 2009). In contrast, Mikhak 
et al found that Th2 polarised OT-II cells deficient in CCR4 were reduced in number 
in the lung after OVA challenge, and that this was as ociated with a reduction in the 
severity of AAI (Mikhak et al., 2009). The chemokines CCL17 and CCL22 (both 
ligands for CCR4), were reduced in lung and BAL in the PIT treated group in the 
aforementioned Campbell et al study (Campbell et al., 2009). It is thus possible that 
if pOVA PIT had altered the chemokine receptor exprssion on Th2 cells and/or the 
Chapter 4 Results 
 167 
chemokine milieu in the lung, that this may account for the reduced severity of AAI 
in Figure 4.25-4.27.  
 
4.3.7 Does pOVA PIT induce deletion of Th2 CD4 + OT-II cells upon 
encountering OVA in the lung? 
Another possibility is that pOVA PIT induces OT-II Th2 cells to become more 
susceptible to apoptosis upon encountering OVA. This could fit with the recognised 
phenomenon that cells encountering strong antigenic stimulation during particular 
stages of the cell cycle are very sensitive to apoptosis (Yu et al., 1996, Lenardo et al., 
1999), and the likelihood that a substantial proportion of the transferred Th2 
population proliferates following adoptive transfer [(Hu et al., 2001), and discussed 
above].  
 
Inadequate survival signals are also implicated in th s respect. Recently, signalling 
through CX3CR1 (the receptor for the chemokine CX3CL1 - which is expressed by 
cells such as DCs and epithelial cells, and the production of which is known to be 
increased in inflammatory settings), was examined i AAI (Mionnet et al., 2010). In 
that study, the severity of AAI was found to be reduced in CX3CR1-deficient mice 
(Mionnet et al., 2010). In CX3CR1-sufficient mice, CX3CR1 was found to be 
upregulated on Th2 cells in the lung and BAL after the induction of AAI (Mionnet et 
al., 2010). CX3CR1-deficient allergen-reactive Th2 cells [polarised in vitro from 
naïve transgenic CD4+ cells reactive towards the leishmania homolog of receptors for 
activated C kinase (LACK) antigen], were able to reach the lung in a model of 
LACK-induced AAI (Mionnet et al., 2010). However, these cells were more 
susceptible to apoptosis than CX3CR1-sufficient Th2 cells, during LACK airway 
challenges (Mionnet et al., 2010). CX3CR1-deficient Th2 cells were also susceptible 
to apoptosis in the mLN (Mionnet et al., 2010). It is interesting to speculate that if 
pOVA PIT impaired/abrogated the expression of chemokine receptors such as 
CX3CR1, this could lead to increased apoptosis of Th2 OT-II cells upon 
encountering OVA, although this hypothesis would fit less well with the lack of a 
significant reduction in OT-II cells in mLN in the pOVA PIT group (Figure 4.27d,e). 
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Another potential candidate is OX40. Croft et al found that costimulation via OX40 
was required by memory Th2 cells (generated after 3 days in vitro with pOVA in 
Th2 promoting conditions, followed by 3-6 days rest), to induce AAI, in a model 
similar to that shown in Figure 4.20 using Th2 polarised OT-II cells (Salek-Ardakani 
et al., 2003). Although OX40-/- OT-II Th2 memory cells could proliferate and 
produce cytokines early upon pOVA stimulation in vitro, their survival was much 
reduced, particularly from day 2 onwards (Salek-Ardakani et al., 2003). In vivo, 
OX40 was increased on Th2 OT-II memory cells shortly after allergen challenge 
(Salek-Ardakani et al., 2003). Adoptive transfer of OX40-/- Th2 OT-II memory cells 
followed by OVA challenge, led to less severe AAI compared to that seen after 
transfer of OX40+/+ Th2 OT-II cells, and was associated with fewer Th2 OT-II cells 
in mLN and lung (Salek-Ardakani et al., 2003). Therefo e, despite their reduced 
costimulatory requirements, costimulation via OX40 did appear to be required for an 
efficient memory Th2 cell response in that study. It is possible that pOVA PIT may 
have impaired OX40 expression on Th2 polarised OT-II cells. This could account for 
the reduction in OT-II cells in the lung in Figure 4.27b; again however, such a 
mechanism would not appear to correlate with the apparent lack of reduction of OT-
II cells in the mLN (Figure 4.27e). 
 
4.3.8 Does pOVA PIT induce anergic and/or regulator y 
mechanisms in Th2 polarised OT-II cells? 
Figure 4.33 shows that 4 days after pOVA PIT, the IL-2 produced by splenocytes 
from pOVA PIT treated mice in response to pOVA was reduced (yet still very high), 
compared to PBS treated controls (Figure 4.33b). A dose dependent response of 
splenocytes to OVA was not found in either group (Figure 4.33a), and it may be that 
background proliferation was already too strong to elicit this. IL-5 recall responses to 
pOVA were similar between the two groups (Figure 4.33c,d). Hence, despite around 
five times as many CD4+ OT-II cells in spleens of pOVA PIT treated mice, these 
appeared less responsive (yet still responsive) to pOVA in vitro. This perhaps 
indicates that a degree of anergy has been induced. In a dition, a dose dependent IL-
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10 response to pOVA was detected from splenocytes in the pOVA PIT treated group 
(Figure 4.33f). This could simply be as a consequence of the increased number of 
OT-II cells present in the splenocyte cultures in the pOVA PIT group. Alternatively, 
it could imply that the induction of IL-10 may play  role in the therapeutic effects of 
pOVA PIT seen in this model, as has been proposed in other PIT studies (Campbell 
et al., 2009, Vissers et al., 2004). In either case, IL-10 production has not been 
switched off. It is thus possible that PIT-induced stimulation of Th2 OT-II cells may 
have led to the generation of IL-10 producing cells.  
 
4.3.9 CD4+ epitopes in addition to pOVA are likely to be impl icated 
in the OVA-driven immune response  
The abrogated IL-2 response to pOVA after OVA sensitisat on in the pOVA PIT 
treated group compared to PBS treated controls indicates tolerance induction of 
CD4+ pOVA-reactive T cells (Figure 4.5b). However, this was not associated with a 
significant reduction in the IL-2 response to OVA in the pOVA PIT group (Figure 
4.5a). Importantly, IL-2 produced by splenocytes in response to OVA in Figure 4.5a 
will represent responses from CD4+ OT-II cells and from host CD4+ T cells as a 
consequence of OVA/alum sensitisation. Thus, despit pOVA PIT inducing tolerance 
of pOVA-reactive CD4+ OT-II cells, it appeared that host CD4+ T cells were 
responding to additional epitope(s) within OVA. Although Yang et al have recently 
described three potential additional I-Ad CD4+ T cell epitopes within OVA in 
BALB/c mice (Yang and Mine, 2009), to the author’s knowledge, formal 
characterisation of OVA epitopes in I-Ab restricted C57BL/6 mice, has not 
previously been reported. It was therefore likely that additional epitope(s) were 
involved in the CD4+ T cell response to OVA in this model. If this were so, then the 
data shown in Figure 4.5 would suggest that pOVA PIT does not inhibit CD4+ T 
responses to other potential OVA epitope(s) i.e. thre is a lack of  linked suppression. 
This could be a reason behind the lack of therapeutic ffect of pOVA PIT in OVA-
induced AAI in Chapter 3. These observations formed the basis for the experiments 
described in the next chapter. 
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4.3.10 Concluding remarks 
In summary, the data in this chapter have demonstrated:- 
 
• pOVA PIT given intravenously can tolerise naïve CD4+ pOVA-reactive cells 
in the setting of one OVA sensitisation. This is like y to be effected primarily 
via deletional mechanisms. 
• pOVA PIT reduces the severity of OVA-induced AAI when this is solely 
mediated by Th2 polarised pOVA-reactive CD4+ cells. 
• It is unclear how pOVA PIT effects tolerance in theTh2 OT-II AAI model. 
Possible mechanisms include impaired Th2 cell homing to the lung, apoptosis 
of Th2 cells upon encountering OVA in the lung and/or the induction of IL-
10. 
• Epitopes other than pOVA are likely to be implicated in the T cell response to 
OVA. pOVA PIT does not appear to induce linked suppression of responses 
directed towards these additional epitopes. 
 
The experiments in the next chapter were therefore designed to further delineate 
T cell responses induced towards OVA in C57BL/6 mice. 
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5 Epitope mapping the T cell response to OVA in C57 BL/6 
mice and implications for PIT in OVA-driven AAI. 
5.1 Introduction 
The findings discussed in Chapters 3 and 4 implied that CD4+ T cell epitopes in 
addition to pOVA may contribute to OVA driven responses in C57BL/6 mice. This 
could account for the lack of therapeutic effect seen using pOVA PIT in OVA-
induced AAI in Chapter 3, despite the tolerogenic effects of pOVA PIT demonstrated 
on trackable pOVA-reactive CD4+ T cells in Chapter 4. However, in Chapter 3, it 
was not possible to say whether or not tolerance of host CD4+ pOVA-reactive T cells 
had occurred, because of the inability to reliably detect an in vitro recall response of 
splenocytes from OVA sensitised C57BL/6 mice to pOVA. It was therefore 
important to determine whether or not pOVA PIT could induce tolerance of (non-
transgenic) pOVA-reactive CD4+ T cells, and also to characterise any additional T 
cell epitopes implicated in OVA-induced T cell responses in C57BL/6 mice. 
 
pOVA 323-339 was initially identified as an immunodominant CD4+ T cell epitope 
in the context of I-Ad (expressed by BALB/c mice) using OVA reactive T cell 
hybridomas and OVA fragments generated by trypsinatio  (Shimonkevitz et al., 
1984). C57BL/6 mice (which express I-Ab) also respond to pOVA (Barnden et al., 
1998). In BALB/c mice CD4+ T cell responses to pOVA are known not to constitute 
the full T cell response to OVA, and pOVA has been described as contributing 
between 25-60% of the CD4+ T cell response to OVA (Renz et al., 1993, Janssen et 
al., 1999). In BALB/c mice, Yang et al recently found that PIT using pOVA together 
with two additional peptides, containing recently identified CD4+ T cell epitopes 
(Yang and Mine, 2009), improved disease in a model f OVA-driven food allergy 
(Yang et al., 2010). This meant it was possible that a similar scenario was occurring 
in the experiments in Chapter 3. However, differences in MHC haplotypes between 
BALB/c and C57BL/6 mice meant that any additional CD4+ T cell epitopes were 
unlikely to be the same as those described for BALB/c mice. To the author’s 
knowledge, formal characterisation of the C57BL/6 T cell response to OVA has not 
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previously been carried out. Epitope mapping experim nts were therefore designed, 
to identify additional epitopes within OVA, which could then be utilised for PIT. 
 
5.1.1 Aims 
This chapter aimed to: 
i) Assess the in vitro recall response to pOVA by LN cells from C57BL/6 mice.  
ii)  Confirm that tolerance of pOVA-reactive T cells is induced following pOVA 
PIT in C57BL/6 mice. 
iii)  Characterise any additional T cell epitopes within OVA in C57BL/6 mice. 
iv) To test tolerogenic efficacy of epitope(s) identified in (iii), either alone or in 
combination with pOVA, in the OVA-induced AAI model. 
 
5.1.2 Approach 
Initially, in vitro recall responses to OVA and to pOVA, and the effects of pOVA 
PIT, were assessed following OVA/CFA immunisation; si ce this is known to induce 
strong immune responses after one immunisation. Short-term T cell lines were then 
generated from peripheral LN of C57BL/6 mice immunised with OVA/CFA. These 
T cell lines were cultured with a panel of overlapping peptides which encompassed 
the full sequence of OVA and incorporated a 5 amino acid shift and a 10 amino acid 
overlap. Data from these experiments led to the synthesis of a peptide encompassing 
amino acids 263-278 from OVA (hereafter referred to as p263-278). The antigenicity 
of p263-278 and the relative contribution of T cell r sponses to this peptide to the 
overall OVA-induced T response, was examined. The effects of PIT using p263-278 
alone and in combination with pOVA were then assessed in OVA-driven AAI. 
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5.2 Results 
5.2.1 In vitro proliferative responses to pOVA do not constitute 
the full response to OVA in C57BL/6 mice  
In order to characterise T cell responses to epitopes within OVA, a strong OVA 
induced immune response was required. The adjuvant CFA was therefore chosen for 
these experiments instead of alum. When LN cells were cultured from pOVA/CFA 
immunised mice, proliferative responses to OVA and to pOVA were similar to one 
another (Figure 5.1b). Figure 5.1c shows that one OVA/CFA immunisation induced 
a robust proliferative response of LN cells to OVA. Importantly, in vitro recall 
responses to pOVA were lower than to OVA (Figure 5.1c). It appeared that maximal 
proliferative responses were achieved in response to pOVA even at the lowest 
concentration tested, however this was still an antige  dependent response when 
compared to the low background proliferation seen upon culturing splenocytes with 
medium alone (Figure 5.1c, dotted line). It seems likely that the stronger immune 
response generated following OVA/CFA immunisation compared to OVA/alum 
immunisation, facilitates the detection of in vitro proliferative responses to pOVA, 
which are considerably lower than seen in response to OVA (Figure 5.1c). 
Furthermore, use of LN cells (which are more easily obtainable in large numbers 
following immunisation with CFA than after OVA/alum immunisation) and not 
splenocytes may also be a factor in the ability to detect proliferation in response to 
pOVA in these experiments. These data thus suggest, consistent with data from 
others in the context of BALB/c mice (Janssen et al., 1999, Yang and Mine, 2009), 
that T cell responses to pOVA do not constituent the full response to OVA. It was 
also noted during these experiments that responses to pOVA following OVA/CFA 
immunisation often varied between individual mice (data not shown). The extent to 
which T cell responses are directed towards pOVA following OVA/CFA 
immunisation therefore seems subject to some variability etween individual mice. 
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5.2.2 pOVA PIT reduces but does not abolish the in vitro recall 
response to OVA following OVA/CFA immunisation in 
C57BL/6 mice.  
pOVA PIT or PBS as a control were administered 7 days prior to OVA/CFA 
immunisation (the approach shown in Figure 5.2a). 10 days later, in vitro recall 
responses of LN cells to OVA and to pOVA were assesed (Figure 5.2b-d). 
Tolerance was induced towards pOVA in pOVA PIT treated mice, as shown by the 
lack of a detectable in vitro recall response to pOVA in this group (Figure 5.2b). 
Proliferative responses to OVA in the pOVA PIT treaed group were reduced, but not 
abolished at higher antigen doses, compared to PBS treated controls (Figure 5.2b). 
However, at limiting doses of antigen pOVA PIT significantly reduced the response 
to OVA (Figure 5.2b) and the overall effect of pOVA PIT on the response to 
increasing concentrations of antigen was significantly reduced (Figure 5.2b).  IFN-γ 
in culture supernatants from the PBS treated group was above the limit of detection 
for all concentrations of OVA tested, however, pOVA PIT resulted in a reduction in 
IFN-γ production in response to OVA since this was now within the limit of 
detection at lower concentrations of OVA (Figure 5.2c)  Compatible with the 
proliferation data, IFN-γ was not detected in supernatants from LN cells from pOVA 
PIT treated mice in response to pOVA (Figure 5.2d). IFN-γ was produced (but to a 
variable degree) by LN from PBS treated mice in respon e to pOVA (Figure 5.2d). 
Overall, these data demonstrate that pOVA PIT given prior to OVA/CFA 
immunisation is capable of tolerising pOVA-reactive T cells in C57BL/6 mice. 
However, although this reduces the overall response to OVA it does not abolish it 
(Figure 5.2b,c). This meant that, despite the induction of tolerance of pOVA-reactive 
T cells following pOVA PIT, a significant response till remained towards OVA. 
 
5.2.3 Epitope mapping the T cell response to OVA in  C57BL/6 
mice 
In order to map the T cell response to epitope(s) contained within OVA in the 
context of C57BL/6 mice, short-term OVA-reactive T cell lines were generated as 
shown in Figure 5.3. A panel of 75 peptides was commissioned encompassing the 
amino acid sequence of OVA. These 15mer peptides incorporated a 5 amino acid 
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shift, and therefore a 10 amino acid overlap, to facilit te epitope mapping. OVA-
reactive T cells were cultured with irradiated splenocytes (which acted as APC) and 
peptide. Responses to OVA, pOVA and medium alone were also included. Figure 
5.4 shows the proliferative response of the OVA-reactive T cell line to each peptide 
in the panel. As predicted, proliferation occurred in response to peptides 321-335 and 
326-340, representing a response to the T cell epitope contained within pOVA 
(Figure 5.4, blue bars). Proliferative responses were also seen in response to peptides 
261-275 and 266-280 (Figure 5.4). Since these two peptides overlapped each other 
this strengthened the likelihood that they contained a T cell epitope within them. This 
experiment was conducted twice, once using 10µM of each peptide (Figure 5.4) and 
once using 2 µM of each peptide (data not shown). Data from these two experiments 
consistently showed proliferative responses to peptid s 321-335 and 326-340, and 
261-275 and 266-280. In addition, proliferation was also seen in response to peptide 
26-40 (Figure 5.4). Low level proliferative responses were also consistently seen to 
peptide 301-315 (Figure 5.4) in both experiments, but not consistently in response to 
any other peptide. The proliferative response to an equimolar OVA concentration 
was around 6 times greater than seen to any individual peptide (Figure 5.4 – refer to 
figure legend for OVA response).  
 
In summary, short-term OVA-reactive T cell lines proliferated in response to 
peptides spanning the pOVA sequence, and also in response to peptides 261-275 and 
266-280. Proliferative responses were also consistently seen towards peptides 26-40 
and 301-315. 
 
5.2.4 A short term OVA-reactive T cell line respond s to an epitope 
shared by peptides 261-275 and 266-280, in addition  to 
responding to pOVA  
In vitro recall responses of an OVA-reactive T cell line towards identified peptides of 
interest from the peptide panel were next determined. Dose-dependent proliferation 
was seen in response to pOVA and to peptides 261-275 and 266-280 (Figure 5.5). No 
proliferative response was seen in response to peptide 171-185, which was included 
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as a negative control (Figure 5.5). Although proliferative responses to peptide 26-40 
and to peptide 301-315 were above background levels, this response was relatively 
low and did not appear to be dose-dependent (Figure 5.5).  Furthermore, it had been 
noted upon reconstitution of the peptides that peptid  26-40 was not fully soluble, so 
it was hypothesised that this may play a role in the proliferation response elicted by 
this peptide. Interestingly, peptide 301-315 appeared toxic at high concentrations 
(indicated by the proliferative response to this peptide in Figure 5.5 and also noted 
during microscopic examination of cell cultures).  
 
IFN-γ was produced by the T cell line in a dose-dependent fashion to OVA, pOVA 
and to peptides 261-275 and 266-280 (Figure 5.6). Overall, the proliferative and 
cytokine response to peptide 261-275 was lower thano peptide 266-280 (Figure 5.5 
and Figure 5.6). IFN-γ was not detected in response to the negative control peptide 
171-185, nor to 26-40 or 301-315 (Figure 5.6).  
 
To ensure that the results described above were applic ble to T cell responses 
following direct ex-vivo isolation, rather than specific to the short-term T cell line, 
recall responses of LN from OVA/CFA immunised mice w re assessed in response 
to the peptides of interest (Figure 5.7). A similar p ttern of response as had been seen 
using the short-term T cell line, was again seen. 
 
Cumulatively, the above experiments led to the conclusion that immunisation with 
OVA led to T cell responses to an additional epitope shared by peptides 261-275 and 
266-280.  
 
5.2.5 p263-278 induces proliferation of LN cells fr om OVA/CFA 
immunised mice and reconstitutes the response seen to 
OVA when cultured together with pOVA 
The core sequence shared by peptides 261-275 and 266-280 is 266-275. A 16mer 
peptide (263-278, hereafter referred to as p263-278), was thus synthesised to provide 
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three “flanking” residues on either side of this sequ nce. The sequence of p263-278 
and the proposed T cell epitope contained within it is shown in Figure 5.8a. p263-
278 induced proliferation of LN cells from OVA/CFA immunised mice (Figure 
5.8c). A similar degree of proliferation was also seen in response to pOVA (Figure 
5.8c). Interestingly, a combination of equimolar con entrations of pOVA and p263-
278 appeared to almost fully reconstitute the recall response seen to OVA, as 
measured either by proliferation or by IFN-γ production (Figure 5.8c,d). Hence, it 
appeared that the T cell response to OVA was predominantly, if not entirely, directed 
towards epitope(s) contained within pOVA and p263-278. 
 
5.2.6 The effects of giving pOVA and p263-278 in co mbination as 
PIT prior to the induction of OVA-induced AAI 
Figure 5.9 shows the approach used to assess the effects of PIT using intravenous 
administration of p263-278, either alone or in combination with pOVA, upon OVA-
induced AAI. There were no differences in peri-vascular or peri-bronchiolar lung 
inflammation scores between any of the groups (Figure 5.10a,b). There were no 
significant differences in the percentage of goblet cells in the airways or in total BAL 
cells between the groups (Figure 5.10c,d and Figure 5.11a). However, there were 
significantly fewer eosinophils in the BAL from pOVA+p263-278 PIT treated mice, 
compared to PBS treated controls (Figure 5.11c). In co trast, the number of 
eosinophils (and lymphocytes) in BAL was increased in the pOVA PIT group 
compared to the PBS group (Figure 5.11c,e). This is different to the findings 
following pOVA PIT in Chapter 3 – it is possible that differences in the route of 
airway challenge (intranasal versus intratracheal) may be implicated in these 
findings. There was also significantly less OVA-specific IgE detected in serum from 
the pOVA+p263-278 PIT treated mice, compared to PBS treated controls (Figure 
5.12c). There was no significant difference in OVA-specific IgE levels from pOVA 
PIT or p263-278 PIT treated mice, compared to controls (Figure 5.12a,b). No 
significant difference in OVA specific IgG1 was detected in serum from PBS treated 
compared to pOVA+p263-278 PIT treated mice (data not shown). There was 
substantial inter-mouse variability between levels of OVA-specific IgG2a detected in 
serum from pOVA+p263-278 PIT treated mice (as indicated in Figure 5.12d). 
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Although at some (higher) serum dilutions the levels of IgG2a attained significance 
in this group versus PBS treated controls, the variability in IgG2a levels within the 
pOVA+p263-278 PIT group makes it difficult to draw a firm conclusion from these 
data (Figure 5.12d). 
 
mLN cells were also harvested on D36, groups pooled an  in vitro proliferative 
responses assessed to pOVA, p263-278 and OVA (Figure 5.13). mLN cells from the 
pOVA PIT group had an abrogated proliferative response to pOVA, although this 
had limited impact on the response to OVA (Figure 5.13a,c). The proliferative 
response to p263-278 was highest in the pOVA PIT group (Figure 5.13b).  
Proliferation in response to p263-278 was low in all other groups and did not appear 
to be reduced following p263-278 PIT (Figure 5.13b). The overall proliferative 
response to OVA in the pOVA + p263-278 PIT group was lower than seen in all 
other groups (Figure 5.13c). This could perhaps suggest that PIT using pOVA 
together with p263-278 can reduce (but not ablate) th  response to OVA. As also 
found in Chapter 3, no recall response to pOVA (and in this case also to p263-278) 
could reliably be demonstrated from splenocytes from any group (data not shown). 
 
Overall, PIT using a combination of pOVA and p263-278 significantly reduced the 
total number of eosinophils in the BAL and the leve of OVA-specific IgE, but did 
not significantly improve other AAI parameters such as pulmonary inflammation 
scores or the percentage of goblet cells in the airways.  
 
5.2.7 The effects of pOVA+p263-278 PIT on in vitro proliferation 
responses following OVA/CFA immunisation 
A shorter experiment was carried out in order to further assess the effects of PIT 
using pOVA+p263-278 upon OVA responses, by administering PIT prior to 
OVA/CFA immunisation (this approach is shown in Figure 5.14a). Again, as seen 
previously in Figure 5.2, proliferation did not occur in response to pOVA in pOVA 
PIT treated groups (Figure 5.14b), indicating that tolerance had been achieved. This 
occurred regardless of whether pOVA PIT was given alo e or in combination with 
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p263-278 (Figure 5.14b). Proliferation of LN cells from PBS treated mice in 
response to p263-278 was greater than seen to pOVA, implying that responses to 
p263-278 may be more dominant in this experiment (Figure 5.14a,b). PIT using 
p263-278 substantially reduced p263-278 proliferation but did not completely 
abolish it (Figure 5.14c). Surprisingly however, despite the reduction in p263-278 
and pOVA responses following pOVA+p263-278 PIT, this ad no effect on the 
overall response to OVA (Figure 5.14d). This is also unexpected given that 
cumulative cpm to pOVA alone and to p263-278 alone in the PBS treated group at 
10µM of peptide, are similar to the cpm seen in respon e to 10µM OVA (Figure 
5.4b-d). This observation together with the findings shown in Figure 5.8c, would be 
consistent with T cell responses towards pOVA and p263-278 constituting a major 
part of the T cell response to OVA. The lack of effect that inducing tolerance 
towards pOVA and p263-278 apparently had upon the overall response to OVA in 
Figure 5.14d, is therefore difficult to account for.   
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Figure 5-1: Proliferative responses to pOVA in vitro are demonstrable following OVA/CFA 
immunisation but do not constitute the full OVA response in C57BL/6 mice
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Figure 5-2: pOVA PIT reduces but does not abrogate the in vitro recall response to OVA 
following OVA/CFA immunisation in C57BL/6 mice
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Figure 5-3: Generating short-term T cell lines for use in peptide recall assays
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Figure 5-4: Responses of an OVA-reactive short-term T cell line to a panel of overlapping 
peptides encompassing the sequence of OVA
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Figure 5-5: Dose-dependent proliferation of an OVA-reactive short-term T cell line to pOVA 
and to peptide 261-275 and 266-280
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Figure 5-6: Dose-dependent IFN-γ production from an OVA-reactive short-term T cell line to 
pOVA and to peptides 261-275 and 266-280
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Figure 5-7: Dose-dependent proliferation of LN cells following OVA immunisation to pOVA 
and to peptides 261-275 and 266-280
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Figure 5-8: pOVA in combination with p263-278 induces similar proliferation of LN cells from 
OVA/CFA immunised mice as seen in response to OVA alone
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Figure 5-9: Experimental approach to assess the effcts of PIT using pOVA+p263-278 prior to 
AAI induction in C57BL/6 mice
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Figure 5-10: Assessment of the effects of PIT using p263-278 in combination with pOVA on 
pulmonary inflammation in OVA-induced AAI
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Figure 5-11: Assessment of the effects of PIT using pOVA+p263-278 on BAL parameter in AAI
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Figure 5-12: Assessment of the effects of PIT using pOVA+p263-278 on OVA-specific IgE on 
D36
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Figure 5-13: In vitro proliferation responses of mLN cells appear to be reduced in response to 
OVA in mice that received pOVA+p263-278 PIT prior to induction of AAI
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Figure 5-14: Assessment of the effects of PIT using pOVA+p263-278 prior to OVA/CFA 
immunisation on in vitro proliferation
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5.3 Discussion 
5.3.1 pOVA and p263-278 both contain immunodominant  
epitope(s) implicated in OVA-induced T cell respons es in 
C57BL/6 mice 
The experiments in this chapter have demonstrated that pOVA and p263-278 both 
contain T cell epitopes important for OVA-induced responses in C57BL/6 mice. 
Although there were previous difficulties in elicitng recall responses of splenocytes 
to pOVA following OVA/alum sensitisation, as discussed in Chapter 3, recall 
responses from LN cells to pOVA following OVA/CFA immunisation were 
demonstrated in this chapter (for example in Figure 5.1a). Such findings suggest that 
a strong in vitro recall response towards OVA, reflecting strong clona  expansion in 
vivo, is required in order to elicit a reliable in vitro response to pOVA. This is 
consistent with data from Sun et al, who found that splenocytes from OVA/alum 
sensitised mice did not proliferative in vitro in response to pOVA (Sun et al., 2010), 
and with the findings of Fifis et al, who showed that splenocytes responded to pOVA 
in vitro following a strong immunisation protocol comprising OVA, anti-CD40 and 
the viral mimetic (and TLR3 ligand), polyinosinic:polycytidylic acid (poly I:C), 
(Fifis et al., 2004). 
  
Although T cell epitopes in addition to those contained within pOVA have recently 
been characterised in the context of I-Ad expressing BALB/c mice (Yang and Mine, 
2009), to the author’s knowledge, the findings in this chapter represent the first 
formal characterisation of T cell epitopes implicated in OVA-induced immune 
responses in C57BL/6 mice. In these experiments, responses to two overlapping 
peptides were found which shared the core sequence of 266-275, and subsequent 
experiments demonstrated responses to the 16mer peptide p263-278 (Figures 5.4-
5.8). Following these experiments, more refined litera ure searches were carried out 
based upon the 263-278 sequence. The results of these s arches unexpectedly 
highlighted that an OVA-derived epitope comprising the 265-280 sequence had been 
used previously by others, in a limited number of studies involving C57BL/6 mice. 
The first such study appears to be from Maecker et al. They examined cytotoxic T 
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cell responses following immunisation with a vector encoding a known CD8+ T cell 
OVA epitope (SIINFEKL), together with the 265-280 epitope which they described 
as “the MHC class II-restricted T cell epitope of OVA” (Maecker et al., 1998). In 
that study, vector expression of 265-280 and the presence of CD4+ T cells were both 
required to generate a strong cytotoxic T cell respon e to OVA (Maecker et al., 
1998). Those findings are consistent with the data shown in this chapter. However, 
Maecker et al do not reference the 265-280 epitope so it is unclear from that paper 
where the information regarding this has been drawn. Following personal 
communication with the authors (Maecker HT and Levy S with Mackenzie KJ – 
personal communication), it appears that 265-280 was chosen using predication 
algorithms for peptide binding to I-Ab, and not following functional assessment. 
Subsequent studies, also focusing upon CD4+ T cell influences on CD8+ T cell 
responses, have also utilised 265-280, and also reference the initial Maecker et al 
study. In a recent publication by Mizukami et al, 265-280 is described as “a 
presumed helper epitope” (Mizukami et al., 2008). Again, the inclusion of the 265-
280 epitope in a vaccine designed to induce cytotoxic T cell responses was found to 
enhance cytotoxic T cell responses to OVA-expressing tumour cells (Mizukami et 
al., 2008). Furthermore, in order to compare CD4+ T cell responses in transgenic 
mice with glycosphingolipid storage disease to naïve controls, Gadola et al showed 
that IFN-γ was produced by splenocytes from OVA immunised C57BL/6 mice in 
response to the 265-280 peptide (Gadola et al., 2006). Proliferative responses were 
however not assessed in that study. 
 
Thus, although CD4+ response to the 265-280 sequence have previously been 
described in a limited number of studies, the epitope mapping experiments in this 
chapter have enabled formal characterisation of the T c ll response to pOVA, and 
have demonstrated that the T cell response to OVA is predominantly directed 
towards epitope(s) within pOVA and p263-278. 
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5.3.2 What are the relative contributions of respon ses to 
epitope(s) within pOVA and p263-285 to the overall OVA-
induced T cell response? 
The findings described in this chapter enable some tentative predictions as to the 
relative contribution of pOVA and p263-278 directed T cell responses to the overall 
OVA-induced T cell response. 
 
The proliferative response of OVA-derived T cell lines to pOVA was around 20% of 
that induced by OVA (Figure 5.4 and Figure 5.5 – note that the mean response to 
OVA is included in the figure legend). Experiments involving freshly isolated LN 
cells from OVA/CFA immunised mice show greater variability in terms of the 
pOVA–induced proliferative response as a percentage of the OVA response. 
Responses to 10µM pOVA ranged from around 20-50% of the responses to 10µM 
OVA in different experiments (Figures 5.2, 5.7, 5.8and 5.14). This is comparable to 
BALB/c mice where pOVA induced T cell responses have previously been described 
as contributing to between 25-60% of the T cell response to OVA (Renz et al., 1993, 
Janssen et al., 1999).  
 
Figure 5.8c indicates that the proliferative response of LN cells from OVA/CFA 
immunised mice to p263-278 comprised around 50% of that seen in response to 
OVA. Data from the PBS treated OVA/CFA immunised group in Figure 5.14c, are 
also consistent with this. Interestingly, in Figure 5.8c, the recall response of LN cells 
to equimolar concentrations of pOVA and p263-278 in combination, appeared to 
reconstitute the response to OVA. This would support the conclusion that T cell 
responses induced by OVA immunisation are predominantly directed towards 
epitope(s) contained within pOVA and p263-278. However, the data in Figure 5.14 
do not fully support this, because despite evidence that tolerance was induced 
towards pOVA and p263-278 using pOVA+p263-278 PIT (Figure 5.14b,c), this did 
not substantially reduce the overall recall response to OVA (Figure 5.14d).  
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In summary, the majority of data in this chapter are consistent with the tentative 
estimation that responses directed towards epitope(s) within pOVA contribute to 20-
50% and to p263-278 contribute to around 50%, of the overall OVA induced T cell 
response. More accurate quantification would require additional experiments, for 
example by assessing the peptide-induced responses of hybridomas generated 
following OVA/CFA immunisation (Robertson et al., 2000), or via peptide recall 
assays using enzyme-linked immunosorbent spot (ELISPOT) techniques. 
  
5.3.3 The effects of pOVA+p263-278 PIT on OVA-drive n immune 
responses and AAI 
Given the apparent substantial contributions of pOVA and p263-278 responses to the 
overall OVA induced response, PIT using a combination of pOVA+p263-278 was 
predicted to induce tolerance of a substantial proportion of the OVA-induced T cell 
response, and reduce the severity of AAI. This was true for some AAI parameters; 
the total number of eosinophils in BAL was reduced in the pOVA+p263-278 PIT 
group compared to PBS treated controls (Figure 5.11c), and there was also a 
significant reduction in the levels of OVA-specific IgE  in the serum of mice from 
the pOVA+p263-278 PIT group compared to PBS treated controls (Figure 5.12c). 
Furthermore, the proliferation of pooled mLN cells in response to OVA was lower in 
the pOVA+p263-278 PIT group compared to other groups (Figure 5.13c). However, 
pOVA+p263-278 PIT did not significantly reduce the p rcentage of goblet cells in 
the airways, nor did it lead to reduced pulmonary inflammation scores (Figure 5.10). 
Overall, the effects of pOVA+p263-278 PIT upon OVA-induced AAI were variable 
but encouraging, particularly when compared to the eff cts of PIT using pOVA or 
p263-278 alone, which did not reduce the severity of any AAI parameter or reduce 
the proliferation of mLN cells to OVA (Figure 5.10-5.13).  Furthermore, in Figure 
5.11c, the total number of eosinophils in BAL was actu lly increased in the pOVA 
PIT group compared to PBS treated controls.  
 
The findings in Figure 5.14 demonstrate some important further points. Firstly, 
pOVA PIT and p263-278 successfully induced tolerance to themselves in the setting 
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of OVA/CFA immunisation, as indicated by the abrogated recall proliferation 
responses (Figure 5.14b,c). Secondly, neither peptid  g ven alone as PIT induced 
linked suppression to the other peptide (Figure 5.14b,c). Additonally, in the 
OVA/CFA setting, pOVA+p263-278 PIT did not appear to reduce the overall recall 
proliferative response of LN cells to OVA (Figure 5.14d). This is different to the 
reduction in the recall proliferation response of mLN cells to OVA in the 
pOVA+p263-278 PIT group following the induction of AAI in Figure 5.13c. It is 
possible that the very strong stimulus provided by OVA/CFA immunisation could 
play a role in these differences, and this is further discussed below.  
 
Taken together, the findings described in this chapter have some similarities with 
other studies, particularly with those of Yang et al (Yang et al., 2010). In that study, 
two OVA-derived peptides, previously identified by the same group as containing 
immunodominant OVA epitopes in the context of BALB/c mice (Yang and Mine, 
2009), were used along with pOVA as PIT in a model of OVA-induced food allergy 
(Yang et al., 2010). PIT was given after oral sensitisation to OVA and prior to oral 
OVA re-challenge. PIT using the three peptides together, reduced allergic responses 
upon oral OVA re-challenge, indicating tolerance induction (Yang et al., 2010). 
However, when used alone, none of the three peptides reduced the allergic response 
to OVA, and PIT using only one of the peptides (147- 61), increased disease severity 
(Yang et al., 2010). Therefore, in that model, the immunodominant OVA peptides 
had to be given in combination to exert therapeutic effects. Similarly in other studies 
pOVA PIT did not reduce OVA-induced responses (Jansse  et al., 1999, Barbey et 
al., 2004), and in one study pOVA PIT exacerbated OVA-induced AAI (Janssen et 
al., 1999). Hence, it appears from the data described n this chapter and the findings 
of others (Barbey et al., 2004, Yang et al., 2010, Janssen et al., 1999), that PIT for 
OVA-induced allergic disease may only generate therap utic effects when 
immunodominant peptides are used in combination. The lack of evidence for linked 
suppression suggested by the data in this chapter and by the findings of Yang et al 
(Yang et al., 2010),  are likely, in part, to be implicated in this. This is in contrast to 
the linked suppression previously demonstrated in the Campbell et al PIT study 
(Campbell et al., 2009). IL-10 dependent mechanisms were found to be implicated in 
Chapter 5 Results 
 202 
tolerance induction in that study and attributed to the linked suppression that was 
found (Campbell et al., 2009). The induction of IL-10 may have been related to the 
intradermal and low dose PIT administration regime chosen in that study (Campbell 
et al., 2009) and is different to the high dose, intravenous, approach used here, 
which, as discussed in Chapter 4, is thought to lead to a predominantly deletional 
mode of tolerance (Hochweller and Anderton, 2005, Kearney et al., 1994).  
 
The findings in this chapter have thus demonstrated that PIT using pOVA or p263-
278 alone did not induce linked suppression and did not reduce the severity of OVA-
induced AAI. However, PIT using pOVA and p263-278 in combination reduced, but 
did not ablate, some, but not all, of the parameters of OVA-induced AAI. In contrast, 
in the context of OVA/CFA immunisation, pOVA+p263-278 PIT did not appear to 
reduce the overall recall proliferation response of LN cells to OVA. So what reasons 
could account for these findings? 
 
5.3.4 Why does pOVA+p263-278 PIT not ablate OVA-dri ven AAI, 
nor reduce the overall recall response to OVA follo wing 
OVA/CFA immunisation? 
There are several possibilities that could account for the limited effects of 
pOVA+p263-278 PIT on OVA-induced responses, seen in this chapter:- 
 
i) Are “minor” OVA-derived T cell epitopes still capable of promoting 
OVA-induced responses? 
It is possible that if T cell responses were additionally directed towards minor 
OVA-derived epitopes, this might not have been detect d in the overlapping 
peptide experiments described in this chapter. If so, and in the absence of 
linked suppression, it is possible that responses to uch epitopes could still 
generate an overall T cell response to OVA. This seems unlikely given the 
apparently substantial contribution of responses to pOVA and p263-278 to 
the overall OVA response, found in the majority of experiments in this 
chapter.    
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ii)  Is incomplete tolerance induction and/or residual effector cytokine 
production by anergic T cells implicated? 
If some pOVA and/or p263-278-reactive T cells escaped tolerance induction and 
remained pathogenic, then the continued restimulation of such cells to OVA in 
the AAI protocol (2 x OVA/alum sensitisation and 3 airway challenges) could be 
sufficient to generate OVA-induced AAI. Indeed, in vitro proliferation towards 
p263-278 was not completely abolished following p263- 78 PIT (Figure 5.14c).  
 
Another possibility could relate to anergic pOVA and p263-278-reactive T cell 
populations. These could have been induced following pOVA+p263-278 PIT if 
the same predominantly deletional and anergic mechanisms as were implicated in 
the experiments utilising naïve OT-II cells (discussed in Chapter 4) also occurred 
in the non-transgenic setting. Although anergic cells have substantially impaired 
proliferative and IL-2 producing capacities, the ability of anergic cells to generate 
effector cytokines in response to antigen can vary (Tanchot et al., 2001, Malvey 
et al., 1998, Schwartz, 2003). Hence, it is feasible that the multiple exposures to 
OVA during the AAI induction protocol could still be sufficient to generate Th2 
cytokines from anergic cells and induce AAI. 
 
iii)  Do exogenous soluble pOVA and p263-278 target all populations of 
pOVA and p263-278-reactive T cells that are generated following 
endogenous processing of OVA?  
Immunisation with an immunodominant peptide can induce T cell responses that 
are not found following immunisation with the whole protein. This can occur 
because immunisation with peptide enables “cryptic epitopes” to be displayed on 
MHC II – for example epitopes that are normally destroyed during processing of 
the whole protein (Sweenie et al., 2007, Anderton et al., 2002). Immunisation 
with peptide can also induce responses from T cells that can only respond to 
exogenously delivered peptide, but not to the same peptide when this is processed 
from whole protein (so-called Type B cells) (Unanue, 2002, Cirrito et al., 2001, 
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Viner et al., 1996). This is thought to occur as a result of conformational 
differences in peptide-MHC II complexes arising from differences in processing 
of exogenously delivered peptide versus the same peptide derived from a whole 
protein. For example, Viner et al demonstrated these ffects in the context of 
immunisation with hen egg lysosyme. In that study, immunisation with protein 
stimulated a response from type A cells (cells thatcould recognise peptide when 
naturally processed from the whole protein). whereas immunisation with peptide 
could induce type A cells or type B cells (Viner et al., 1996). Therefore, if pOVA 
and p263-278 PIT favoured particular MHC II binding conformations, this could 
lead to tolerance induction of particular, but not all, pOVA and p263-278 reactive 
T cell populations. If the T cell populations that escaped tolerance induction via 
PIT could respond to OVA but not to exogenously processed peptides, this could 
perhaps account for the findings in Figure 5.14. This possibility has previously 
been suggested by others in the context of PIT in experimental autoimmune 
encephalomyelitis (EAE) (Anderton et al., 2002). Such studies, together with the 
results in Figure 5.14, thus demonstrate the complexity of designing peptides for 
therapeutic intervention and highlight the importance that such peptides must 
mimic the response to that peptide generated after natural processing from whole 
protein. 
 
Another potential reason as to why pOVA+p263-278 PIT had limited impact on 
the response to OVA concerns post-translational modifications (PTM). It is 
known that during antigen processing amino acids within a peptide can undergo  
PTM which can alter the nature of the resulting T cell response [discussed in 
(Anderton, 2004)]. Many different potential PTM have been described which can 
be mediated through enzymatic activities within the APC (Anderton, 2004). For 
example, certain amino acids such as glutamine and asparagine can undergo 
deamidation (Anderton, 2004). Deamidation of glutamine to glutamic acid has 
been found to increase proliferative responses of gluten-reactive T cell lines 
derived from patients with coeliac disease, most likely as a consequence of 
increased MHC II binding affinity (Arentz-Hansen et al., 2000). Hydroxylation 
+/- glycosylation of certain amino acids can also influence the T cell response. In 
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a mouse model of collagen induced arthritis, collagen-reactive T cells were found 
to predominantly respond to an immunodominant collagen-II-derived peptide 
containing a hydroxlated and glycosated lysine residue (Corthay et al., 1998). 
PIT using this modified peptide was found to be much more effective than using 
an unmodified peptide (Backlund et al., 2002).  
 
PTM arising during the OVA-induced immune responses d cribed in this 
chapter, could have generated T cell responses that were not detected in the 
epitope mapping experiments. Potential candidates might, for example, be the 
asparagine residue in pOVA (at position 335, which could undergo deamidation), 
the threonine residues in p263-278 (at positions 265 and 268, which would be a 
candidate for hydroxylation and subsequent glycosylation), or the serine residues 
in p263-278 (positions 269 and 270), where post-translational phosphorylation 
could occur (Anderton, 2004). PTM of amino acids outwith the pOVA and p263-
278 sequences could also be implicated. To investigate this further, T cell 
responses to deliberately modified OVA-derived peptides could be examined, 
however this would be strategically difficult as well as costly, on account of the 
wide variation in potential PTM. Intriguingly, PTM appear to be particularly 
associated with strong inflammatory responses, perhaps on account of potent 
APC activation (Scott et al., 2000, Herzog et al., 2005). It is interesting to 
speculate that PTMs could be more influential upon the nature of the T cell 
response in the OVA/CFA setting compared to the AAIsetting. 
 
 
5.3.5 Concluding Remarks 
The conclusions that can be drawn from the findings  this chapter are, that:- 
 
• pOVA and p263-278 both contain epitope(s) that are major constituents of 
OVA-induced immune responses in C57BL/6 mice. 
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• The contribution of T cell responses to epitope(s) within pOVA and p263-278 
towards the overall OVA response have not been quantified. However, the 
majority of experiments in this chapter point to a significant contribution of 
pOVA and p263-278 T cell responses to the overall T cell response towards 
OVA.  
• pOVA+p263-278 PIT induced tolerance to both peptides in the context of 
OVA/CFA immunisation, as determined by the abrogated recall proliferation 
response of LN cells. However, this had little impact on the overall OVA 
proliferative recall response in this model. 
• PIT using either pOVA or p263-278 alone did not induce linked suppression 
of responses towards the other peptide.  
• PIT using a combination of pOVA+p263-278 reduced the severity of some 
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6 General Discussion 
The findings from this thesis can be summarised as follows:- 
 
• pOVA PIT given intravenously and in high dose prior t  OVA sensitisation 
did not reduce the severity of OVA-induced AAI in C57BL/6 mice. However, 
the same pOVA PIT regime did induce tolerance of naïve CD4+ OT-II cells 
in settings of OVA/CFA immunisation and one OVA/alum sensitisation; this 
was likely to be effected predominantly via deletional and anergic 
mechanisms.  
• Difficulties were encountered when trying to incorprate adoptive transfer of 
naïve CD4+ T cells into models of AAI. This was most likely due to poor 
viability of naive OT-II cells. 
• A model of AAI induced by Th2 polarised OT-II cells was subsequently 
established. High dose, intravenous pOVA PIT given prior to OVA 
challenge, reduced the severity of AAI in that model. This was associated 
with a reduced number of OT-II cells in the lung, but not in mLN. 
Splenocytes from pOVA PIT treated mice, and not from PBS treated controls, 
produced IL-10 in response to pOVA. 
• In C57BL/6 mice (in the absence of OT-II cell transfer), pOVA PIT in the 
OVA/CFA setting induced tolerance to pOVA, with limited impact on the 
response to OVA. 
• Formal epitope mapping of T cell responses demonstrated that pOVA and 
p263-278 both contained T cell epitopes important for OVA-induced immune 
responses in C57BL/6 mice.  
• In the OVA/CFA setting, pOVA+p263-278 PIT abrogated r call proliferation 
to pOVA and to p263-278, however, this had no substantial impact on the 
overall recall proliferation response to OVA. Furthermore, there was no 
evidence of linked suppression following pOVA or p263-278 PIT. 
• PIT using a combination of pOVA+p263-278 given in high dose, 
intravenously prior to OVA sensitisation, had some efficacy in OVA-driven 
AAI – reducing some parameters, but not others. 
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Hence, the findings in this thesis support part (i) but not part (ii) of the hypothesis, 
since pOVA PIT induced tolerance to pOVA but did not induce linked-suppression, 
and did not reduce the severity of OVA-induced AAI. pOVA PIT used in 
combination with p263-278 reduced the severity of some features of OVA-induced 
AAI. 
 
6.1 How can the findings in this thesis be most eff ectively 
utilised and built-upon to aid the clinical transla tion of PIT? 
In the allergic setting, it is likely that the majority of allergen-reactive T cells will be 
antigen-experienced (Wambre et al., 2010, Bateman et l., 2006). Hence, the model 
developed in this thesis, using pOVA PIT in AAI driven by Th2 polarised OT-II 
cells, may hold particular relevance for the clinical translation of PIT. One intriguing 
aspect in this context was the preferential production of IL-10 by splenocytes from 
pOVA PIT treated mice (Figure 4.33). It is thus pertinent to consider how these data 
may fit with current concepts surrounding allergen-specific immunotherapy. 
 
The immunoregulatory function of IL-10 is apparent [reviewed in (Moore et al., 
2001)]. For example, the development of colitis in IL-10 deficient mice is thought to 
result from dysregulated immune responses in the gut (K hn et al., 1993). T cell 
production of IL-10 has been shown to be important in he natural induction of 
tolerance (Meiler et al., 2008) and has been attributed to therapeutic efficacy in 
several mouse and human allergen-specific immunotherapy studies (Vissers et al., 
2004, Campbell et al., 2009, O'Neill et al., 2006). However, IL-10 producing 
regulatory T cells represent a heterogeneous population [discussed in (Hawrylowicz 
and O'Garra, 2005)]. The “Tr1” subset has been assigned to T cells that produce IL-
10 in the absence of typical Th1 or Th2 signature cytokines (Barrat et al., 2002, Buer 
et al., 1998), whereas in other studies Tr1 cells may produce IL-10 in combination 
with other cytokines (Groux et al., 1997). Interestingly, IL-10 can be induced or 
preferentially expressed by effector T cells, such as Th1 cells, often in conditions of 
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chronic or strong antigenic stimulation [discussed in (Cope et al., 2011)]. Indeed, IL-
10 was first cloned from a human T cell line that expr ssed IFN-γ+ (as well as other 
cytokines such as IL-5) (Vieira et al., 1991). Recently, Jankovic et al found that IFN-
γ
+ IL-10+ effector T cells were present in mice infected with Toxoplasma Gondii (a 
protozoan parasite) (Jankovic et al., 2007). IL-10 is known to be required to prevent 
exaggerated Th1 responses and subsequent death in Toxoplasma Gondii infected 
mice (Gazzinelli et al., 1996). In the Jankovic et al study, even IL-10- IFN-γ+ cells 
from infected mice could be induced to produce IL-10 after additional in vitro 
stimulation (Jankovic et al., 2007). IFN-γ+ IL-10+ cells have similarly been found in 
other situations linked to strong and/or chronic Th1 cell stimulation both in humans 
and mice (Morita et al., 1998, Belkaid et al., 2001) and IL-10 appears to act via a 
negative feedback loop to regulate the Th1 response (Gabrysova et al., 2009). Th17 
cells can also modulate their IL-10 production, and consequently their pathogenic 
potential, in response to variations in cytokine stimulation (McGeachy et al., 2007). 
The situation is perhaps more complicated for Th2 cells in light of their propensity to 
produce IL-10 (Mosmann et al., 1990). However, IL-10 production by memory Th2 
cells upon restimulation in vitro is variable, but has been shown to be favoured by 
repeated in vitro stimulation of Th2 cells in the presence of IL-4, most likely as a 
result of epigenetic effects upon the IL-10 locus (Chang et al., 2007, Lohning et al., 
2003).  
 
The production of IL-10 by effector cells in situations of strong and/or chronic 
antigenic stimulation appears to represent an important self-regulatory mechanism to 
limit the immune response and subsequent damage to the host. Recently, Sabatos-
Peyton et al have proposed a model in which these mechanisms could be harnessed 
to best effect in PIT (Sabatos-Peyton et al., 2010). This model is based on many 
studies from the Wraith group, several of which have utilised a model of EAE in 
transgenic mice which have TCRs reactive to the Ac1-9 peptide from myelin basic 
protein. Multi-dose intranasal PIT using an altered Ac1-9 peptide with high affinity 
for MHC II [known as Ac1-9 (4Y)], led to inhibition of IL-2 and IFN-γ from Ac1-9-
reactive T cells, and induced IL-10 production (Burkhart et al., 1999). However, PIT 
using the wild-type Ac1-9 peptide, which has weak MHC II affinity, inhibited IL-2 
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and IFN-γ but did not enhance IL-10 production (Gabryšová and Wraith, 2010). The 
IL-10 production induced by PIT using the high affinity Ac1-9 (4Y) peptide was key 
to the enhanced therapeutic efficacy seen using this peptide in EAE (Gabryšová and 
Wraith, 2010). Such findings have led to the proposal that high signal strength 
favours the production of IL-10 producing peptide-reactive T cells, whereas low 
signal strength favours a predominantly anergic T cell response (Sabatos-Peyton et 
al., 2010). 
 
This proposal can be cautiously interpreted in relation to the IL-10 production seen 
following pOVA PIT in the Th2 model in this thesis. Following Th2 polarisation, 
OT-II cells produced more IL-2, IL-13 and IL-5 in response to pOVA, compared to 
naïve OT-II cells (Figure 4.18). Hence the signal strength generated by applying 
pOVA PIT to the Th2 transfer model is likely to be high. This could thus favour IL-
10 production in accordance with the Sabatos-Peyton e  al model. Furthermore, it is 
probable that IL-2 and IL-5 production from OT-II cells following pOVA PIT was 
reduced on an individual cell basis. This could, therefore, also fit with the Sabatos-
Peyton model where reductions in effector cytokine production are associated with 
increases in IL-10 production in situations of high signal strength. Further 
investigation would be needed to address these possibilities, for example by 
assessing IL-10 and signature Th2 cytokine production by OT-II cells following 
pOVA PIT on an individual cell level (e.g. by using intracellular cytokine staining). 
Notably, AAI was reduced, but not abolished, using pOVA PIT in the Th2 transfer 
model. This is probably due to the continued (but most likely reduced) production of 
Th2 cytokines by OT-II cells despite pOVA PIT. It is tempting to speculate that, in 
accordance with the Sabatos-Peyton model, multiple doses of pOVA PIT prior to 
airway challenge in the Th2 OT-II model may further r duce the severity of disease 
by increasing IL-10 production and hence regulating he remaining effector response. 
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6.2 Future work 
6.2.1 Further mechanistic assessment of the effects  of pOVA PIT 
in the Th2 OT-II model established in this thesis. 
Additional avenues to investigate the role of IL-10 in the effects of pOVA PIT in the 
Th2 OT-II model have been outlined above. Other particular areas of interest include 
aspects such as the assessment of chemokine receptors on OT-II cells following 
pOVA PIT e.g. CCR4, CCR8, and the quantification of chemokines within the lung 
and BAL e.g. CCL17 and CCL22. Determining the expression of survival-associated 
molecules relevant in this setting such OX40 and CX3 R1 would also be justified, 
as would the quantification of OT-II cell death in the lung, e.g. by using terminal 
deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining. Together 
these approaches would help to elucidate the mechanisms of tolerance induced by 
pOVA PIT in the polarised Th2 cell setting. It would also be of value to utilise the 
Th2 OT-II pOVA PIT  model developed here to assess the susceptibility of different 
memory and effector T cell populations to tolerance induced by PIT (for example by 
cell-sorting Th2 polarised OT-II cells based on CD62L and CD44 expression and 
adoptively transferring these populations separately). 
 
6.2.2 Can the efficacy of pOVA+p263-278 PIT in OVA- induced AAI 
be improved? 
The lack of linked suppression in the pOVA+p263-278 model could be relevant to 
the limited therapeutic effect seen here, particularly if T cell responses to minor 
epitopes, or to peptides that have undergone PTM, are implicated. It would therefore 
be interesting to see whether efficacy could be enhanced by varying the route of 
delivery and/or the regime; for example by using reimes in accordance with other 
studies reporting either the induction of IL-10 and/or linked suppression or the 
induction of other regulatory mechanisms. Such an approach could include multi-
dose regimes to favour IL-10 production as described above (Gabryšová and Wraith, 
2010, Sabatos-Peyton et al., 2010) or alternatively r  low dose regimes to favour 
the induction of regulatory T cells (Kang et al., 2007, Apostolou and von Boehmer, 
2004). An intradermal approach, after sensitisation, has previously been found to 
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induce linked suppression (Campbell et al., 2009). Such an approach may also be 
effective here.  
 
6.3 Concluding remarks 
Antigen-experienced T cells are often thought difficult to tolerise, yet are probably 
more representative of T cell populations that are lik ly to predominate in allergic 
patients. Many previous PIT studies have focused on the effects of PIT on naïve T 
cells. In this thesis, pOVA PIT was found capable of inducing tolerance in polarised 
Th2 pOVA-reactive T cells, resulting in a significant reduction in disease severity; 
this model therefore holds particular importance for future PIT studies. Furthermore, 
to the author’s knowledge, the data presented in this thesis also represent the first 
formal characterisation of T cell epitopes involved in OVA-induced T cell responses 
in C57BL/6 mice. The pOVA+p263-278 PIT model developed here, will serve as a 
valuable tool for the further assessment of PIT in AAI.  
 
In summary, the findings in this thesis contribute to, and provide a mechanistic 
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Blood samples were taken from OT-II mice at weaning a d analysed using flow cytometry. CD4+ T 
cells in blood were gated on and the prescence of theVβ5.1 and Vα2 TCR chains confirmed. The 
prescence of the congenic marker CD45.1, and the abs nce of the CD45.2 isoform (present in 
C57BL/6 mice), were also confirmed.
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8.2 Appendix 2 Anaesthetic protocols  
Table 4: Anaesthesia used for intratracheal instillations 





















5mg/ml 0.4ml Reversal 









Table 5: Anaesthesia used for invasive plethysmography 
Purpose Drug Stock  Conc Volume 
used 
Dose/mouse Route 
Ketamine (Fort 
Dodge Animal 
Health Ltd) 
100mg/ml 1.4ml 
Xylazine 
hydrochloride 
(Bayer 
Healthcare) 
20mg/ml 0.7ml 
Induction 
0.9% w/v 
(Baxter 
Healthcare Ltd) 
 7.9ml 
0.1ml/10g i.p 
 
Repeat 
with a 
further 
50% dose 
every 30 
minutes if 
required 
 
 
